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Abstract 
 
Islet transplants have been successfully used as treatment for diabetes, but are 
limited by shortages of cadaveric insulin-producing β-cells. An alternate source may be the 
dedifferentiation, expansion, and subsequent redifferentiation of pancreatic islets or β-cells 
using in vitro techniques prior to transplant. Based on protocols which described the 
dedifferentiation of human islets to ductal-like cells, we hypothesized that neonatal mouse 
islets could be similarly dedifferentiated in vitro.  
Dedifferentiation techniques produced significant duct-like cells, but 
redifferentiation to insulin-expressing cells was limited. RIPCre;Z/AP+/+ mice were 
consequently utilized to lineage trace β-cell fate during culture by a human placental 
alkaline phosphatase (HPAP) reporter.  The proportion of HPAP+ β-cells decreased 
significantly in culture, but the rare remaining cells expressed the ductal marker CK19. Flow 
cytometric sorting of β-cell subpopulations from whole pancreas showed that the 
HPAP+CK19+ cells had derived from insulin-positive, glucose-transporter-2-negative 
(Ins+Glut2-) cells, previously purported as insulin-expressing progenitor cells. In P7 mouse 
pancreas, these  Ins+Glut2- cells represent 3.5% of all insulin+ cells, the majority of which 
were found outside of islets within β-cell aggregates (BCA, <5 β-cells). Ins+Glut2- cells 
demonstrated greater proliferation rates in vivo and in vitro as compared to Ins+Glut2+ cells, 
and a subset could differentiate into endocrine, ductal, and neural lineages. We sought to 
quantify the presence of these progenitor cells throughout life in both mouse and human 
pancreata, and how their abundance and location changes with age. The presence of 
Ins+Glut2- cells in human and mouse pancreas demonstrated similar distributions and 
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ontogenies, being more abundant in BCA than islets at all ages sampled, and decreasing 
with age. Finally, neonatal rodents can regenerate β-cell mass after streptozotocin (STZ) 
exposure, but this response is mitigated in adulthood. As STZ accesses the β-cell via Glut2, 
we hypothesized that the β-cell regenerative capacity in early life involves mobilization of 
Ins+Glut2- cells, and used RIPCreER;Z/AP+/+ mice to trace these during damage and 
regeneration.  We found that Ins+Glut2- cells indeed survived STZ exposure, and 
subsequently matured into Ins+Glut2+ cells.  
These Ins+Glut2- cells represent a transitional cell type, the majority of which 
contribute to pancreas maturation, and a subset of which retains multipotential lineage 
capability.   
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Introduction 
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 1.1         Diabetes 
Diabetes mellitus is a metabolic disease of the pancreas, characterized by increased 
levels of glucose in the blood (hyperglycemia). It is caused by an insufficient production of 
insulin, as found in Type I diabetes (T1D), or by cells that do not effectively or appropriately 
respond to the insulin produced, as found in Type II diabetes (T2D). The hormone insulin is 
secreted by pancreatic β-cells located in the islets of Langerhans, a spherical cluster of 
endocrine cells containing predominantly insulin-producing β-cells. Without insulin, the 
body cannot derive energy from carbohydrate metabolism for use in its target tissues, 
including liver, muscle, and adipose. Patients with undiagnosed or untreated diabetes 
typically present with fatigue, increased urination, increased thirst, and weight loss.  
Diabetes was first described >3000 B.C. by the Egyptians, and later by Greek physicians 
who coined the term diabetes, meaning, “to siphon”, referring to the large quantities of 
urine produced. The disease had also been described in India 400 B.C. as “honeyed urine”  
(1,2).  For most of history, a diagnosis of type I diabetes was tantamount to a death 
sentence; it was not until 1922 that Frederick Banting and colleagues Charles Best, James 
Collip, and John Macleod discovered the hormone insulin, which was life-saving for patients 
with the disease (3,4).   
Today, diabetes affects more than 285 million people worldwide, 9 million of them living 
in Canada with diabetes or pre-diabetes (5). This number is expected to surpass 438 million 
people worldwide by 2030. The vast majority of new cases is due to T2D, and attributable to 
a variety of factors, including an aging population, a sedentary lifestyle, and the worldwide 
2
 obesity epidemic (5).  The cost to the Canadian healthcare system is expected to reach 
$16.9 billion by 2020 (5).   
While a diagnosis of diabetes today does not carry with it the imminent death sentence 
it did a century ago, it is still the fourth leading cause of death by disease globally, with a 
morbidity rate of 4.6 million people annually (6). Death is associated with diabetes, but is 
commonly ascribed to complications of the disease, and only rarely to acute metabolic 
circumstances such as severe hyperglycemia and accompanying ketoacidosis, or its 
opposite, hypoglycemia (7). The long term sequelae of the disease are broadly classified 
into micro- and macro-vascular complications, as a result of both endothelial cell damage to 
small vessels, and elevated blood lipids which are deleterious to large vessels (7). Sustained 
exposure to hyperglycemia cause severe complications such as retinopathy (8,9), 
neuropathy (10), cardiovascular disease (11), and nephropathy (12). The majority of people 
with diabetes die of heart disease or stroke (6).  
While the complications experienced are similar between diabetes types, <10% of all 
patients with the disease have T1D. T1D differentiates from T2D in that it is an autoimmune 
disease which specifically destroys the β-cells in the islets of Langerhans, mediated by T-cell 
activation and islet-specific autoantibody presence (13). The conditions which allow this 
autoimmune storm to proceed are still unclear, although a combination of environmental 
triggers, such as viral exposure (14), and genetic susceptibility, especially by the presence of 
the HLA alleles DR3-DQ2/DR4-DQ8 (15), have been implicated. T1D was historically termed 
“juvenile diabetes” as it was thought to strike only those under 30 years of age; it is now 
known that persons of any age can develop the disease (16), although it is still most 
3
 commonly diagnosed in the young.  While pharmacological and bioengineering advances 
have improved the purity and delivery of the hormone, the current and standard treatment 
for T1D is still limited to exogenous insulin therapy.  Despite advances, persons with T1D 
live, on average, 15 years less than those without the disease (6).  
In 2000, a breakthrough procedure coined the “Edmonton Protocol” was introduced, in 
which islets of Langerhans were transplanted into patients with diabetes (17,18). This was 
an improvement from the only other transplant option – an entire pancreas – available 
solely to patients undergoing concurrent kidney transplant (19). Despite the relative success 
of islet transplants, it is limited by the need for immune-modulating drugs, as well as the 
high number of islets needed for transplant: the endocrine portion equivalent from up to 
three pancreata per recipient, derived from cadaveric sources (17). Even considering these 
limitations however, the benefits gained to patients seem to outweigh the risks, such as 
increased circulating C-peptide levels, decreased HbA1C, and improved micro-vascular 
health (20). Indeed, recent refinements in the procedure have allowed most patients insulin 
injection independence for >3 years post-transplant (21). 
 
1.2  Pancreas anatomy and function 
The head of the pancreas is attached at the initial curve of the duodenum and 
stretches across the abdomen where the tail attaches to the spleen. The pancreas has dual 
functions: the exocrine (acinar) cells produce digestive enzymes and bicarbonate, which 
access the intestine by the highly branched ductal system; and the regulation of blood 
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 glucose by the endocrine component, the islets of Langerhans, which account for ≤2% of 
the organ (22). A schematic illustration of the pancreas anatomy is shown in Figure 1.1 (23).  
The islets of Langerhans contain 5 distinct endocrine cell types, each of which 
produces its own hormone. Pancreatic α (alpha) cells release glucagon, which raises glucose 
by releasing glycogen from the muscle and liver, whereas β (beta) cells release insulin, 
which lowers blood glucose concentrations by stimulating glucose uptake in the liver, 
muscle and adipose tissues; these two hormones act synergistically to maintain glucose 
homeostasis. δ- (delta) cells produce somatostatin (or growth hormone-inhibiting hormone, 
GHIH), a  peptide hormone that regulates the endocrine system and affects 
neurotransmission, cellular proliferation, and gastric emptying (24,25). ε- (epsilon) cells 
produce ghrelin, found also in the stomach, which acts to stimulate appetite (26–28) and is 
the counter-regulatory hormone to leptin. γ-cells (also termed PP cells) produce pancreatic 
polypeptide, which acts to self-regulate both endocrine and exocrine pancreas secretions 
(29,30). 
In the rodent pancreas, α-cells are located in the mantle of the islet, and account for 
14-20% of islet mass, whereas β-cells are located in the islet core, representing 75-80% of 
islet mass (31–33).  δ -cells account for 10% of islet cell proportion (31), with γ-cells and ε -
cells composing the remaining minority compartments. In the human, the proportional 
representation and islet architecture is more heterogeneous: the β-cell proportion varies 
widely from 28-75% (32,34,35), whereas α-cells represent 10-65% of cells, and δ-cells 
account for 1.2-22% (32). Moreover, the cells are not organized in a core-mantle 
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Figure 1.1. Anatomical location of the pancreas  
The pancreas is located within the abdomen, and serves to accommodate 
dual functions: the production of digestive enzymes and bicarbonate by 
exocrine (acinar) cells, which access the intestine by the highly branched 
ductal system; and the regulation of blood glucose by the endocrine 
component, the islets of Langerhans, which account for only 1-2% of the 
organ. The islets contain 5 distinct cell types, each of which makes its own 
hormone: β (green, insulin), α (red, glucagon), δ (blue, somatostatin), γ 
(yellow, pancreatic polypeptide), and ε (purple, ghrelin).  
 
Reproduced from McKinley, M. and O’Loughlin V.D. Human Anatomy, 2nd 
Edition, 2003.  
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 arrangement as found in rodent islets (31,36), which may be due to alterations in their 
vasculature arrangement (36).  
 
1.3  Pancreas development 
Pancreas development begins in the mouse at embryonic day (e) 8.5 (Figure 1.2 
(37)), when the presence of the transcription factor and homeodomain protein Pancreatic 
duodenal homeobox-1 (Pdx1/Ipf1) delineates multiple structures, including the pancreas, 
stomach, duodenum, and bile duct (38,39), and which is expressed in all pancreatic cell 
progenitors (40). Pdx1 is known as the pancreatic master regulator, playing a critical role in 
early pancreas development,  as well as β-cell differentiation and the maintenance of 
mature β-cell function later in development (41).  Pdx1-/- mice present with complete 
pancreas agenesis and lethality shortly after birth (42), while inactivation of Pdx1 after bud 
formation prevents any further islet or acinar differentiation (43–45). By e9.0-9.5, two 
pancreatic lobes – dorsal and ventral – arise from the posterior foregut, in a region of pre-
patterned epithelium (37,46,47), as shown in Figure 1.2. 
This early epithelium begins an evagination process into the surrounding 
mesenchyme, as epithelial buds form at a bulge of primary pancreatic multipotent 
progenitor cells (47) (MPC, red, Figure 1.3A (48)). Each pancreatic bud develops into an 
extensively branched ductal tree between e10.5-e12.5, forming two primordial organs, in a 
phase termed the primary transition (Figure 1.2). Endocrine cells arise from progenitor cells 
present within the e9.5 gut endoderm in the ductal epithelium, while the acini and ducts 
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Figure 1.2. Mouse pancreatic development 
On embryonic day 8 (e8), patterned epithelium of the primitive foregut 
forms dorsal pancreas (DP) and ventral (VP) buds by e9.5. These buds then 
develop into branching ducts and undifferentiated epithelium  by e12.5, 
during the first (developmental) transition. The undifferentiated epithelium 
contains scattered single endocrine cells. The buds begin to differentiate 
into endocrine and exocrine cellular lineages by e14, with proliferation and 
expansion at the second transition. By e15, the two pancreata rotate, fuse, 
and form a nearly developed pancreas by e19, containing the endocrine 
cells organized into isolated clusters, termed the islets of Langerhans (third 
transition). The tertiary transition is characterized by the maturation of 
endocrine cells, continues for until weaning at postnatal day 21. The 
representative transcription factors expressed during the program of 
development are indicated in blue. The approximate embryonic age (in 
days) is designated for each stage of development.  
 
Reproduced from Habener JF, Kemp DM, Thomas MK. Minireview: 
transcriptional regulation in pancreatic development. Endocrinology. 
2005;146(3):1025–34. Permission granted from The Endocrine Society. 
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Figure 1.3. Mouse pancreas organogenesis  
A: Upper diagram: A region of gut tube epithelium becomes pancreas-specified 
around E9, at a bulge of pancreatic multipotent progenitor cells (MPC, red), which 
expands to form a bud. At E11, cells within this bud initiate polarization and 
constriction, forming multiple microlumens. Coalescence and proliferation at e12.5 of 
the lumen produces epithelial tubes by e14.5. Ultimately, these tubes remodel, 
forming a ductal tree as part of the mature pancreas. Lower diagram: Epithelium 
specialization towards acinar (red), or endocrine/duct lineages (blue/green), which 
delineate from cells within the tip or trunk. Tip and trunk compartmentalization occurs 
around the time of tube formation (E12). Tip regions are distributed broadly 
throughout the epithelium. MPC that form tip regions (red) proliferate and undergo 
tip-splitting, causing outgrowth into the mesenchye, and generating additional trunk 
epithelium with bipotentiality for endocrine (blue) or duct (green) fates. ‘Mature 
pancreas’ shows that acinar cells (red) form the tips of branched ducts. Islets comprise 
β-cells (blue) surrounded by other endocrine cell types (yellow). B: Transcription 
factors expressed at each stage of pancreas development. Note that the same ductal 
epithelial transcription factors are expressed in early development as well as late.  
 
Reproduced from Pan FC, Wright C. Pancreas organogenesis: from bud to plexus to 
gland. Dev Dyn. 2011;240(3):530–565.  Permission granted from John Wiley and Sons.  
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 develop by e14.5 (49). These early endocrine cells contain minimal amounts of glucagon; by 
e10 – e10.5, they co-express glucagon and insulin, then divide into distinct lineages (37). 
Early lineage tracing experiments by Herrera showed that adult α- and β-cells derive from 
independent lineages (50); however, recent experiments by the same group have suggested 
that α-cells retain the ability to transdifferentiate to β-cells under conditions of extreme β-
cell loss (51), and by forced Pdx1 expression (52). Conversely, β-cells have been shown to 
trans-differentiate to α-cells during T2D diabetes progression (53), further confounding the 
loss of β-cell mass, and which was postulated to represent β-cell dedifferentiation, and 
failure as a result of stress (54).  
By e12.5, these MPCs have proliferated, the epithelium has stratified, and epithelial 
tube formation has occurred (Figure 1.3A).  Around e14, the pancreatic buds begin to 
differentiate into distinct endocrine and exocrine lineages, a phase termed the secondary 
transition. Zhou and colleagues found that this differentiation was due to “tip-trunk 
segregation” of the epithelium, where the tip cells become acinus, and the trunk cells 
remain as uncommitted trunk (duct-endocrine) cells (55) (Figure 1.3A). These bipotent 
trunk cells are identified by a signature of transcription factors including Pdx1, SRY (sex-
determining region Y) box9 (Sox9)(56–58), hepatocyte nuclear factor 1 beta (Hnf1β/Tcf2) 
(59), and hepatocyte nuclear factor 6 (Hnf6) (60) (Figure 1.3B).   
After the bifurcation of the exocrine compartment from duct-endocrine fates, the 
expression of the bHLH transcription factor neurogenin3 (Ngn3) represents a lineage switch, 
distinguishing cells that become endocrine pancreas from ductal epithelium (61–63)  (Figure 
1.3B). Ngn3 is expressed only in endocrine progenitors and is promptly down-regulated 
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 during terminal differentiation (62). Ngn3-/- animals completely lack all pancreatic endocrine 
cell types (64).  
Around e15, the dorsal and ventral pancreata rotate and fuse, forming a nearly 
complete pancreas by e19 as shown in Figure 1.2. Immature β-cells express multiple 
transcription factors after fate specification from Ngn3+ precursors, including v-Maf 
musculoaponeurotic fibrosarcoma onco- gene homologue A (MafA) and MafB (Figure 1.4 
(65)).  Between e14-birth, MafA levels increase and MafB levels decrease in β-cells, and 
MafB expression becomes restricted to α-cells (65,66).  
By e19, the endocrine cells have organized into clusters, the islets of Langerhans. 
Mature β-cells express multiple transcription factors, including Neurogenic Differentiation1 
(NeuroD/Beta2) (67), Paired box gene4 (Pax4) (68), Pax6 (49,69), Homeobox protein 
Nkx_2.2 (Nkx2.2) (70), and Nkx6.1 (71). The transcriptional cascade during islet 
development is shown in Figure 1.3B.  After e19-e21/P0 (birth), endocrine cells undergo 
further maturation during the third developmental transition, which continues for 2-3 
weeks after birth (37). It is generally assumed, but not entirely proven, that islet cell 
regeneration in the postnatal period, or progenitor cell differentiation in vitro, will proceed 
by similar (canonical) pathways.  
After bifurcating from the common bipotent trunk progenitor state shared with 
endocrine cells, duct cells maintain the expression of some transcription factors (Sox9, 
Hnf1β, and Hnf6) but notably lose expression of Pdx1, whilst gaining functional markers 
such as carbonic anhydrase II (CAII) (72) and cytokeratin 19 (CK19) (73).  
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Figure 1.4. The transcription factors MafA and MafB undergo a 
developmental switch during β-cell maturation 
In early development (e13.5), β-cells exhibit high expression of MafB and 
low levels of MafA; by the secondary transition at e14.5, MafA expression 
has increased significantly. By birth, these two transcription factors 
demonstrate a developmental switch, with MafA expression overtaking 
that of MafB. By postnatal day 28, MafA is expressed in high proportion in 
insulin-expressing β-cells, whereas MafA expression is generally restricted 
to the glucagon-producing α-cells.   
 
Reproduced from Artner I, Hang Y, Mazur M, Yamamoto T, Guo M, Lindner 
J, Magnuson MA, Stein R. MafA and MafB Regulate Genes Critical to Beta 
Cells in a Unique Temporal Manner. Diabetes. 2010;59(October):2530–39. 
Copyright © 2010 American Diabetes Association, Inc. 
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 In early postnatal mammalian life, further macro-organization of the endocrine 
pancreas occurs. Meier et al showed that neonatal human pancreas displayed significant 
small clusters of β-cells, and which organized into proto-typical islet structures during 
childhood (74). They, and others (75), found that these clusters of β-cells were more 
proliferative than those found within islets in the young human and rodent. The 
coordinated expansion of these small clusters, and fission of islet-like clusters contributes to 
the fully mature pancreas (75). Consistent with this, the proportion of β-cells present within 
clusters declines by adulthood, instead being found in islets (75,76).  
 
1.4  β-cell function 
In the β-cell, two other markers of mature function are glucokinase (Gck) and the 
glucose transporter-2 (Glut2). Gck is known as the “glucose sensor” (77,78), and is involved 
in the first step of glycolysis by phosphorylating glucose (79,80). Glut2 is a trans-membrane 
carrier protein which allows the facilitated movement of glucose across cell membranes in 
liver, kidney, and pancreatic β-cells, and is stimulated to initiate transport by high glucose 
concentrations outside of the cell. In humans, this protein is encoded by the SLC2A2 gene 
(81).  Glut2 is required for the initial step in glucose-induced insulin secretion by glucose 
uptake (82,83).  In studying metabolic disease,  is important to note that human β-cells use 
both GLUT2 and GLUT1 (preferentially GLUT1), whereas in the rodent pancreas, β-cells 
exclusively utilize Glut2 (84). Pdx1 is involved in trans-activating Glut2 in addition to its role 
in activating the insulin gene (41).   
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 1.5  Sources of (new) β-cells, islet plasticity, and regeneration 
The availability of a renewable pool of insulin-producing cells would alleviate the 
need for cadaveric-sourced islet transplants, and much work has focussed on identifying 
new or replicable sources of β-cells. The β-cell mass in vivo is maintained by a delicate 
balance of cellular growth and regression. In the neonatal period, rodents undergo 
significant remodelling of their pancreatic endocrine component, with increased rates of 
replication, neogenesis, and apoptosis (85). These processes lead to an increase in β-cell 
mass soon after weaning (86); but both replication and apoptosis drop significantly 
thereafter. Under normal circumstances, islet neogenesis (the generation of new pancreatic 
endocrine cells) in the rodent ceases after birth (87),  although examples of endocrine 
regeneration after injury are well documented (88).  Central to this debate are two 
expansive, yet related, questions: (i) under what circumstance(s) is β-cell regeneration 
possible? and, (ii) what is (are) the source(s) of the regenerating cells?  
Two broad categories for the generation of any cell are the replication of pre-
existing cells, and the differentiation from stem/progenitor cells. In the pancreas, these 
have been depicted by Bonner-Weir in Figure 1.5 (89) as (i) replication of pre-existing β-
cells, (ii) differentiation from ductal progenitor cells, (iii) differentiation from 
stem/progenitor cells outside of the ductal epithelium, and (iv) acinar transdifferentiation. 
The first 3 will be discussed in enhanced detail below.  
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Figure1.5. Sources of new β-cells within the pancreas  
Four broad categories of cell source within the pancreas are (i) replication 
of pre-existing β-cells, (ii) differentiation from progenitors present within 
the ductal epithelium, (iii) differentiation from stem/progenitor cells 
outside of the ductal compartment, and (iv) transdifferentiation from 
acinar cells.  
 
Reproduced from Bonner-Weir S, Weir GC. New sources of pancreatic 
beta-cells. Nat Biotech. 2005;23(7):857–61. Permission granted from 
Nature Publishing Group.  
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 1.5.1   Replication of pre-existing β-cells  
1.5.1.1  β-cell turnover with age 
In rodents, β-cell proliferation occurs postnatally at a rate of between 0.5% (90) to 
~4% daily (85,91,92) between P30 – 100, and is countered by apoptosis rates of 
approximately 0.5% (91,92). This rate of proliferation then decreases to <1% per day after 1 
year of age, with some estimates of β-cell replication at only ~0.2%/24 hours (93–95), 
indicating an increase in β-cell mass during early life (91).  Multiple publications have 
addressed the issue of tissue turnover and β-cell mass expansion with age, and the 
consensus findings have suggested that the β-cell is capable of efficient compensatory 
proliferation in young animals, which diminishes with advancing age (88,95,96).  
Human β-cell proliferation estimates have shown similarly low rates, with the few 
available publications indicating that the highest rate of β-cell replication occurs during the 
mid-fetal period (17-32 weeks gestation) at 3.2 ± 0.5% (97,98). By birth, the highest rate of 
proliferation was 2.6% in one case (74), and decreased thereafter, with β-cells replicating 
only 0.2%/day by early adulthood (74,98). Cnop et al showed that 97% of the human β-cell 
population was established by the age of 20 years (99). It was noted that in young humans, 
the proliferation was highest in small islets and scattered β-cells, there was wide variability 
between samples, and surprisingly, there was no wave of proliferation during adolescence 
as hypothesised (74). Furthermore, data from human pancreas studies suggest a mitigated 
ability of β-cell mass to proliferate based on physiologic demand when compared to young 
rodents (100), and that there was no adaptive response to increased insulin demands by 
replication in adult islets (99). Figure 1.6 demonstrates the decline in human β-cell 
proliferation rate in the first 20 years of life (74).  
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Figure 1.6. β-cell proliferation rate decreases with advancing age  
While there is decreasing proliferation frequency with increasing age 
overall, intra-sample variability is high.  
 
Reproduced from Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, 
Bhushan A, Rizza RA, Butler PC. Beta Cell Replication is the Primary 
Mechanism Subserving the Postnatal Expansion of beta-Cell Mass in 
Humans. Diabetes. 2008;57 (June):1584–1594. Copyright © 2008 
American Diabetes Association, Inc.  
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 The mechanisms which control the cell cycle in pancreatic β-cells are still not yet 
fully elucidated. Genetically, cell cycle progression requires DNA replication (S phase), and 
cell division or mitosis (M phase), which is halted between phases by a number of gaps (G). 
It has been shown that control of β-cell proliferation is greatly influenced by the cell cycle 
checkpoint at the G1/S phase transition (101,102). Successful transition from the G1/S 
checkpoint is accomplished via a family of transcriptional activators and repressors called 
the E2F proteins (102). The retinoblastoma protein (pRb), in addition to related pocket 
proteins p130 and p107, is regarded as the molecular brake on cell cycle progression, 
resulting in G1/S arrest (102). pRb binds preferentially to E2F-1, -2, and -3, which serves to 
repress their transcriptional activity (102,103). This process is further regulated by a group 
of proteins such as cyclin D1/D2 (104) and their associated cyclin-dependent kinases (CDKs), 
specifically CDK4 (105),  which act to promote β-cell proliferation.  Conversely, proliferation 
can be inhibited by up-regulation of such proteins as the INK4 cell cycle inhibitors. One such 
negative regulator is p16INK4a, which inhibits the CDK4-cyclinD2 complex in β-cells, and 
therefore inhibits cell cycle progression and cell proliferation. Moreover, expression of 
p16INK4a increases markedly with advancing age, further restricting the capacity for β-cell 
regeneration (96,106). This age-dependent decline in proliferation was recently shown to be 
a result of platelet-derived growth factor (PDGF) signalling, which controls the replication 
refractory period (107). Furthermore, it was also shown that nearly all G1/S cell cycle control 
molecules are located in the cytoplasm and not the nucleus (108), but actively traffic to the 
nucleus for proliferation initiation (109). A detailed schematic illustrating the genetic control 
of β-cell replication is shown in Figure 1.7 (109). Interestingly however, the age-dependent 
decline in β-cell proliferation was demonstrated to be reversible when adult quiescent β-
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Figure 1.7. Old and new models for β-cell proliferation and progression 
through the G1/S checkpoint  
Previous (A) and recent (B) models of β-cells at quiescence, and new models 
of successful (C) and unsuccessful (D) transition through the G1/S checkpoint 
during β-cell proliferation. The new model indicates a trafficking of cell cycle 
inhibitors and associated proteins including Cdk6 and cyclin D3 from the 
cytoplasm into the nucleus.  
 
Reproduced from Fiaschi-Taesch NM, Kleinberger JW, Salim FG, Troxell R, 
Wills R, Tanwir M, Casinelli G, Cox AE, Takane KK, Srinivas H, Scott DK, Stewart 
AF. Cytoplasmic-nuclear trafficking of G1/S cell cycle molecules and adult 
human β-cell replication: a revised model of human β-cell G1/S control. 
Diabetes. 2013;62(7):2460–70. Reprint available for teaching, copyright © 
2013 American Diabetes Association, Inc.  
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 cells were transplanted into young mice. This phenomena was postulated to be the result of 
a circulating β-cell trophic factor present in early life, and independent of p16INK4a 
expression (110). This new data opens up the field to new therapeutic options for targeting 
β-cell replication and regeneration.  
In a now-seminal publication, Dor and colleagues from the Melton group proposed 
that all (postnatally formed) adult β-cells arise from pre-existing β-cells, and not from stem 
cell differentiation (111). The group performed a pulse-chase experiment using the 
transgenic mouse model RIPCreER;Z/AP, which constitutively tags a subset of β-cells with a 
human placental alkaline phosphatase (HPAP) reporter protein after injection of the 
selective estrogen receptor modulater, tamoxifen (TM). The HPAP-tagged β-cells were then 
followed over the course of a year. They found that the ratio of tagged: untagged β-cells 
remained constant, indicating that no new β-cells arose from non- β-cell source, or that the 
contribution from stem cells was negligible. This was similarly concluded by the Kushner lab 
using sequential thymidine labelling of β-cells (112). However, there are caveats to this 
restrictive conclusion, including the lineage-tracing system utilized, which relies on 
interpretation of the frequency changes in labelling rates from a small percentage of tagged 
cells, with some inherent leakiness of the Cre transgene, as well as assessment on a small 
sample number (113).  
The low rate of β-cell replication combined with the lack of definitive evidence for a 
β-cell stem/progenitor population would then suggest that the endocrine pancreas has a 
limited ability for growth in the postnatal setting; however, there are physiological instances 
documented where significant β-cell expansion is possible, such as during pregnancy (114–
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 116), or in response to obesity (34,117,118).  Saisho and colleagues reported that in 
humans, a 50% increase in β-cell mass was found in (non-diabetic) obese patients (119). β-
cell proliferation is also affected by various physiological stimuli, including glucose 
metabolism: sustained exposure to hyperglycemia has been shown to induce a modest 
increase in β-cell mass (120), and genetic defects in Gck show reduced β-cell proliferation, 
whereas activation of the enzyme increased proliferation (121). Related to these 
phenomena, insulin resistance in patients with T2D has been shown to promote an increase 
in β-cell proliferation (122–124). This has been suggested to be the result of a secreted 
protein termed “betatrophin” from liver and adipose cells, which selectively, and strikingly, 
increased β-cell proliferation in both mice and humans (125). The potential therapeutic 
opportunity provided by this new hormone is staggering in its scope for human disease 
modulation, predominantly for patients with T2D.  However, recent evidence has somewhat 
tempered the supposition of this hormone to be the “magic bullet” for curing the disease 
alone, as the effects seen in mice were not replicated in human islet transplant experiments 
(126).  
Combining both aging and disease, studies have examined islet/endocrine function 
from patients with long standing T1D. Recent reports have challenged the presumption that 
β-cell destruction is a one-time, static process, instead showing evidence for β-cell 
regeneration attempts in patients with long-term T1D (16,127). The Medalist Study 
examined histological sections from 9 pancreata donated post mortem of patients with >50-
year duration of T1D (128). Of 4 pancreata selected based on positive antibody titres, two 
showed evidence of insulin+ TUNEL+ (apoptotic) cells, and one pancreas exhibited insulin+ 
Ki67+ (proliferative) cells, indicating active tissue turnover (128).    
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 What is evident from these reports is that the rate of β-cell apoptosis outstrips the 
rate of β-cell regeneration/proliferation. However, reversal of T1D may be accomplished by 
mitigating the auto-immune destruction of the β-cell and allowing endogenous 
regeneration to occur. This could be provided by autologous hematopoietic stem cell 
transplant, which has shown to be effective in other autoimmune diseases including 
multiple sclerosis (129), or by immuno-modulatory therapy (130). However, the etiology 
and progression of T1D, with substantial loss of β-cell mass prior to overt symptoms, may 
limit full endogenous regeneration from occurring even if the autoimmune destruction can 
be controlled. Immuno-modulatory therapy may therefore be of use only for patients 
previously identified as at-risk for diabetes development, and not necessarily those with 
established disease present.  
 
1.5.1.2  Models of β-cell injury and regeneration 
Multiple injury models have been shown to induce endocrine regeneration, such as 
partial pancreatectomy (Px) (111,131,132), pancreatic duct ligation (PDL) (133–136),  the 
injection of the β-cell toxin streptozotocin (STZ) or its related drug, alloxan, and recently, by 
genetically-based methods of specific β-cell ablation.  
 
Partial pancreatectomy 
Partial pancreatectomy involves the surgical resection of up to 90% of the pancreas 
in rodent models, and Bonner-Weir and colleagues have performed multiple studies 
demonstrating both endocrine and exocrine regeneration capacity in the weeks following 
surgery (131,132,137–139). Dor and colleagues also performed Px in parallel to the aging 
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 model so as to ascertain if there was a difference in developmental origin of newly formed 
β-cells formed during regeneration. They concluded that after Px, similar to aging, β-cells 
from adult mice primarily arose from pre-existing β-cells, and not progenitor cell source 
(111).  
 
Pancreas duct ligation 
Pancreas duct ligation involves surgically obstructing the pancreatic duct, causing 
digestive enzymes to be shunted, and hence accumulate, in the ligated portion of the organ. 
This initiates severe inflammation and acinar apoptosis, similar to pancreatitis in humans 
(140). This model has been used extensively for islet regeneration (141–144), with new β-
cells putatively arising from the ductal compartment (135). However, recent evidence has 
indicated that these results have been confounded by extensive (global) pancreatic damage 
and that endocrine regeneration does not occur (145). 
 
STZ 
STZ and alloxan are glucose mimetics and as such, access the β-cell via Glut2 
(146,147); a structural comparison between the two compounds is shown in Figure 1.8 
(146).  STZ (2-deoxymethyl-nitrosurea-glycopyranose) destroys the rodent β-cell by 
transferring a methyl group to DNA, leading to DNA fragmentation. Attempts to repair DNA 
by stimulation of poly (ADP-ribose) polymerase leads to cellular depletion of NAD+ and ATP 
stores (148,149), and necrosis of the β-cell ultimately causes hyperglycemia within days of 
administration (147,150–152). However, due to its use of Glut2 as a mode of entry, other 
cell types which utilize this transporter are also damaged after drug administration (e.g. 
23
Figure 1.8. Schematic illustration showing the structural similarities of 
the β-cell toxin streptozotocin (STZ) to glucose 
 
In rodents, both STZ and glucose enter the pancreatic β-cell via the glucose 
transporter Glut2.  
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 liver, kidney), and care must be taken to avoid damage to distal organs which can confound 
interpretation of the diabetogenic effect of the drug (147). Moreover, human β-cells, which 
predominantly utilize GLUT1, are less susceptible to these effects than rodent β-cells (153). 
In rodents, STZ has also been shown to induce inflammation and peri-islet lymphocyte 
infiltration, suggesting that it not only causes β-cell apoptosis and hyperglycaemia, but also 
closely models TID disease development. However, this response is more classically seen 
after multiple low-dose STZ treatment, and not after a single bolus (154,155).   
 Interestingly, the regenerative capacity after administration of STZ is temporally 
defined: rodents given STZ during the neonatal time period can partially regenerate their 
endocrine pancreas (96,150,156–162), whereas the regenerative response is mitigated 
when the drug is administered in adulthood (96,146). The regenerative capacity also 
depends partly on the timing of STZ administration: a single bolus of 100 mg/kg of the toxin 
at P0 showed glucose normalization and β-cell mass re-establishment by 3 weeks of age 
(150), whereas STZ given after P5 showed a less-robust regenerative capacity (146), 
although it was still seen in mice up to 6 weeks of age as compared to adults (96). The 
mechanism(s) behind this temporal regeneration capacity have not been determined. 
 
β-cell ablation by genetic manipulation 
A new mode of β-cell damage is the Insulin-rtTA;TET-DTA model, combining a 
transgenic mouse strain that expresses the reverse tetracycline-dependent transactivator in 
pancreatic β-cells (Insulin-rtTA)  with a mouse strain that expresses the diphtheria toxin A 
(DTA) subunit under a rtTA-responsive promoter (TET-DTA) (163). In the presence of 
doxycycline, rtTA induces the expression of DTA, causing β cell apoptosis (164). The benefit 
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 of this model is that it specifically targets only the β-cell, and avoids confounding issues of 
inflammation, or effects on other organs that are observed in other injury models.  
Nir and colleagues found that after giving doxycycline (Dx), 70-80% of β-cells were 
destroyed and overt hyperglycemia and diabetes was noted. Interestingly, upon withdrawal 
of Dx, insulin expression normalized, islets regained their architecture to 90%, and there 
was a remission of hyperglycemia, although full glucose tolerance was only complete after 8 
months. These results were consistent regardless of the age at which the mouse β-cells 
were ablated. The authors then lineage traced the β-cells during this process, and found 
that the labelling indices of both regenerating and non-regenerating mice (injured and non-
injured, respectively) were the same, and that proliferation rates were the same between 
the two groups, leading to the conclusion that β-cell regeneration is possible, but the cell 
source was exclusively pre-existing β-cells (164).   
A separate publication from the same group then knocked out Pdx1-expressing 
pancreatic progenitor cells at multiple time points, using a similar diphtheria-toxin 
expressing strain (165). Here, the Pdx1tTA mouse was crossed with a tetODTA mouse: addition 
of tetracycline maintained the normal developmental program, while cessation of 
tetracycline induced Pdx1+-cell ablation. When tetracycline was administered throughout 
pregnancy or after e9.5, the progeny developed normally. However, if tetracycline was 
withdrawn entirely, or after e11.5, the resultant pups had near complete pancreatic 
agenesis. These results suggested that there are no stem cells in the embryonic or adult 
pancreas, and that final pancreas size (and by default, regenerative ability), is restricted by 
the number of progenitor cells present between e8.5-e12.5. Knocking out these progenitor 
cells before e12.5 completely abrogated the formation of Pdx1+ pancreatic progenitor cells 
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 with the ability to rescue normal pancreas development.  The authors stated, “...our studies 
show that compensatory growth during pancreas development is either quite limited or 
does not occur at all. Thus, embryonic progenitor cells represent a critical and limiting 
determinant of pancreas size” (165).  
Another study proposed that the restriction of β-cell proliferation in aged mice was a 
result of the injury model used (such as STZ, high fat diet, or partial pancreatectomy), and 
instead subjected their mice to β-cell damage by DTA using the transgenic approach as 
described previously (166). Addition of Dx to very old (25 month old) insulin-rtTA;TET-DTA 
mice caused a disruption in both normoglycemia and islet architecture; removal of the toxin 
resulted in a 3-fold increase of replication from basal rates. Addition of a glucokinase 
inhibitor, which enhanced glycolysis rates, had a similar effect (166).  These results indicate 
that under multiple circumstances, β-cells are generated postnatally from pre-existing β-
cells.  
 
1.5.1.3  Generation of insulin-expressing cells in vitro 
As has been shown, the majority of β-cells are formed by replication of pre-existing 
β-cells in vivo, which normally exhibit a low rate of cellular proliferation after birth. Since 
islets are in such high demand for use in transplant, then alternative sources of insulin-
expressing cells are required, and expansion of (pre-existing) β-cells in vitro is an attractive 
option. Efforts to alter β-cell proliferation rate directly have generally failed, but 
differentiation techniques have been relatively more successful in vitro (167,168). Cellular 
identity is broadly determined by the interplay of genetic (and epigenetic) and 
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 environmental factors which control gene expression in a cellular system (169). Therefore, 
instructive changes to either/both the environment and/or the genes present may effect a 
change in cell fate. Since all pancreatic cell types arise from a common progenitor cell type, 
in vitro differentiation is a conceivable approach.  Dedifferentiation can be defined as the 
loss of mature, defining and functional characteristics from a partially or terminally 
differentiated cell type (169), whereas transdifferentiation is broadly defined as a change 
from one differentiated phenotype to another, involving morphological and functional 
phenotypic markers (170). These operational terminologies are utilized to describe the 
differentiation, dedifferentiation, or transdifferentiation of pancreatic cells towards or away 
from the genetic, morphological, and functional properties of mature β-cell. Importantly, 
cellular transdifferentiation can be induced by a multitude of factors, such as direct 
reprogramming induced by transcription factor over-expression, or alternatively by 
modified progression through dedifferentiation to a multipotent progenitor-like stage, and 
subsequent redifferentiation. These cellular fate (re)specifications are depicted by Puri et al 
in Figure 1.9  (169), and show that terminal cellular differentiation in the endocrine 
pancreas is not as unidirectional as previously supposed.  
One group published multiple reports over a number of years on the culture of 
human fetal pancreas cells, and demonstrated that these cells could be induced to expand 
and express insulin (171–177). They and others induced islet expansion and/or 
differentiation by the  use of in vitro techniques, such as extracellular matrix selection 
(175,178,179), or specific combinations of growth factors such as hepatocyte growth factor 
(HGF) (180), fibroblast growth factor-2 (FGF-2), keratinocyte growth factor (KGF/FGF-7) and 
insulin-like growth factor – II (IGF-II) (177,181), activin, betacellulin, exendin-4, and HGF 
28
Figure 1.9. Transition states as a result of environmental/genetic 
manipulation or stress, and relationship to pancreatic disease.  
Illustration of differentiation potential of cells, resulting from either 
stress/disease, or by genetic and/or environmental manipulation. Note that 
“transdifferentiation” can occur by direct means from “normal” (1), or by 
prior “dedifferentiation” (2). Regeneration is hypothesized to occur by a 
return to “ normal” from the “dedifferentiated” state.  
 
Reproduced from Puri S, Folias AE, Hebrok M. Plasticity and 
Dedifferentiation within the Pancreas: Development, Homeostasis, and 
Disease. Cell Stem Cell. 2014:1–14. 
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 (182), basic FGF (bFGF) and leukemia inhibitory factor (LIF) (183), epidermal growth factor 
(EGF) and cholera toxin (179,184), or insulin/ transferring/selenium (ITS) (185), and 
generally, the use of serum-free media.  
Many groups contended that the resultant cells, with extensive proliferation of 
fibroblast-like cells, had arisen from β-cells, due to the re-expression of insulin (186,187).  
However, the insulin generated from in vitro culture was much lower than would be found 
in vivo.  Epithelial-to-mesenchymal transition (EMT) and its subsequent reversal (MET) have 
been proposed as a requirement for differentiation (188), but there is now substantial 
evidence that it is not causally related (182,183).  
The advent of lineage tracing technology allowed β-cell fate to be followed during in 
vitro culture conditions, and demonstrated that the majority of mouse β-cells were, in fact, 
eliminated from culture (167,168,182,183,185).  A few studies were able to dedifferentiate 
a small subset (<5%) of adult mouse β-cells (167,168) or adult human β-cells (189) to non-
insulin-expressing states, showing some β-cell dedifferentiation potential.  Why some 
protocols have resulted in successful β-cell differentiation and survival, while others did not, 
has yet to be determined. Moreover, it also remains to be determined why some β-cells are 
capable of differentiation whereas the majority of them are not.  Interestingly, it emerged 
that human β-cells potentially retain a higher plasticity potential than do mouse β-cells 
(167,190), which was postulated as due to β-cell “chromatin memory” (167), although the 
mechanisms behind this have not been elucidated.  
Collectively, these data would suggest that replication of pre-existing β-cells 
accounts for the de novo generation of the majority of postnatal β-cells. Indeed, replication 
of existing β-cells may be the default mode of endocrine mass maintenance; however, the 
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 contribution from putative progenitors, or the situations in which they are required, has not 
been thoroughly examined to exclude them entirely.   
 
1.5.2   Differentiation of stem/progenitor cells to β-cells 
An alternate mechanism for the generation of insulin-producing cells is through 
directed stem/progenitor cell differentiation (Figure 1.5 (89)).  The use or role of 
stem/progenitor cells in medicine and tissue repair, especially in the field of diabetes, has 
been hotly debated and anticipated.  Multiple examples of endocrine regeneration have 
prompted investigation into the role of stem cells. A widely accepted definition of any stem 
cell is based on functional properties, exhibiting an unlimited capacity for self-renewal and 
retaining the ability to generate multiple cell types (or, multi-potentiality), which may or 
may not be in response to injury. A progenitor cell, on the other hand, is a proliferative cell 
with a limited capability for self-renewal and which is most often uni-potent (191,192). The 
distinction between these two cell states is often fluid and vaguely indeterminate in the 
literature, but may yield important and definitive outcomes for medicine. Similarly, 
subdivisions in definition exist for the somatic, or tissue-specific, stem cells vs. embryonic 
stem cells, namely that the latter demonstrates the capacity to generate progeny across all 
primary germ layers. However, precedents exist to suggest that this is not always rigidly 
adhered to, as has been demonstrated by haematopoietic and neural stem cells forming 
tissues from germ layers other than mesoderm- and ectoderm-lineage, respectively (193–
196).  
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 Endogenous stem cell repair mechanisms have been demonstrated following 
hyperglycemia and during endocrine regeneration. Transplants of mesenchymal stem cells 
(MSCs) after injury aided in the endogenous regeneration of tissue, instead of direct 
differentiation from stem cells to β-cells (197).  In some cases composite cells from 
MSCs/endothelial cells were detected (198), which assisted in revascularization of islets or 
counteracted innate immunity response after transplant (199).  This action was replicated 
by endogenous hematopoietic stem cells homing to injury site and enhancing β-cell mass 
regeneration through endothelial interaction (161,200). That the stem cells did not directly 
differentiate into new tissue either in vivo or after injecting ex vivo was perhaps surprising, 
implying instead that regeneration occurred through differentiation of tissue-specific 
stem/progenitor cells, and/or replication of surviving cells, rather than activation of 
haematopoietic stem cell differentiation.  
Bone-marrow-derived progenitor cells purified based on aldehyde deydrogenase 
(ALDH) activity, a conserved characteristic of multipotent progenitor lineages, were shown 
to correct hyperglycemia in mouse models of diabetes. When uncultured ALDHhi cells were 
transplanted to STZ-treated recipients, islet-specific proliferation and pro-angiogenic 
programs were induced. If the ALDHhi cells were instead cultured prior to transplant, an 
increase in small islet clusters was noted, and which were associated with the ductal 
epithelium (201). This indicated that the subtype(s) of stem/progenitor cells presented to 
injured pancreas modulated distinct endogenous repair mechanisms. Moreover, if these 
ALDHhi cells were transplanted directly into the pancreas instead of injected intravenously, 
there was a significantly higher β-cell regeneration capacity. Furthermore, these cells could 
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 be obtained from umbilical cord blood rather than bone marrow, representing an easily 
obtainable stem cell source (202). 
Alternatively, a few groups have created insulin-producing cells directly from 
differentiation of human embryonic stem (hES) cells (203–205), although these cells had 
overall limited function.   In the past decade, insulin-producing cells have been successfully 
generated from hES cells in a system that could be reproducibly, and potentially safely 
applied for future clinical use (206–209). The approach was to use a 5-stage, stepwise 
protocol which recapitulates endocrine pancreas development, in conjunction with the use 
of large scale cell production and cell differentiation cassettes for transplants that reduce 
opportunities for autoimmune destruction (210). The differentiation of hES cells to extra-
embryonic and definitive endoderm was shown to be regulated by SOX7 and SOX17, 
respectively, and importantly, a stable population of endoderm progenitor cells could be 
generated by the constitutive expression of these transcription factors in hES cells (211). 
The Melton group has also successfully generated insulin-producing β-cells from hESCs, 
which were shown to be closer in phenotype to human fetal β-cells than adult β-cells, with 
poor glucose responsiveness and an immature β-cell transcriptome (212). Importantly, 
these results provide a novel toolbox of transcription factors where research efforts can be 
concentrated for future study. However,  despite these advances, these “beta-like” cells 
often require in vivo transplantation to be fully glucose-responsive (213),  and the 
associated risks of uncontrolled cell growth and teratoma formation are not to be 
underestimated, and therefore currently infeasible for human clinical application.  
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 1.5.3  Differentiation of β-progenitor cells found within the ductal epithelium  
Besides extraneous sources of stem cells, the search for intra-pancreatic progenitor 
cells is an attractive option. Significant data has historically suggested that the ductal 
compartment contains the predominant source of pancreas-derived β-cell progenitors 
(73,91,134,138,214–218).   
Developmentally, pancreatic endocrine cells are derived from cells within the ductal 
epithelium which share a common pathway via a bipotent progenitor with duct cells (55). As 
noted earlier, pancreatic duct ligation (PDL) has been shown to be an important mode of 
endocrine pancreas regeneration.  Wang et al performed PDL and found a replacement of 
acinar cells for ductal complexes and significant growth of islet tissue (134). There was a 
doubling of the β-cell population, an increase in small islets and islet clusters, and an 
increase in cell proliferation in the ligated portion of the organ, indicating islet neogenesis 
from cells resident within the duct.   
An in vitro model of expanded human ductal tissue was used by Bonner-Weir et al  
to effect differentiation to islet structures with the use of FGF-7, nicotinamide, and ITS (73). 
The authors found that after cellular expansion and transfer to Matrigel (a basement 
membrane compound containing primarily laminin, entactin, and collagen), small cyst-like 
structures were formed which expressed insulin as detected by immunohistochemistry, and 
exhibited a 2.3-fold increase in insulin secretion after glucose exposure as compared to 
basal levels (73). Similar results were recently demonstrated by Kim and colleagues (219) 
and by Corritore et al (220) The appeal of this approach is that the ductal compartment 
accounts for ~10% pancreas mass (140), and is entirely discarded after human islet 
isolation. If ducts indeed contain endocrine progenitors or can differentiate directly into β-
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 cells themselves, the shortage of available cells for diabetes treatment would be effectively 
solved. 
Indeed, while extensive data has proposed the contribution of cells from the ductal 
compartment to β-cell mass, the only way to definitively test that new β-cells conclusively 
arise from ductal epithelium is to perform lineage tracing experiments. However, the major 
hurdle for determining pancreatic cellular origins is that early ductal cells lack a definitive 
progenitor marker; while Pdx1 or Ngn3 can be used to assess newly-formed β-cells, and a 
series of transcription factors, such as NeuroD/Beta2, Nkx6.1, Nkx2.2, Pax4, Pax6, MafA, 
and MafB, or mature islet markers such as insulin, Glut2, or Gck can be examined, duct cells 
express the same markers early in development as well as late. Therefore, while transgenic 
technology has revolutionized the field of developmental biology to assess cellular origins, 
the use of mature duct-cell markers is a shortcoming in the absence of a more progenitor-
specific marker.  
In one study, the mature duct cell marker carbonic anhydrase II (CAII) was used to 
assess cell state during pancreas organogenesis from e14.5 to adulthood in the mouse and 
human (136). It was found that all duct cells in the adult pancreas of both species expressed 
CAII, as well as some α-cells in the mouse (72). CAII was notably absent in the β-cells.  CAII 
was expressed in embryonic duct cells as early as e18.5 (72). CAII was subsequently used to 
lineage trace duct cells using the CAII-Cre or CAII-CreER transgenic mice crossed with 
ROSA26 (R26R) mice, which adds a LacZ reporter (expressing β-galactosidase (β-gal))  to any 
cell expressing CAII after induction with tamoxifen (136).  Using longitudinal assessment and 
modelling of β-cell mass, the authors estimated that up to 30% of new β-cells in the 31 day 
old mouse did not arise from replication of pre-existing β-cells (85). When pancreata of 
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 CAII-Cre;R26R mice were examined at P0 and at P28, LacZ expression was found in ducts, in 
patches of acinar cells, and in some islets (marking both α- and β-cells), which increased 
with age, indicating that formation of new islets and acini from ductal progenitors occurred 
in the neonatal time period (136). The authors then used the inducible (CAII-CreER) strain 
combined with a duct ligation regeneration model to assess the role of CAII during pancreas 
remodelling, and found a significant increase in LacZ expression in the ligated portion of the 
pancreas (136), indicating a role for duct cells during endocrine regeneration.  
Xu et al (135) sought to address the contribution of pancreatic progenitor cells’ 
contribution to β-cell mass after injury, and used a recombinant lentivirus encoding two 
Ngn3-specific short hairpin (sh) interfering RNA molecules to tag Ngn3-expressing (Ngn3+) 
cells with an eGFP reporter protein immediately prior to PDL. The shRNA knocked down the 
majority of regeneration in the PDL pancreas, indicating that Ngn3 is required for β-cell 
regeneration. The authors then used the Ngn3-nLacZ mouse, which adds a β-gal reporter to 
any cell expressing Ngn3 at the time of tagging. It was found that 15% of all β-gal+ cells were 
present in the ductal lining 7 days after PDL, and co-expressed cytokeratin (CK). They also 
found that one third of all β-gal+ cells expressed hormones, including insulin.  The authors 
further showed that this was due to Ngn3+ progenitor cell differentiation to hormone+ cells, 
and not mature (hormone+) cell dedifferentiation, by using InsCre;R26R mice to trace 
mature insulin+ cells during injury. They found after PDL, all LacZ+ cells were Ngn3-, 
indicating that this was indeed progenitor cell differentiation.   
Criscimanna and colleagues similarly found that duct cells were capable of both 
endocrine and acinar cell regeneration using either PdxCre;R26DTR or ElacreERT2;R26DTR 
transgenic lines; interestingly, they also found that the mode of regeneration,  either 
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 recapitulation of the developmental program, or direct differentiation of duct to acinar 
cells, was directly associated with the severity of damage (221).  
These studies are countered by articles which examined the role of insulin+ cells 
present in the ducts during aging and after injury. One study lineage traced the early ductal 
transcription factor Hnf1β using an Hnf1β-CreER;R26R mouse model (59), and found, similar 
to other reports, that Hnf1β+ cells are precursors for all pancreatic- epithelial cell types 
(acinar, duct, and endocrine) during early gestation, which exclude acinar cell fates by mid-
gestation (59). However, it was reported that the Hnf1β+ cells do not contribute to 
endocrine cell fate after birth, at 6 months of age follow-up, or following two separate 
models of endocrine injury using PDL and alloxan treatment. The authors tried to reconcile 
their findings with the significant data that propose that duct cells are the progenitors for 
islets, and suggested instead that ducts share a “tissue milieu” that favors the formation of 
new endocrine cells. They further proposed that while some endocrine cells may reside in 
the ductal epithelium and expand after regenerative stimulus (such as injury), these cells 
were not ultimately derived from duct cells postnatally (59).   
Another paper sought to determine the origins of insulin+ cells found in the ductal 
epithelium  after injury, and found that insulin+ cells indeed arise from ductal epithelial cells 
during development, but not after birth (222). Using a model of ductal hyperplasia induced 
by transforming growth factor-α (TGFα), they lineage traced pancreatic cells and showed 
that the ducts had arisen in some limited cases from acinar cell trans-differentiation, but 
not from insulin+ cells.  The authors further reported that the majority of insulin+ cells 
present within the ductal epithelium had arisen from pre-existing β-cells and not duct or 
acinar cells (222). However, the authors conceded that up to 5% of these insulin+ cells 
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 contained the lineage marker from acinar cells, but concluded that this was due to 
either/both transgene “leakiness” (and not proof of acinar – or duct - to-endocrine 
transdifferentiation) or an insignificant contribution from those compartments.  This has 
been independently shown using a mucin1 (Muc1)-lineage tracing mouse model (223).  
Overall, many of these reports provide evidence in support of  current dogma, that 
β-cells primarily arise from pre-existing β-cells in the in vivo adult pancreas (111), during 
aging and after injury and consequent regeneration, indicating that the potential for 
contribution from ductal cells and/or ductal progenitors in the postnatal time period is 
limited. However, to dismiss the substantive data amassed previously would be imprudent, 
and differential interpretations of phenomena may be required.  
 
1.5.4  Differentiation of stem/progenitor cells within the endocrine pancreas 
The search for stem/progenitor cells present within the endocrine pancreas itself 
has yielded frustratingly little information, as proto-typical “stem” cells have not been 
readily identified within the pancreas as can be found in other organs, such as the intestine 
(192).  However, recent paradigm shifts have changed the focus to looking within the 
endocrine pancreas itself as the source of regeneration. Szabat et al traced human and 
mouse β-cells with a dual reporter system, using a lentivirus which differentially labelled 
Pdx1 and insulin. The authors reported that a subpopulation of adult β-cells from both 
species exhibited negative/low expression of insulin while maintaining expression of Pdx1 
(Pdx1+Inslowcells) in relatively high proportion (15-25%), which could differentiate into 
Pdx1+Ins+ cells without cell division, implying differentiation (224). Furthermore, these 
Pdx1+Ins- cells displayed a progenitor phenotype, lacking expression of Glut2, Gck, and 
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 MafA, whilst being proliferative. Interestingly, these Pdx1+Ins- cells could be sub-divided into 
two groups: those that matured into insulin-expressing cells, and those that maintained a 
progenitor phenotype (224).   
A separate study examined the role of nutritional insult in early life with regard to β-
cell regeneration potential (159).The authors found that there was no effect on Pdx1+Ins- 
cell number when mice were protein-restricted during gestation, or treated with STZ 
independently. However, the cells were present in higher proportion in pancreas exposed 
to STZ and low protein simultaneously, suggesting that the ability of progenitor cells to 
mature and differentiate to functioning β-cells was mitigated as a result of the in utero 
insults (159).  
 Data from Liu and colleagues directly contradicted work by Dor et al  (111), in that 
lineage tracing of the β-cell, using the same RIPCreER;Z/AP+/+ transgenic mouse model, 
resulted in an increase in HPAP+ (reporter) β-cell labelling with age, as well as the presence 
of HPAP+ insulin- cells after aging and STZ-mediated injury (225). They found that HPAP+Ins- 
cells demonstrated an immature phenotype, with expression of Pdx1 and MafB, and the 
lack of Nkx6.1 and Glut2. Furthermore, HPAP+ Ins- cells were proliferative after STZ as 
demonstrated by expression of Ki67, and were 2-fold smaller than typical β-cells. The 
relative proportion of HPAP+Ins- cells after injury was found to be 0.1% of all insulin+ (β-) 
cells. Liu and colleagues concluded that these cells represented β-cell progenitors which, by 
default of expressing the β-cell reporter, must have exhibited active insulin expression at 
the time of Cre induction. Only after injury or aging, and hence after differentiation to 
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 proto-typical mature β-cells, was insulin expressed, which accounted for the increase in 
HPAP+ labelled Ins+ cells with increased age (225).  
Seaberg et al found that rare cells within mouse islets and ductal preparations could 
form clonal spheres with the capacity to generate neural and pancreatic exocrine and 
endocrine lineages (226); these cells could then be further differentiated into functional β-
cells which demonstrated glucose-sensitive insulin release. The group determined that 
these cells were not derived from embryonic stem cell origin, nor from neural crest, nor 
from mesoderm-lineage, but instead from “multipotent precursor” (progenitor) cells found 
within the pancreas (226).  A subsequent study from the same group replicated 
experiments by Dor et al (111), and found that HPAP+ cells tagged non-β-cells after a long 
chase period including endocrine and non-endocrine cells, indicating that cell fate may not 
be as immutable as was previously stated (227). Moreover, after replicating the clonal 
sphere assay (226), it was revealed that these multipotent cells had derived from insulin-
expressing cells. However, the multipotent cells were found to represent a unique subset of 
β-cells in that they demonstrated decreased levels of Nkx6.1 and Pdx1, increased levels of 
Ngn3, and importantly, lacked Glut2. These cells were present within adult mouse and 
human islets in a proportion of <1/5,000, and could be differentiated in vitro to multiple 
endocrine lineages (including α, β, δ, and γ cells), exocrine cells,  and neural lineage cells 
including neurons, (neuro)glia, and oligodendrocytes (227). Moreover, after differentiation 
to β-cells, these were fully capable of ameliorating hyperglycemia after transplant, 
demonstrating their utility as functional endocrine cells (227).  
40
 Based on these reports, there is emerging evidence that β-cell progenitors are 
present within adult pancreas, although the relative contribution of these cells to normal 
physiology has not been determined, nor is it known whether they represent a therapeutic 
target for diabetes.  
 
1.6  Rationale  
Clearly, there are multiple routes to generating β-cells, notwithstanding of variable 
function. As was eloquently stated by AMJ Shapiro, pioneer of the Edmonton protocol, 
“…given the enormous clinical burden of diabetes, the search for alternative sources of 
regulated insulin-producing cells must continue, since the current supply from deceased 
donors cannot meet the demand” (18). Based on the evidence that (i) the generation of 
new β-cells occurs almost entirely by replication of pre-existing β-cells postnatally; (ii) the 
replication rate of mature β-cells is extremely low, and (iii) β-cells develop from a bipotent 
progenitor cell state which shares a common pathway early in development with duct cells, 
the differentiation of pre-existing β-cells to a ductal phenotype may allow the β-cell 
population the ability to expand in vitro.  These cells can then be re-differentiated “back” to 
insulin-producing cells for use in human transplants given the appropriate environment.  
Furthermore, since young mammals exhibit higher growth potential and more lineage 
plasticity than do mature ones, experiments will be conducted using neonatal tissue. 
Characterization of the cell type(s) capable of differentiation will be consequently 
accomplished.  
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 1.7  Hypothesis 
It is hypothesized that neonatal mouse β-cells demonstrate the ability to 
dedifferentiate into alternative cell types, including cells sharing characteristics of ductal 
epithelial cells, which can be subsequently redifferentiated into insulin-producing cells 
based on in vitro environmental cues. Furthermore, the β-cells which retain the capacity for 
differentiation will be involved during regeneration after pancreatic injury.  
 
1.8  Objectives 
 To determine the regenerative potential and lineage plasticity of mouse β-cells 
1. Demonstrate neonatal mouse islet cell plasticity in vitro  
a. Dedifferentiate neonatal mouse islets for the reversion to a proliferative 
ductal phenotype 
b. Establish if the dedifferentiated cells are capable of redifferentiation to 
insulin-producing β-cells 
c. Optimize in vitro conditions for these processes, and whether the cells are 
functional after transplant in vivo 
2. Lineage trace the β-cell in vitro using the transgenic mouse model RIPCre;Z/AP to 
establish whether cell dedifferentiation involves the β-cell 
3. Characterize resultant subpopulations of lineage plastic β-cells 
4. Assess the analogous population of β-cells within the human pancreas, and how it 
changes with age 
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 5. Determine why young rodents are capable of endocrine regeneration after STZ-
ablation but not in adulthood, using the transgenic mouse model RIPCreER;Z/AP.  
 
1.9  References 
1.  Barnett DM, Krall LP. The History of Diabetes. In: Joslin’s Diabetes Mellitus.; 2005:2–
17. 
2.  Schadewaldt H. The History of Diabetes Mellitus. In: Van Englehardt D, ed. Diabetes, 
its medical and cultural history. Springer Verlag; 1987:43–100. 
3.  Banting F, Best C. The internal secretion of the pancreas. J Lab Clin Med. 1922;7:251–
66. 
4.  Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the 
treatment of diabetes mellitus: preliminary report. CMAJ. 1922;145(10):1281–6. 
5.  Canadian Diabetes Association. The Prevalence and Costs of Diabetes. 2012. 
Available at: http://www.diabetes.ca/diabetes-and-you/what/prevalence/. 
6.  Aguirre F, Alwan A, Bowers R, Brown J, Dain K, Dahlquist G, Dodd S, Jacqmain O, 
Jeon C, Mbanya JC, Nicholls H, Patterson C, Pledge J, Reichmann G, Roglic S, Shaw J, 
Soltesz G, Weil C, Zhang P, Zhang X. IDF Diabetes Atlas. (Unwin N, Whiting D, 
Guariguata L, Ghyoot G, Gan D, eds.). Brussels: IDF; 2009. 
7.  Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 
2013;93(1):137–88. 
8.  Aiello LA, Aiello LP, Cavallerano JD. Occular Complications of Diabetes Mellitus. In: 
Kahn R, Weir G, King G, Jacobson A, Smith R, Moses A, eds. Joslin’s Diabetes 
Mellitus.Vol 14. 14th ed.; 2005:901–924. 
9.  Khan ZA, Chakrabarti S. Glucose-Induced Cellular Signaling in Diabetic Retinopathy. 
In: Tombran-Tink J, Barnstable CJ, Gardner TW, eds. Opthalmology Research: Visual 
Dysfunction in Diabetes. New York, NY: Springer New York; 2012:211–232. 
10.  Archer AG, Watkins PJ, Thomas PK, Sharma AK, Payan J. The natural history of acute 
painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry. 
1983;(46):491–499. 
43
 11.  Rask-Madsen C, He Z, King GI. Mechanisms of diabetic microvascular complications. 
In: Khan C, ed. Joslin’s Diabetes Mellitus,.Vol 14. 14th ed.; 2005:823–837. 
12.  Gruden G. Pathogenesis of diabetic nephropathy. In: Khan C, ed. Joslin’s Diabetes 
Mellitus.; 2005:853–866. 
13.  Szablewski L. Role of immune system in type 1 diabetes mellitus pathogenesis. Int 
Immunopharmacol. 2014;22(1):182–191. 
14.  Craig ME, Nair S, Stein H, Rawlinson WD. Viruses and type 1 diabetes: a new look at 
an old story. Pediatr Diabetes. 2013;14(3):149–58. 
15.  Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, 
Todd JA, Bonella P, Fear AL, Lavant E, Louey A, Moonsamy P. HLA DR-DQ haplotypes 
and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics 
consortium families. Diabetes. 2008;57(4):1084–92. 
16.  Meier JJ, Lin JC, Butler a E, Galasso R, Martinez DS, Butler PC. Direct evidence of 
attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 
diabetes. Diabetologia. 2006;49(8):1838–44. 
17.  Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, 
Rajotte R V. Islet transplantation in seven patients with type 1 diabetes mellitus using 
a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8. 
18.  Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, 
Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, 
Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, 
Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano 
L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton 
protocol for islet transplantation. N Engl J Med. 2006;355(13):1318–30. 
19.  Shapiro R, Jordan ML, Scantlebury VP, Vivas CA, Jain A, Chakrabarti P, McCauley J, 
Johnston J, Randhawa P, Rao A, Fung JJ, Corry RJ. Simultaneous pancreas-kidney 
transplantation at the University of Pittsburgh. Clin Transpl. 1999:217–21. 
20.  Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ, Ho S, Worsley D, 
Fung M, Meneilly G, Begg I, Al Mehthel M, Kondi J, Harris C, Fensom B, Kozak SE, 
Tong SO, Trinh M, Warnock GL. Reduced progression of diabetic microvascular 
complications with islet cell transplantation compared with intensive medical 
therapy. Transplantation. 2011;91(3):373–378. 
21.  Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, 
Odorico JS, Garfinkel MR, Levy M, Pattou F, Berney T, Secchi A, Messinger S, Senior 
PA, Maffi P, Posselt A, Stock PG, Kaufman DB, Luo X, Kandeel F, Cagliero E, Turgeon 
44
 NA, Witkowski P, Naji A, O’Connell PJ, Greenbaum C, Kudva YC, Brayman KL, Aull 
MJ, Larsen C, Kay TWH, Fernandez LA, Vantyghem M-C, Bellin M, Shapiro AMJ. 
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 
2012;35(7):1436–45. 
22.  McEvoy RC. Changes in the volumes of the A-, B-, and D-cell populations in the 
pancreatic islets during the postnatal development of the rat. Diabetes. 
1981;30(10):813–817. 
23.  McKinley M, O’Loughlin VD. Human Anatomy. In: Vol 2nd. 2nd ed.; 2003. 
24.  Gahete MD, Cordoba-Chacon J, Duran-Prado M, Malagon MM, Martinez-Fuentes 
AJ, Gracia-Navarro F, Luque RM, Castano JP. Somatostatin and its receptors from 
fish to mammals. Ann NY Acad Sci. 2010;1200:43–52. 
25.  Liu Y, Lu D, Zhang Y, Li S, Liu X, Lin H. The evolution of somatostatin in vertebrates. 
Gene. 2010;463(1-2):21–28. 
26.  Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a 
growth-hormone-releasing acylated peptide from stomach. Nature. 
1999;402(6762):656–660. 
27.  Volante M, Allia E, Gugliotta P, Funaro A, Broglio F, Deghenghi R, Muccioli G, Ghigo 
E, Papotti M. Expression of ghrelin and of the GH secretagogue receptor by 
pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab. 
2002;87(3):1300–1308. 
28.  Pusztai P, Sarman B, Ruzicska E, Toke J, Racz K, Somogyi A, Tulassay Z. Ghrelin: a 
new peptide regulating the neurohormonal system, energy homeostasis and glucose 
metabolism. Diabetes Metab Rev. 2008;24(5):343–352. 
29.  Larsson LI, Sundler F, Hakanson R, Pollock HG, Kimmel JR. Localization of APP, a 
postulated new hormone, to a pancreatic endocrine cell type. Histochemistry. 
1974;42(4):377–382. 
30.  Lonovics J, Devitt P, Watson LC, Rayford PL, Thompson JC. Pancreatic polypeptide. A 
review. Arch Surg. 1981;116(10):1256–1264. 
31.  Brissova M, Fowler MJ, Nicholson WE, Chu A, Hirshberg B, Harlan DM, Powers AC. 
Assessment of human pancreatic islet architecture and composition by laser scanning 
confocal microscopy. J Histochem Cytochem. 2005;53(9):1087–97. 
32.  Brissova M, Shiota M, Nicholson WE, Gannon M, Knobel SM, Piston DW, Wright C 
V, Powers AC. Reduction in pancreatic transcription factor PDX-1 impairs glucose-
stimulated insulin secretion. J Biol Chem. 2002;277(13):11225–32. 
45
 33.  Dubois PM. Ontogeny of the endocrine pancreas. Horm Res. 1989;32(1-3):53–60. 
34.  Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and 
increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 
2003;52(1):102–110. 
35.  Rahier J, Wallon J, Henquin JC. Cell populations in the endocrine pancreas of human 
neonates and infants. Diabetologia. 1981;20(5):540–546. 
36.  Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique 
cytoarchitecture of human pancreatic islets has implications for islet cell function. 
PNAS. 2006;103(7):2334–2339. 
37.  Habener JF, Kemp DM, Thomas MK. Minireview: transcriptional regulation in 
pancreatic development. Endocrinology. 2005;146(3):1025–34. 
38.  Stoffers DA, Heller RS, Miller CP, Habener JF. Developmental expression of the 
homeodomain protein IDX-1 in mice transgenic for an IDX-1 promoter/lacZ 
transcriptional reporter. Endocrinology. 1999;140(11):5374–5381. 
39.  Guz Y, Montminy MR, Stein R, Leonard J, Gamer LW, Wright C V, Teitelman G. 
Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells 
of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors 
during ontogeny. Development. 1995;121(1):11–18. 
40.  Ohlsson H, Karlsson K, Edlund T. IPF1, a homeodomain-containing transactivator of 
the insulin gene. EMBO J. 1993;12(11):4251–4259. 
41.  Kaneto H, Miyatsuka T, Kawamori D, Yamamoto K, Kato K, Shiraiwa T, Katakami N, 
Yamasaki Y, Matsuhisa M, Matsuoka T-A. PDX-1 and MafA play a crucial role in 
pancreatic beta-cell differentiation and maintenance of mature beta-cell function. 
Endocr J. 2008;55(2):235–52. 
42.  Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for 
pancreas development in mice. Nature. 1994;371(6498):606–609. 
43.  Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnuson MA, Hogan BL, 
Wright C V. PDX-1 is required for pancreatic outgrowth and differentiation of the 
rostral duodenum. Development. 1996;122(3):983–995. 
44.  Ahlgren U, Jonsson J, Edlund H. The morphogenesis of the pancreatic mesenchyme is 
uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice. 
Development. 1996;122(5):1409–1416. 
45.  Holland AM, Hale MA, Kagami H, Hammer RE, MacDonald RJ. Experimental control 
of pancreatic development and maintenance. PNAS. 2002;99(19):12236–12241. 
46
 46.  Kemp DM, Thomas MK, Habener JF. Developmental aspects of the endocrine 
pancreas. Rev Endocr Metab Dis. 2003;4(1):5–17. 
47.  Murtaugh LC. Pancreas and beta-cell development: from the actual to the possible. 
Development. 2007;134(3):427–438. 
48.  Pan FC, Wright C. Pancreas organogenesis: from bud to plexus to gland. Dev Dyn. 
2011;240(3):530–565. 
49.  Sander M, German MS. The beta cell transcription factors and development of the 
pancreas. J Mol Med. 1997;75(5):327–340. 
50.  Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two 
independent cell lineages. Development. 2000;127(11):2317–22. 
51.  Thorel F, Nepote V, Avril I, Kohno K, Desgraz R, Chera S, Herrera PL, Népote V, 
Kohno, Kenji, Desgraz R. Conversion of Adult Pancreatic alpha-cells to Beta-cells after 
Extreme Beta Cell Loss. Nature. 2010;464(7292):1149–1154. 
52.  Yang Y-PP, Thorel F, Boyer DF, Herrera PL, Wright CVE. Context-specific α- to-β-cell 
reprogramming by forced Pdx1 expression. Genes Dev. 2011;25(16):1680–5. 
53.  White MG, Marshall HL, Rigby R, Huang GC, Amer A, Booth T, White S, Shaw JAM. 
Expression of mesenchymal and α-cell phenotypic markers in islet β-cells in recently 
diagnosed diabetes. Diabetes Care. 2013;36(11):3818–20. 
54.  Talchai C, Xuan S, Lin H V, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a 
mechanism of diabetic β cell failure. Cell. 2012;150(6):1223–34. 
55.  Zhou Q, Law AC, Rajagopal J, Anderson WJ, Gray PA, Melton DA. A multipotent 
progenitor domain guides pancreatic organogenesis. Dev Cell. 2007;13(1):103–114. 
56.  Seymour PA, Freude KK, Tran MN, Mayes EE, Jensen J, Kist R, Scherer G, Sander M. 
SOX9 is required for maintenance of the pancreatic progenitor cell pool. PNAS. 
2007;104(6):1865–1870. 
57.  Seymour PA, Freude KK, Dubois CL, Shih HP, Patel NA, Sander M. A dosage-
dependent Requirement for Sox9 in Pancreatic Endocrine Cell Formation. Dev Biol. 
2008;323(1):19–30. 
58.  Lynn FC, Smith SB, Wilson ME, Yang KY, Nekrep N, German MS. Sox9 coordinates a 
transcriptional network in pancreatic progenitor cells. PNAS. 2007;104(25):10500–5. 
59.  Solar M, Cardalda C, Houbracken I, Martín M, Maestro MA, De Medts N, Xu X, Grau 
V, Heimberg H, Bouwens L, Ferrer J, Martin M. Pancreatic exocrine duct cells give 
47
 rise to insulin-producing beta cells during embryogenesis but not after birth. Dev Cell. 
2009;17(6):849–860. 
60.  Pierreux CE, Poll A V, Kemp CR, Clotman F, Maestro MA, Cordi S, Ferrer J, Leyns L, 
Rousseau GG, Lemaigre FP. The transcription factor hepatocyte nuclear factor-6 
controls the development of pancreatic ducts in the mouse. Gastroenterology. 
2006;130(2):532–541. 
61.  Sommer L, Ma Q, Anderson DJ. neurogenins, a novel family of atonal-related bHLH 
transcription factors, are putative mammalian neuronal determination genes that 
reveal progenitor cell heterogeneity in the developing CNS and PNS. Mol Cell 
Neurosci. 1996;8(4):221–241. 
62.  Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ 
cells are islet progenitors and are distinct from duct progenitors. Development. 
2002;129(10):2447–2457. 
63.  Grapin-Botton A, Majithia AR, Melton DA. Key events of pancreas formation are 
triggered in gut endoderm by ectopic expression of pancreatic regulatory genes. 
Genes Dev. 2001;15(4):444–454. 
64.  Gradwohl G, Dierich A, LeMeur M, Guillemot F. Neurogenin3 Is Required for the 
Development of the Four Endocrine Cell Lineages of the Pancreas. PNAS. 
2000;97(4):1607–11. 
65.  Artner I, Hang Y, Mazur M, Yamamoto T, Guo M, Lindner J, Magnuson MA, Stein R. 
MafA and MafB Regulate Genes Critical to Beta Cells in a Unique Temporal Manner. 
Diabetes. 2010;59(October):2530–39. 
66.  Nishimura W, Kondo T, Salameh T, El Khattabi I, Dodge R, Bonner-Weir S, Sharma A. 
A switch from MafB to MafA expression accompanies differentiation to pancreatic 
beta-cells. Dev Biol. 2006;293(2):526–539. 
67.  Naya FJ, Stellrecht CM, Tsai MJ. Tissue-specific regulation of the insulin gene by a 
novel basic helix-loop-helix transcription factor. Genes Dev. 1995;9(8):1009–1019. 
68.  Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene is essential 
for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature. 
1997:399–402. 
69.  St-Onge L, Sosa-Pineda, Beatriz, Chowdhury K, Mansouri A, Gruss P. Pax6 is required 
for differentiation of glucagon-producing alpha-cells in mouse pancreas. Nature. 
1997;387(22):406–409. 
48
 70.  Sussel L, Kalamaras J, Hartigan-O’Connor DJ, Meneses JJ, Pedersen R a, Rubenstein 
JL, German MS. Mice lacking the homeodomain transcription factor Nkx2.2 have 
diabetes due to arrested differentiation of pancreatic beta cells. Development. 
1998;125(12):2213–21. 
71.  Watada H, Mirmira RG, Leung J, German MS. Transcriptional and translational 
regulation of beta-cell differentiation factor Nkx6.1. J Biol Chem. 
2000;275(44):34224–30. 
72.  Inada A, Nienaber C, Fonseca S, Bonner-Weir S. Timing and expression pattern of 
carbonic anhydrase II in pancreas. Dev Dyn. 2006;235(6):1571–1577. 
73.  Bonner-Weir S, Taneja M, Weir GC, Tatarkiewicz K, Song KH, Sharma A, O’Neil JJ. In 
vitro cultivation of human islets from expanded ductal tissue. PNAS. 
2000;97(14):7999–8004. 
74.  Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, Bhushan A, Rizza RA, Butler 
PC. Beta Cell Replication is the Primary Mechanism Subserving the Postnatal 
Expansion of beta-Cell Mass in Humans. Diabetes. 2008;57(June):1584–1594. 
75.  Jo J, Kilimnik G, Kim A, Guo C, Periwal V, Hara M. Formation of pancreatic islets 
involves coordinated expansion of small islets and fission of large interconnected 
islet-like structures. Biophys J. 2011;101(3):565–574. 
76.  Bouwens L, Pipeleers DG. Extra-insular beta cells associated with ductules are 
frequent in adult human pancreas. Diabetologia. 1998;41(6):629–33. 
77.  Meglasson MD, Matschinsky FM. New perspectives on pancreatic islet glucokinase. 
Am J Physiol. 1984;246(1 Pt 1):E1–13. 
78.  Matschinsky FM, Glaser B, Magnuson MA. Pancreatic beta-cell glucokinase: closing 
the gap between theoretical concepts and experimental realities. Diabetes. 
1998;47(3):307–15. 
79.  Postic C, Shiota M, Magnuson MA. Cell-specific roles of glucokinase in glucose 
homeostasis. Recent Prog Horm Res. 2001;56:195–217. 
80.  Liang Y, Najafi H, Smith RM, Zimmerman EC, Magnuson MA, Tal M, Matschinsky 
FM. Concordant glucose induction of glucokinase, glucose usage, and glucose-
stimulated insulin release in pancreatic islets maintained in organ culture. Diabetes. 
1992;41(7):792–806. 
81.  Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. 
Pflügers Arch - Eur J Physiol. 2004;447(5):480–89. 
49
 82.  Waebers G, Thompson N, Haefliger J, Nicod P, Expression GG. Characterization of 
the Murine High K , Glucose Transporter GLUT2 Gene and Its Transcriptional 
Regulation by Glucose in a Differentiated Insulin-secreting Cell. J Biol Chem. 
1994;269(43):26912–26919. 
83.  Thorens B. GLUT2 in pancreatic and extra-pancreatic gluco-detection. Mol Membr 
Biol. 2001;18(4):265–73. 
84.  De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, Schuit F. 
Human and rat beta cells differ in glucose transporter but not in glucokinase gene 
expression. J Clin Invest. 1995;96(5):2489–95. 
85.  Scaglia L, Cahill CJ, Finegood DT, Bonner-Weir S. Apoptosis participates in the 
remodeling of the endocrine pancreas in the neonatal rat. Endocrinology. 
1997;138(4):1736–41. 
86.  Petrik J, Arany E, McDonald TJ, Hill DJ. Apoptosis in the pancreatic islet cells of the 
neonatal rat is associated with a reduced expression of insulin-like growth factor II 
that may act as a survival factor. Endocrinology. 1998;139(6):2994–3004. 
87.  Kaung HL. Growth dynamics of pancreatic islet cell populations during fetal and 
neonatal development of the rat. Dev Dyn. 1994;200(2):163–75. 
88.  Rankin MM, Kushner JA. Adaptive beta-cell proliferation is severely restricted with 
advanced age. Diabetes. 2009;58(6):1365–1372. 
89.  Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat Biotech. 
2005;23(7):857–61. 
90.  Scaglia L, Smith E, Bonner-weir S. Apoptosis contributes to the involution of beta cell 
mass in the post partum rat pancreas. Endocrinology. 1995;136(12):5461–8. 
91.  Bonner-Weir S. Perspective: Postnatal pancreatic beta cell growth. Endocrinology. 
2000;141(6):1926–9. 
92.  Finegood D, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat 
pancreas. Estimation with a simple mathematical model. Diabetes. 1995;3:249–56. 
93.  Kushner JA. β-Cell Growth: An Unusual Paradigm of Organogenesis That is Cyclin 
D2/Cdk4 Dependent. Cell cycle. 2006;5(February):234–237. 
94.  Müller R, Laucke R, Trimper B, Cossel L. Pancreatic cell proliferation in normal rats 
studied by in vivo autoradiography with 3H-thymidine. Virchows Arch B Cell Pathol 
Incl Mol Pathol. 1990;59(3):133–6. 
50
 95.  Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA. Very slow turnover of 
beta-cells in aged adult mice. Diabetes. 2005;54(9):2557–2567. 
96.  Tschen SI, Dhawan S, Gurlo T, Bhushan A. Age-dependent decline in beta-cell 
proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes. 
2009;58(June):1312–1320. 
97.  Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B. Beta-cell proliferation and 
apoptosis in the developing normal human pancreas and in hyperinsulinism of 
infancy. Diabetes. 2000;49(8):1325–33. 
98.  Kulkarni RN, Mizrachi E-B, Ocana AG, Stewart AF. Human β-cell proliferation and 
intracellular signaling: driving in the dark without a road map. Diabetes. 
2012;61(9):2205–13. 
99.  Cnop M, Hughes SJ, Igoillo-Esteve M, Hoppa MB, Sayyed F, van de Laar L, Gunter JH, 
de Koning EJP, Walls G V, Gray DWG, Johnson PR V, Hansen BC, Morris JF, Pipeleers-
Marichal M, Cnop I, Clark a. The long lifespan and low turnover of human islet beta 
cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia. 
2010;53(2):321–30. 
100.  Cnop M, Hughes SJ, Walker JN, Cnop I, Clark A. Longevity of human islet alpha and 
beta cells. Diabetes Obes Metab. 2011;13:39–46. 
101.  Pestell RG. The Cyclins and Cyclin-Dependent Kinase Inhibitors in Hormonal 
Regulation of Proliferation and Differentiation. Endocr Rev. 1999;20(4):501–534. 
102.  Cozar-Castellano I, Fiaschi-Taesch N, Bigatel T a, Takane KK, Garcia-Ocaña A, 
Vasavada R, Stewart AF. Molecular control of cell cycle progression in the pancreatic 
beta-cell. Endocr Rev. 2006;27(4):356–70. 
103.  Cobrinik D. Pocket proteins and cell cycle control. Oncogene. 2005;24(17):2796–809. 
104.  Kushner JA, Ciemerych MA, Sicinska E, Wartschow LM, Teta M, Long SY, Sicinski P, 
White MF. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. 
Mol Cell Biol. 2005;25(9):3752–62. 
105.  Rane SG, Dubus P, Mettus R V, Galbreath EJ, Boden G, Reddy EP, Barbacid M. Loss 
of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in 
beta-islet cell hyperplasia. Nat Genet. 1999;22(1):44–52. 
106.  Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, Sharpless 
NE. p16INK4a induces an age-dependent decline in islet regenerative potential. 
Nature. 2006;443(7110):453–7. 
51
 107.  Chen H, Gu X, Liu Y, Wang J, Wirt SE, Bottino R, Schorle H, Sage J, Kim SK. PDGF 
signalling controls age-dependent proliferation in pancreatic β-cells. Nature. 
2011;478(7369):349–55. 
108.  Fiaschi-Taesch NM, Kleinberger JW, Salim FG, Troxell R, Wills R, Tanwir M, Casinelli 
G, Cox AE, Takane KK, Scott DK, Stewart AF. Human pancreatic β-cell G1/S molecule 
cell cycle atlas. Diabetes. 2013;62(7):2450–9. 
109.  Fiaschi-Taesch NM, Kleinberger JW, Salim FG, Troxell R, Wills R, Tanwir M, Casinelli 
G, Cox AE, Takane KK, Srinivas H, Scott DK, Stewart AF. Cytoplasmic-nuclear 
trafficking of G1/S cell cycle molecules and adult human β-cell replication: a revised 
model of human β-cell G1/S control. Diabetes. 2013;62(7):2460–70. 
110.  Salpeter SJ, Khalaileh A, Weinberg-Corem N, Ziv O, Glaser B, Dor Y. Systemic 
regulation of the age-related decline of pancreatic β-cell replication. Diabetes. 
2013;62(8):2843–8. 
111.  Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by 
self-duplication rather than stem-cell differentiation. Nature. 2004;429(6987):41–46. 
112.  Teta M, Rankin MM, Long SY, Stein GM, Kushner JA. Growth and regeneration of 
adult beta cells does not involve specialized progenitors. Dev Cell. 2007;12(5):817–26. 
113.  Bonner-Weir S, Sharma A. Are there pancreatic progenitor cells from which new 
islets form after birth? Nat Rev Endocrinol. 2006;2(5):240–1. 
114.  Sorenson RL, Brelje TC. Adaptation of islets of Langerhans to pregnancy: beta-cell 
growth, enhanced insulin secretion and the role of lactogenic hormones. Horm 
Metab Res. 1997;29(6):301–7. 
115.  Parsons J, Brelje TC, Sorenson R. Adaptation of islets of Langerhans to pregnancy: 
increased islet cell proliferation and insulin secretion correlates with the onset of 
placental lactogen secretion. Endocrinology. 1992;3(130):1459–66. 
116.  Butler a E, Cao-Minh L, Galasso R, Rizza R a, Corradin a, Cobelli C, Butler PC. 
Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in 
human pregnancy. Diabetologia. 2010;53(10):2167–76. 
117.  Butler AE, Janson J, Soeller WC, Butler PC. Apoptosis Prevents Adaptive Increase in 
Beta-cell Mass in Models of Type 2 Diabetes : Evidence for Role of Islet Amyloid 
Formation Rather Than Direct Action of Amyloid. Diabetes. 2003;52(September). 
118.  Domínguez-Bendala J, Inverardi L, Ricordi C. Regeneration of pancreatic beta-cell 
mass for the treatment of diabetes. Expert Opin Biol Ther. 2012;12(6):731–41. 
52
 119.  Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC. β-cell mass and 
turnover in humans: effects of obesity and aging. Diabetes Care. 2013;36(1):111–7. 
120.  Alonso LC, Yokoe T, Zhang P, Scott DK, Kim SK, O’Donnell CP, Garcia-Ocaña A. 
Glucose infusion in mice: a new model to induce beta-cell replication. Diabetes. 
2007;56(7):1792–801. 
121.  Porat S, Weinberg-Corem N, Tornovsky-Babaey S, Schyr-Ben-Haroush R, Hija A, 
Stolovich-Rain M, Dadon D, Granot Z, Ben-Hur V, White P, Girard C a, Karni R, 
Kaestner KH, Ashcroft FM, Magnuson M a, Saada A, Grimsby J, Glaser B, Dor Y. 
Control of pancreatic β cell regeneration by glucose metabolism. Cell Metab. 
2011;13(4):440–9. 
122.  Brüning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a 
novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. 
Cell. 1997;88(4):561–72. 
123.  Kulkarni RN, Jhala US, Winnay JN, Krajewski S, Montminy M, Kahn CR. PDX-1 
haploinsufficiency limits the compensatory islet hyperplasia that occurs in response 
to insulin resistance. J Clin Invest. 2004;114(6):828–36. 
124.  Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, Polonsky KS. Role of 
apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-
cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47(3):358–64. 
125.  Yi P, Park J-S, Melton DA. Betatrophin: A Hormone that Controls Pancreatic β Cell 
Proliferation. Cell. 2013;1:1–12. 
126.  Jiao Y, Le Lay J, Yu M, Naji A, Kaestner KH. Elevated mouse hepatic betatrophin 
expression does not increase human β-cell replication in the transplant setting. 
Diabetes. 2014;63(4):1283–8. 
127.  Meier JJ, Bhushan a, Butler a E, Rizza R a, Butler PC. Sustained beta cell apoptosis in 
patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? 
Diabetologia. 2005;48(11):2221–8. 
128.  Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, Bonner-weir S, King 
GL. Residual Insulin Production and Pancreatic Beta -Cell Turnover After 50 Years of 
Diabetes : Joslin Medalist Study. Diabetes. 2010;59(November):2–9. 
129.  Atkins HL, Muraro P a, van Laar JM, Pavletic SZ. Autologous hematopoietic stem cell 
transplantation for autoimmune disease--is it now ready for prime time? Biol Blood 
Marrow Transpl. 2012;18(1 Suppl):S177–83. 
53
 130.  Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic β-
cell function in type 1 diabetes. Nat Rev Drug Discov. 2011;10(6):439–52. 
131.  Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent 
defect in glucose-induced insulin release. J Clin Invest. 1983;71(6):1544–53. 
132.  Lee HC, Bonner-Weir S, Weir GC, Leahy JL. Compensatory adaption to partial 
pancreatectomy in the rat. Endocrinology. 1989;124(3):1571–5. 
133.  Kirkbride M. The islets of Langerhans after ligation of the pancreatic ducts. J Exp 
Med. 1912;15:101. 
134.  Wang RN, Kloppel G, Bouwens L. Duct- to islet-cell differentiation and islet growth in 
the pancreas of duct-ligated adult rats. Diabetologia. 1995;38(12):1405–1411. 
135.  Xu X, D’Hoker J, Stangé G, Bonné S, De Leu N, Xiao X, Van de Casteele M, Mellitzer 
G, Ling Z, Pipeleers D, Bouwens L, Scharfmann R, Gradwohl G, Heimberg H. Beta 
cells can be generated from endogenous progenitors in injured adult mouse 
pancreas. Cell. 2008;132(2):197–207. 
136.  Inada A, Nienaber C, Katsuta H, Fujitani Y, Levine J, Morita R, Sharma A, Bonner-
Weir S. Carbonic anhydrase II-positive pancreatic cells are progenitors for both 
endocrine and exocrine pancreas after birth. PNAS. 2008;105(50):19915–9. 
137.  Brockenbrough JS, Weir GC, Bonner-Weir S. Discordance of exocrine and endocrine 
growth after 90% pancreatectomy in rats. Diabetes. 1988;37(2):232–6. 
138.  Li WC, Rukstalis JM, Nishimura W, Tchipashvili V, Habener JF, Sharma A, Bonner-
Weir S. Activation of pancreatic-duct-derived progenitor cells during pancreas 
regeneration in adult rats. J Cell Sci. 2010;123(Pt 16):2792–2802. 
139.  Bonner-Weir S, Inada A, Yatoh S, Li W-C, Aye T, Toschi E, Sharma A. 
Transdifferentiation of pancreatic ductal cells to endocrine beta-cells. Biochem Soc 
Trans. 2008;36(Pt 3):353–6. 
140.  Longnecker DS. Pathology and pathogenesis of diseases of the pancreas. Am J Pathol. 
1982;107(1):99–121. 
141.  Hultquist GT, Joensson LE. Ligation of the pancreatic duct in rats. Acta Soc Med Upsa. 
1965;70:82–8. 
142.  Edström C, Falkmer S. Pancreatic morphology and blood glucose level in rats at 
various intervals after duct ligation. Virchows Arch A Pathol. 1968;345(2):139–53. 
54
 143.  Walker NI. Ultrastructure of the rat pancreas after experimental duct ligation. I. The 
role of apoptosis and intraepithelial macrophages in acinar cell deletion. Am J Pathol. 
1987;126(3):439–51. 
144.  Walker NI, Winterford CM, Kerr JF. Ultrastructure of the rat pancreas after 
experimental duct ligation. II. Duct and stromal cell proliferation, differentiation, and 
deletion. Pancreas. 1992;7(4):420–34. 
145.  Rankin MM, Wilbur CJ, Rak K, Shields EJ, Granger A, Kushner JA. β-Cells are not 
generated in pancreatic duct ligation-induced injury in adult mice. Diabetes. 
2013;62(5):1634–45. 
146.  Portha B, Blondel O, Serradas P, McEvoy R, Giroix MH, Kergoat M, Bailbe D. The rat 
models of non-insulin dependent diabetes induced by neonatal streptozotocin. 
Diabete Metab. 1989;15(2):61–75. 
147.  Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. 
Diabetologia. 2008;51(2):216–26. 
148.  Yamamoto H, Uchigata Y, Okamoto H. Streptozotocin and alloxan induce DNA strand 
breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature. 
1981;294(5838):284–6. 
149.  Uchigata Y, Yamamoto H, Kawamura A, Okamoto H. Protection by superoxide 
dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and 
streptozotocin-induced islet DNA strand breaks and against the inhibition of 
proinsulin synthesis. J Biol Chem. 1982;257(11):6084–8. 
150.  Portha B, Levacher C, Picon L, Rosselin G. Diabetogenic effect of streptozotocin in 
the rat during the perinatal period. Diabetes. 1974;23(11):889–895. 
151.  O’Brien B, Harmon B, Cameron DP, Allan D. Beta-cell apoptosis is responsible for the 
development of IDDM in the multiple low-dose streptozotocin model. J Path. 
1996;178(2):176–81. 
152.  Wang RN, Bouwens L, Klöppel G. Beta-cell proliferation in normal and 
streptozotocin-treated newborn rats: site, dynamics and capacity. Diabetologia. 
1994;37(11):1088–96. 
153.  Yang H, Wright JR. Human beta cells are exceedingly resistant to streptozotocin in 
vivo. Endocrinology. 2002;143(7):2491–5. 
154.  Like AA, Rossini AA. Streptozotocin-Induced Pancreatic Insulitis : New Model of 
Diabetes Mellitus. Sci. 1976;193(4251):415–417. 
55
 155.  Rossini AA, Liket AA, Chick WL, Appelt MC. Studies of streptozotocin-induced 
insulitis and diabetes. PNAS. 1977;74(6):2485–2489. 
156.  Bonner-Weir S, Trent DF, Honey RN, Weir GC. Responses of neonatal rat islets to 
streptozotocin: limited B-cell regeneration and hyperglycemia. Diabetes. 
1981;30(1):64–69. 
157.  Nicholson JM, Arany EJ, Hill DJ. Changes in islet microvasculature following 
streptozotocin-induced beta-cell loss and subsequent replacement in the neonatal 
rat. Exp Biol Med. 2010;235(2):189–198. 
158.  Thyssen S, Arany E, Hill DJ. Ontogeny of regeneration of beta-cells in the neonatal rat 
after treatment with streptozotocin. Endocrinology. 2006;147(5):2346–2356. 
159.  Cox AR, Gottheil SK, Arany EJ, Hill DJ. The effects of low protein during gestation on 
mouse pancreatic development and beta cell regeneration. Pediatr Res. 
2010;68(1):16–22. 
160.  Marchand KC, Arany EJ, Hill DJ. Effects of atorvastatin on the regeneration of 
pancreatic {beta}-cells after streptozotocin treatment in the neonatal rodent. Am J 
Physiol Endocrinol Metab. 2010;299(1):E92–E100. 
161.  Chamson-Reig A, Arany EJ, Hill DJ. Lineage tracing and resulting phenotype of 
haemopoietic-derived cells in the pancreas during beta cell regeneration. 
Diabetologia. 2010;53(10):2188–2197. 
162.  Dutrillaux MC, Portha B, Rozé C, Hollande E. Ultrastructural study of pancreatic B cell 
regeneration in newborn rats after destruction by streptozotocin. Virchows Arch B 
Cell Pathol Incl Mol Pathol. 1982;39(2):173–85. 
163.  Herrera PL, Huarte J, Zufferey R, Nichols A, Mermillod B, Philippe J, Muniesa P, 
Sanvito F, Orci L, Vassalli JD. Ablation of islet endocrine cells by targeted expression 
of hormone-promoter-driven toxigenes. PNAS. 1994;91(26):12999–3003. 
164.  Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J 
Clin Invest. 2007;117(9):2553–2561. 
165.  Stanger BZ, Tanaka AJ, Melton D a. Organ size is limited by the number of embryonic 
progenitor cells in the pancreas but not the liver. Nature. 2007;445(7130):886–91. 
166.  Stolovich-Rain M, Hija A, Grimsby J, Glaser B, Dor Y. Pancreatic beta cells in very old 
mice retain capacity for compensatory proliferation. J Biol Chem. 
2012;287(33):27407–14. 
167.  Russ HA, Bar Y, Ravassard P, Efrat S. In vitro proliferation of cells derived from adult 
human beta-cells revealed by cell-lineage tracing. Diabetes. 2008;57(6):1575–1583. 
56
 168.  Weinberg N, Ouziel-Yahalom L, Knoller S, Efrat S, Dor Y. Lineage tracing evidence for 
in vitro dedifferentiation but rare proliferation of mouse pancreatic beta-cells. 
Diabetes. 2007;56(5):1299–1304. 
169.  Puri S, Folias AE, Hebrok M. Plasticity and Dedifferentiation within the Pancreas: 
Development, Homeostasis, and Disease. Cell Stem Cell. 2014:1–14. 
170.  Okada T. Transdifferentiation in animal models: fact or artifact? Dev Growth Differ. 
1986;28:213–221. 
171.  Beattie GM, Hayek A, Levine F. Growth and genetic modification of human beta-cells 
and beta-cell precursors. Genet Eng. 2000;22:99–120. 
172.  Beattie GM, Leibowitz G, Lopez AD, Levine F, Hayek A. Protection from cell death in 
cultured human fetal pancreatic cells. Cell Transpl. 2000;9(3):431–438. 
173.  Demeterco C, Beattie GM, Dib SA, Lopez AD, Hayek A. A role for activin A and 
betacellulin in human fetal pancreatic cell differentiation and growth. J Clin 
Endocrinol Metab. 2000;85(10):3892–3897. 
174.  Halvorsen TL, Beattie GM, Lopez AD, Hayek A, Levine F. Accelerated telomere 
shortening and senescence in human pancreatic islet cells stimulated to divide in 
vitro. J Endocrinol. 2000;166(1):103–109. 
175.  Beattie G, Rubin JS, Mally MI, Otonkoski T, Hayek A. Regulation of proliferation and 
differentiation of human fetal pancreatic islet cells by extracellular matrix, 
hepatocyte growth factor, and cell-cell contact. Diabetes. 1996;45(9):1223–9. 
176.  Beattie GM, Itkin-Ansari P, Cirulli V, Leibowitz G, Lopez a D, Bossie S, Mally MI, 
Levine F, Hayek a. Sustained proliferation of PDX-1+ cells derived from human islets. 
Diabetes. 1999;48(5):1013–9. 
177.  Otonkoski T, Beattie G, Rubin JS, Lopez AD, Baird A, Hayek A. Hepatocyte growth 
factor/scatter factor has insulinotropic activity in human fetal pancreatic cells. 
Diabetes. 1994;43(7):947. 
178.  Kerr-Conte J, Pattou F, Lecomte-Houcke M, Xia Y, Boilly B, Proye C, Lefebvre J. 
Ductal cyst formation in collagen-embedded adult human islet preparations. A means 
to the reproduction of nesidioblastosis in vitro. Diabetes. 1996;45(8):1108–14. 
179.  Yuan S, Rosenberg L, Paraskevas S, Agapitos D, Duguid WP. Transdifferentiation of 
human islets to pancreatic ductal cells in collagen matrix culture. Differentiation. 
1996;61(1):67–75. 
57
 180.  Kayali AG, Flores LE, Lopez AD, Kutlu B, Baetge E, Kitamura R, Hao E, Beattie GM, 
Hayek A. Limited capacity of human adult islets expanded in vitro to redifferentiate 
into insulin-producing beta-cells. Diabetes. 2007;56(3):703–708. 
181.  Movassat J, Beattie GM, Lopez AD, Portha B, Hayek A. Keratinocyte growth factor 
and beta-cell differentiation in human fetal pancreatic endocrine precursor cells. 
Diabetologia. 2003;46(6):822–829. 
182.  Chase LG, Ulloa-Montoya F, Kidder BL, Verfaillie CM. Islet-derived fibroblast-like 
cells are not derived via epithelial-mesenchymal transition from Pdx-1 or insulin-
positive cells. Diabetes. 2007;56(1):3–7. 
183.  Atouf F, Park CH, Pechhold K, Ta M, Choi Y, Lumelsky NL. No evidence for mouse 
pancreatic beta-cell epithelial-mesenchymal transition in vitro. Diabetes. 
2007;56(3):699–702. 
184.  Jamal A-M, Lipsett M, Sladek R, Laganière S, Hanley S, Rosenberg L. Morphogenetic 
plasticity of adult human pancreatic islets of Langerhans. Cell Death Differ. 
2005;12(7):702–12. 
185.  Morton RA, Geras-Raaka E, Wilson LM, Raaka BM, Gershengorn MC. Endocrine 
precursor cells from mouse islets are not generated by epithelial-to-mesenchymal 
transition of mature beta cells. Mol Cell Endocrinol. 2007;270(1-2):87–93. 
186.  Ouziel-Yahalom L, Zalzman M, Anker-Kitai L, Knoller S, Bar Y, Glandt M, Herold K, 
Efrat S. Expansion and redifferentiation of adult human pancreatic islet cells. 
Biochem Biophys Res Commun. 2006;341(2):291–298. 
187.  Lechner A, Nolan AL, Blacken RA, Habener JF. Redifferentiation of insulin-secreting 
cells after in vitro expansion of adult human pancreatic islet tissue. Biochem Biophys 
Res Commun. 2005;327(2):581–588. 
188.  Gershengorn MC, Hardikar AA, Wei C, Geras-Raaka E, Marcus-Samuels B, Raaka 
BM. Epithelial-to-mesenchymal transition generates proliferative human islet 
precursor cells. Science (80- ). 2004;306(5705):2261–2264. 
189.  Hanley SC, Pilotte A, Massie B, Rosenberg L. Cellular origins of adult human islet in 
vitro dedifferentiation. Lab Investig. 2008;88(7):761–72. 
190.  Russ HA, Sintov E, Anker-Kitai L, Friedman O, Lenz A, Toren G, Farhy C, Pasmanik-
Chor M, Oron-Karni V, Ravassard P, Efrat S. Insulin-producing cells generated from 
dedifferentiated human pancreatic beta cells expanded in vitro. PLoS One. 
2011;6(9):e25566. 
58
 191.  Seaberg RM, van der Kooy D. Stem and progenitor cells: the premature desertion of 
rigorous definitions. Trends Neurosci. 2003;26(3):125–31. 
192.  Potten CS, Loeffler M. Stem cells: attributes , cycles, spirals , pitfalls and 
uncertainties. Lessons for and from the Crypt. Development. 1990;1020(110):1001–
1020. 
193.  Clarke D, Johansson C, Wilbertz J, Veress B, Nilsson E, Karlstro H, Lendahl U, Frise J. 
Generalized Potential of Adult Neural Stem Cells. Science (80- ). 
2000;288(June):1660–1664. 
194.  Brazelton TR, Rossi FM V, Keshet GI, Blau HM. From Marrow to Brain : Expression of 
Neuronal Phenotypes in Adult Mice. Science (80- ). 2000;290(December):1775–1779. 
195.  Galli R, Borello U, Gritti A, Minasi MG, Bjornson C, Coletta M, Mora M, Angelis MGC 
De, Fiocco R, Cossu G, Vescovi AL. Skeletal myogenic potential of human and mouse 
neural stem cells. Nat Neurosci. 2000;3(10):986–991. 
196.  Bjornson C, Rietze R, Reynolds B, Magli M, Vescovi A. Turning Brain into Blood : A 
Hematopoietic Fate Adopted by Adult Neural Stem Cells in Vivo. Science (80- ). 
2003;442(1997):534–7. 
197.  Hess D, Li L, Martin M, Sakano S, Hill D, Strutt B, Thyssen S, Gray DA, Bhatia M. 
Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotech. 
2003;21(7):763–770. 
198.  Johansson U, Rasmusson I, Niclou SP, Forslund N, Gustavsson L, Nilsson B, Korsgren 
O, Magnusson PU. Formation of composite endothelial cell-mesenchymal stem cell 
islets: a novel approach to promote islet revascularization. Diabetes. 
2008;57(9):2393–401. 
199.  Johansson U, Elgue G, Nilsson B, Korsgren O. Composite islet-endothelial cell grafts: 
a novel approach to counteract innate immunity in islet transplantation. Am J 
Transpl. 2005;5(11):2632–9. 
200.  Lee RH, Seo MJ, Reger RL, Spees JL, Pulin A a, Olson SD, Prockop DJ. Multipotent 
stromal cells from human marrow home to and promote repair of pancreatic islets 
and renal glomeruli in diabetic NOD/scid mice. PNAS. 2006;103(46):17438–43. 
201.  Bell GI, Broughton HC, Levac KD, Allan D a, Xenocostas A, Hess D a. Transplanted 
human bone marrow progenitor subtypes stimulate endogenous islet regeneration 
and revascularization. Stem Cells Dev. 2012;21(1):97–109. 
59
 202.  Bell GI, Putman DM, Hughes-Large JM, Hess D a. Intrapancreatic delivery of human 
umbilical cord blood aldehyde dehydrogenase-producing cells promotes islet 
regeneration. Diabetologia. 2012;55(6):1755–60. 
203.  Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M. Insulin 
Production by Human Embryonic Stem Cells. Diabetes. 2001;50(8):1691–1697. 
204.  Segev H, Fishman B, Ziskind A, Schulman M, Itskovitz-Eldor J oseph. Differentiation 
of Human Embryonic Stem Cells into Insulin-producing Clusters. Stem Cells. 
2004;22:265–274. 
205.  Roche E, Sepulcre P, Reig JA, Santana A, Soria B. Ectodermal commitment of insulin-
producing cells derived from mouse embryonic stem cells. FASEB J. 2005;21:1–21. 
206.  D’Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, Moorman MA, 
Kroon E, Carpenter MK, Baetge EE. Production of pancreatic hormone-expressing 
endocrine cells from human embryonic stem cells. Nat Biotech. 2006;24(11):1392–
401. 
207.  Nostro MC, Cheng X, Keller GM, Gadue P. Wnt, activin, and BMP signaling regulate 
distinct stages in the developmental pathway from embryonic stem cells to blood. 
Cell Stem Cell. 2008;2(1):60–71. 
208.  Nostro MC, Sarangi F, Ogawa S, Holtzinger a., Corneo B, Li X, Micallef SJ, Park I-H, 
Basford C, Wheeler MB, Daley GQ, Elefanty a. G, Stanley EG, Keller G. Stage-specific 
signaling through TGF  family members and WNT regulates patterning and pancreatic 
specification of human pluripotent stem cells. Development. 2011;138(7):1445–1445. 
209.  Nostro MC, Keller G. Generation of beta cells from human pluripotent stem cells: 
Potential for regenerative medicine. Sem Cell Dev Biol. 2012;23(6):701–10. 
210.  Schulz TC, Young HY, Agulnick AD, Babin MJ, Baetge EE, Bang AG, Bhoumik A, Cepa 
I, Cesario RM, Haakmeester C, Kadoya K, Kelly JR, Kerr J, Martinson L a, McLean AB, 
Moorman M a, Payne JK, Richardson M, Ross KG, Sherrer ES, Song X, Wilson AZ, 
Brandon EP, Green CE, Kroon EJ, Kelly OG, D’Amour K a, Robins AJ. A scalable 
system for production of functional pancreatic progenitors from human embryonic 
stem cells. PLoS One. 2012;7(5):e37004. 
211.  Séguin C a, Draper JS, Nagy A, Rossant J. Establishment of endoderm progenitors by 
SOX transcription factor expression in human embryonic stem cells. Cell Stem Cell. 
2008;3(2):182–95. 
212.  Hrvatin S, O’Donnell CW, Deng F, Millman JR, Pagliuca FW, DiIorio P, Rezania A, 
Gifford DK, Melton DA. Differentiated human stem cells resemble fetal, not adult, β 
cells. PNAS. 2014;111(8):3038–43. 
60
 213.  Kroon E, Martinson L a, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson 
M, Smart NG, Cunningham J, Agulnick AD, D’Amour K a, Carpenter MK, Baetge EE. 
Pancreatic endoderm derived from human embryonic stem cells generates glucose-
responsive insulin-secreting cells in vivo. Nat Biotech. 2008;26(4):443–52. 
214.  Ramiya VK, Maraist M, Arfors KE, Schatz D a, Peck a B, Cornelius JG. Reversal of 
insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. 
Nat Med. 2000;6(3):278–82. 
215.  Oshima Y, Suzuki A, Kawashimo K, Ishikawa M, Ohkohchi N, Taniguchi H. Isolation 
of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow 
cytometric cell sorting. Gastroenterology. 2007;132(2):720–32. 
216.  Lardon J, Corbeil D, Huttner WB, Ling Z, Bouwens L. Stem cell marker prominin-
1/AC133 is expressed in duct cells of the adult human pancreas. Pancreas. 
2008;36(1):e1–6. 
217.  Rovira M, Scott S-G, Liss AS, Jensen J, Thayer SP, Leach SD. Isolation and 
characterization of centroacinar/terminal ductal progenitor cells in adult mouse 
pancreas. PNAS. 2010;107(1):75–80. 
218.  Bonner-weir S, Toschi E, Inada A, Reitz P, Sy F, Aye T, Sharma A, Toschi E, Inada A, 
Reitz P, Fonseca SY. The pancreatic ductal epithelium serves as a potential pool of 
progenitor cells. Pediatr Diabetes. 2004;5(Suppl 2):16–22. 
219.  Kim H, Hong S, Oh S, Kim J, Lee S, Lee M. Activin A , Exendin-4 and Glucose Stimulate 
Differentiation of Human Pancreatic Ductal Cells. J Endocrinol. 2013;(March):1–38. 
220.  Corritore E, Dugnani E, Pasquale V, Misawa R, Witkowski P, Piemonti L, Sokal EM, 
Lysy P a. β-Cell differentiation of human pancreatic duct-derived cells after in vitro 
expansion. Cell Reprogram. 2014;16(6):456–66. 
221.  Criscimanna A, Speicher J a, Houshmand G, Shiota C, Prasadan K, Ji B, Logsdon CD, 
Gittes GK, Esni F. Duct cells contribute to regeneration of endocrine and acinar cells 
following pancreatic damage in adult mice. Gastroenterology. 2011;141(4):1451–62. 
222.  Blaine S, Ray KC, Anunobi R, Gannon M, Washington MK, Means AL. Adult 
pancreatic acinar cells give rise to ducts but not endocrine cells in response to growth 
factor signaling. Development. 2010;137(14):2289–96. 
223.  Kopinke D, Murtaugh LC. Exocrine-to-endocrine differentiation is detectable only 
prior to birth in the uninjured mouse pancreas. BMC Dev Biol. 2010;10:38. 
224.  Szabat M, Luciani DS, Piret JM, Johnson JD. Maturation of adult beta-cells revealed 
using a Pdx1/insulin dual-reporter lentivirus. Endocrinology. 2009;150(4):1627–1635. 
61
 225.  Liu H, Guz Y, Kedees MH, Winkler J, Teitelman G. Precursor cells in mouse islets 
generate new beta-cells in vivo during aging and after islet injury. Endocrinology. 
2010;151(2):520–528. 
226.  Seaberg RM, Smukler SR, Kieffer TJ, Enikolopov G, Asghar Z, Wheeler MB, Korbutt 
G, van der Kooy D. Clonal identification of multipotent precursors from adult mouse 
pancreas that generate neural and pancreatic lineages. Nat Biotech. 
2004;22(9):1115–1124. 
227.  Smukler SR, Arntfield ME, Razavi R, Bikopoulos G, Karpowicz P, Seaberg R, Dai F, 
Lee S, Ahrens R, Fraser PE, Wheeler MB, van der Kooy D. The adult mouse and 
human pancreas contain rare multipotent stem cells that express insulin. Cell Stem 
Cell. 2011;8(3):281–93.  
 
62
  
 
 
 
CHAPTER 2 
 
 
Culture of Neonatal Mouse Islets under 
Dedifferentiation and Redifferentiation Conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Christine A. Beamish, Brenda J. Strutt, Edith Arany, Gediminas Cepinskas, David A Hess, 
Andrew Pepper, Delfina Siroen, and David J. Hill 
 
63
 2.1  Introduction 
The de novo generation of insulin-producing cells in the pancreas has been a subject 
of great research focus, ultimately for β-cell replacement therapy for patients with diabetes.  
The current gold standard treatment is islet transplantation, but is limited by the availability 
of cadaveric-sourced tissue. Multiple reports have demonstrated moderate success in the 
directed differentiation of human embryonic or induced pluripotent stem cells to β-cells (1–
4). Alternatively, the dedifferentiation, expansion, and subsequent redifferentiation of pre-
existing β-cells as a source of insulin-producing cells has been suggested (5–7). 
Dedifferentiation is the loss of mature, defining and functional characteristics from a 
partially or terminally differentiated cell type (8).  While transdifferentiation  is defined as a 
change from one differentiated phenotype to another, involving morphological and 
functional phenotypic markers (9), it can be preceded by cellular dedifferentiation (8).  One 
such protocol involving the use of epidermal growth factor (EGF) and cholera toxin has 
indicated that human islets may be dedifferentiated to a proliferative monolayer of cells 
positive for markers of ductal epithelium (10–13). Resultant cells were shown to increase 
proliferation by 1500%, and demonstrated a precursor-like phenotype.  Using a subsequent 
“redifferentiation” protocol which includes the ductal mitogen keratinocyte growth factor 
(KGF/FGF-7) and insulin-like growth factor- 2 (IGF-II), “islet-like clusters” could be generated 
that demonstrated insulin secretion (14–16). 
 Experiments carried out by Lammert and colleagues showed that explanted e8.5 
mouse endoderm grown in vitro formed a structure similar to a gut tube, but did not show 
any pancreatic differentiation, lacking both Pdx1 and insulin expression (17). When this 
same explanted endoderm was co-cultured with dorsal aortae, both insulin and Pdx1 were 
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 expressed, and pancreatic buds were visible in ~30% of the structures. Moreover, insulin 
was shown adjacent to the endothelium. Follow-up reports by the same authors illustrated 
that endothelial cells induce crucial steps in the development of both liver and pancreas 
(18,19). It has been shown that microvascular loss is a contributing factor in the initial 
apoptosis and dedifferentiation of islets during transplantation (20), and islets cultured with 
endothelial cells prior to transplantation demonstrate enhanced survival (21) which can be 
attributed to decreased immune rejection and increased revascularization in the recipient 
(22). Furthermore, after pancreatic injury, mesenchymal stem cells have been shown to 
home to the site of injury and initiate repair, postulated to promote an increase in 
angiogenesis (23,24). Therefore, the role of endothelial cells in the revascularization of islets 
after isolation may have a major influence on their capacity for differentiation in vitro and in 
vivo. Indeed, multiple studies have demonstrated that the formation of new β-cells or other 
endocrine cells from embryonic stem cells (25) or human fetal pancreas (26) requires 
transplantation in vivo for full maturation and glucose responsiveness.  
 Using conditions as described by Yuan and colleagues (10) for islet dedifferentiation, 
and a combination of factors for redifferentiation including IGF-II, KGF, and Matrigel, we 
first sought to explore the capacity of neonatal mouse islets to dedifferentiate to a 
proliferative phenotype, and subsequently redifferentiate back towards functional 
endocrine cells in vitro. We hypothesized that changes in environment would provide the 
inductive signals for insulin re-expression. The redifferentiation potential was also examined 
after co-culture with mouse endothelial cells, and after transplantation into immune-
deficient mice to assess whether the in vivo environment was more effective than that 
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 provided in vitro in re-directing the resultant islet-derived cell-aggregates into functional 
insulin-producing cells capable of ameliorating hyperglycemia.  
 
2.2  Materials and methods 
2.2.1 Islet and duct isolation 
  Animal experimentation was approved by the Western University Animal Use Ethics 
Committee and in accordance with the Canadian Council on Animal Care. Reagents were 
obtained from Invitrogen (Carlsbad, CA) unless otherwise specified. Islets were isolated 
using a modified protocol as described (27). Briefly, postnatal day 7 (P7) C57Bl/6 mice 
(Charles River Laboratories, Wilmington MA) were euthanized by decapitation and their 
pancreata excised, starting at the tail of the spleen, and placed in a Petri dish.  One millilitre 
(1 mL) of digestion buffer, consisting of 1 mg/mL collagenase type V (Sigma Chemical, St. 
Louis, MO) in Hank’s Buffered Salt Solution (HBSS), was perfused through each pancreas 
using a 23 G needle until it expanded, and collected in an additional 1 mL digestion buffer 
per pancreas. Pancreata were placed in a shaking water bath at 37°C for 20-30 min and 
additionally shaken by hand gently for 1 min. Digested tissue was passed through a 14 G 
needle and washed in HBSS + 5% (v/v) fetal bovine serum (FBS). Intact islets were separated 
from acinar and duct cells using sequential Dextran (MP Biomedical, Solon, OH) gradients at 
27, 23 and 11% (v/v), and centrifuged for 25 min at 610 x G. Islets were collected from the 
27-23% interface using a 14 G syringe and washed in HBSS + 5% FBS, then placed in a Petri 
dish with HBSS + 5% FBS and handpicked using an inverted microscope.  
  Intact ducts were isolated similarly to islets, but the digestion time was decreased 
to prevent the loss of intact structures, and hand-shaking was omitted. The pancreatic cell 
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 mixture was passed through 2 mesh basins containing filters, one 30 μm and the other 70 
μm; large ducts being collected between these two, while intact islets collected at the 
bottom.  The ducts were then handpicked. 
 
2.2.2 Islet dedifferentiation  
Isolated islets were cultured in media as described (10), similar in composition to 
that used for the culture of generalized epithelial cells, including mammary (28), prostate 
(29), and cornea (30).   Such media commonly contain EGF, a corticosteroid, serum, insulin, 
and cholera toxin, which acts as a cAMP-elevating agent (28). Specifically, the formulation 
used for pancreatic ductal epithelial culture was composed of DMEM/F-12 (Gibco, Grand 
Island, New York), 10%  FBS, 100 mM Penicillin/Streptomycin (Gibco), 10 mM Fungizone 
(Gibco), 1 μg/mL insulin (Sigma), 100 ng/mL cholera toxin (Cedarlane Labs, Burlington ON), 
1 μM dexamethasone (Sigma), 0.1 mg/mL soybean trypsin inhibitor (Gibco), and 10 ng/mL 
EGF (ID Labs, London, ON). Islets were cultured on type I (rat-tail) collagen as a basement 
membrane (10).  
 
2.2.3 Redifferentiation of islet-derived cells  
After 1-4 weeks in ductal dedifferentiation culture, collagen was digested using 
Collagenase XI (Sigma), and the cell monolayer dispersed into a single cell suspension using 
Dispase and Accutase (BD Biosciences, Mississauga ON) as per manufacturer’s instructions. 
Cells were cultured for endocrine redifferentiation on 0.5 mL Matrigel (BD Biosciences) 
diluted 1:1 with DMEM/F12, and supplemented with media composed of DMEM/F12, 10% 
FBS, 100 mM Penicillin/Streptomycin, 10 mM Fungizone (Gibco), 100 ng/mL IGF-II (ID Labs) 
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 and 50 ng/mL KGF (FGF-7) (ID Labs). Alternatively, dispersed and dedifferentiated cells were 
cultured in media previously shown to promote endocrine maturation as described by Russ 
et al (31), and similar to Seaberg et al (32) consisting of 25 mmol/L D-glucose, 1%  bovine 
serum albumin (BSA), ITS (Sigma), N2 and B27 supplements (Gibco), 10 mmol/L 
nicotinamide (Sigma), 8 nm exendin-4 (Bachem Chemical, Bubendorf  Switzerland), and 8 
nm activin-A (Cedarlane Labs, Burlington, ON), in 6-well plates coated with Matrigel (1:25 
dilution). 
 
2.2.4 RNA isolation and qualitative Reverse Transcription-Polymerase Chain Reaction  
For analysis of cells at various stages of development or differentiation, RNA was 
assessed. Isolated cells were stored in RNAprotect (Qiagen, Venlo, Netherlands), and  total 
RNA extracted using RNeasy Plus Mini/Micro kits where appropriate (Qiagen). One 
nanogram (1 ng) total RNA was reverse transcribed to cDNA using Superscript II, Oligo(dT)12-
18 and 10 mM dNTPs.  Four microlitres of RT (cDNA) was amplified for specific genes of 
interest using 20 μM forward and reverse primers (Sigma) as described in Table 2.1, with 1 
U (0.2 μL) Taq DNA Polymerase (UBI Life Sciences Inc, Saskatoon, SK). Annealing 
temperatures were determined using Fast-PCR software (PrimerDigital Ltd, Helsinki 
Finland). RT-PCR was performed for islet markers insulin (Ins), glucokinase (Gck), and 
glucose transporter 2 (Glut2); transcription factors Pancreatic Duodenal Homeobox-1 
(Pdx1), Neurogenin3 (Ngn3), Neurogenic Differentiation1 (NeuroD), Paired box gene4 
(Pax4), Pax6, Homeobox protein Nkx_2.2 (Nkx2.2), Nkx6.1, v-Maf musculoaponeurotic 
fibrosarcoma onco- gene homologue A (MafA) and MafB; the mesenchymal marker 
vimentin (Vim); ductal (precursor) transcription factors SRY (sex-determining region Y) box 9 
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Table 2.1. Primer sequences designed for the amplification of mouse cDNA  
 
Gene  Sense primer (5’-3’) Antisense Primer (5’-3’)      Band Size  
Insulin ccctgctggccctgctctt aggtctgaaggtcacctgct 214  
Pdx1 tgtaggcagtacgggtcctc ccaccccagtttacaagctc 326  
Gck gcagatcctggcagagttcca ggaaggagaaggtgaagccca 408  
Glut2 caagatcaccggaaccttgg attccgcccactgcaaagct 313  
NeuroD cttggccaagaactacatctgg ggagtagggatgcaccgggaa 230  
Ngn3 ggcgcctcatcccttggatg cagtcacccacttctgcttcg 161  
Pax4 gtgagcaagatcctaggacgc cggggagaagatagtccgatt 379  
Pax6 aaacaaacgccctagctctcc ccgcccttggttaaagtcctc 118  
Nkx2.2 ctcttctccaaagcgcagac aacaaccgtggtaaggatcg 515  
Nkx6.1 ttctctggacagcaaatcttcg ctgagtgattttctcgtcgtca 298  
MafA tcactctgcccaccatcac tgacctcctccttgctgaag 198 
MafB ggtataaacgcgtccagcag cgagtttctcgcacttgacc  138    
CK19 gtgccaccattgacaactcc aatccacctccacactgacc 289  
Sox9 ttcatgaagatgaccgacga gtccagtcgtagcccttcag 242  
Hnf6 cgcggtgactcagctacaga atctgtgaccaccattgcag 103  
Hnf1β atctgtgaccaccattgcag tgcggtgactcagctacaga 178 
CAII agattggacctgcctcaccaa ttacttaaaggacgctttga 220 
      β-tub tcactgtgcctgaacttacc ggaacatagccgtaaactgc 319  
      FSP-1 atggcaagacccttggagga cattgcacatcatggcaatg 263 
      Vim aatgcttctctggcacgtct tcttccatctcacgcatctg 414 
Pdx1: pancreatic duodenal homeodomain box 1; Glut2: glucose transporter 2; Gck, 
glucokinase; Ngn3: neurogenin3; β-tub: β-tubulin; Ck19: cytokeratin 19; Sox9 : SRY 
(sex determining region-Y) box-9; Hnf6: hepatocyte nuclear factor 6; Hnfβ: 
Hepatocyte nuclear factor-β; MafA : V-maf musculoaponeurotic fibrosarcoma 
oncogene homolog A, Nkx2.2: homeobox protein Nkx_2.2;  Pax 4: paired box gene 
4; NeuroD: neurogenic differentiation 1; CAII: Carbonic Anhydrase II;  Vim: 
vimentin; FSP-1: fibroblast-specific protein 1 
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 (Sox9), Hepatocyte nuclear factor 6 (Hnf6), Hnf1β, mature duct markers, carbonic anhydrase 
II (CAII), and cytokeratin 19 (CK19), and β-tubulin used as control. PCR conditions were 
established to ensure linear amplification of PCR products using varying cycle numbers (26-
40 cycles). Amplified cDNA was run on a 2% agarose gel and visualized under UV-light, 
counterstained with ethidium bromide.   
 
2.2.5 Immunofluorescent cytochemistry 
For imaging of cells grown in vitro, collagen was digested using collagenase XI 
(Sigma) and Accutase (BD Biosciences, Mississauga ON), and Matrigel digested using 
Dispase (BD Biosciences), and washed in PBS to remove serum. Dispersed cells in PBS were 
then added to glass-bottomed Mattek dishes (Mattek Corp, Ashland, USA) adsorbed with 
diluted Cell-Tak (BD Biosciences) for 15 min. Adherent cells were fixed with 4% (v/v) 
paraformaldehyde (PFA) (Electron Microscopy Sciences, Hatfield, PA) for 15 min. Whole 
mount tissues such as intact islets or cell clusters were alternately handpicked and placed 
on Cell-tak-coated Mattek dishes for 30 min and fixed for 30 min in 4% PFA. Fixed cells 
adherent on Mattek dishes were stored in PBS at 4°C until immunocytochemistry was 
performed. Isolated cells were permeabilized with 0.3% (v/v) triton-X-100/PBS for 30 min 
before blocking with Background Sniper (Biocare Medical, Concord CA) for 8 min.  Primary 
antibodies were incubated in Antibody Diluting Solution overnight at 4°C and secondary 
antibodies for 2 h at room temperature. A list of antibodies and dilutions is provided in 
Table 2.2. Cell proliferation was determined by the addition of 0.05% (v/v) EdU (5-ethynyl-
2´-deoxyuridine)/PBS to the media for 6 h prior to fixation. Cells were stained with EdU 
Click-It Reaction kit. Nuclei were visualized by counterstaining with 4’, 6-diamidino-2-
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Table 2.2.  Antibodies used for immunofluorescent histochemistry 
 
Protein Animal Company          Dilution 
Insulin mouse Sigma Chemical (St Louis, MO)            1:2000 
Insulin rabbit Santa Cruz (Santa Cruz, CA)         1:200 
Pdx1 rabbit Abcam Inc (Toronto ON)         1:1000 
CK19 rabbit Abcam          1:100 
CK19 mouse Dako (Glostrup, Denmark)         1:100 
E-cadherin mouse Abcam          1:100 
Ki67  rabbit Neomarkers (Freemont CA)         1:200 
Ki67  mouse BD Biosciences (Mississauga ON)        1:50 
Ngn3 mouse DSHB *          1:40 
Vimentin rabbit  Santa Cruz          1:100 
 
*DSHB, Developmental Studies Hybridoma Bank, University of Iowa,  
Department of Biology, Iowa City, Iowa 
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 phenlindole (DAPI, blue), Sytox Green, or ToPro Red. Cells/sections were imaged on a Zeiss 
Laser Scanning Confocal Microscope (LSCM) (Zeiss, Oberkochen, Germany), and counted 
manually using the Zeiss LSM Image Browser.  The EdU staining kit utilized a far-red 
fluorophore (647 nm).  A beam splitter was placed on the LSCM at 560 nm, allowing a red 
fluorophore (543 nm/ 555 nm) to be used simultaneously with a far-red fluorophore (647 
nm).   
 
2.2.6 Transplantation experiments  
NOD/scid IL-2rγ-/- mice were utilized as transplant recipients, as these animals are 
deficient in T cells, B cells, all lymphocytes, and natural killer (NK) cells, and have been used 
previously in islet transplant experiments (33). Transplant recipient mice (n = 6) were 
maintained in barrier cages with free access to (sterilized) food and water at St. Joseph 
Animal Care Facility. Five hundred freshly isolated mouse islets and 1000 clusters from 
female C57Bl6 mice were transplanted to individual sites under the left kidney capsule of 
eight-week old NOD/scid IL-2rγ-/- male mice. Sex-mismatched transplants were chosen to 
distinguish donor from host cells if necessary using a gender-specific biomarker (Star*FISH, 
Cambio Ltd, Cambridge UK). Mice were anaesthetized using isofluorane, and post-surgical 
ketoprofen was administered as anaesthetic.  Mice were monitored daily after surgery.  
Intraperitoneal glucose tolerance tests (IPGTT) were performed 1 month post-
transplant to assess functionality. Animals were fasted 4 h prior to injection with 2 g/kg D-
glucose. Blood glucose measurements were taken at 0, 5, 15, 30, 60, and 90 min, and 50 μL 
blood samples were taken at 0, 15, and 90 min. Serum insulin values were assessed using 
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 Ultrasensitive Insulin radioimmunoassay (RIA) (range 0.02-1 ng/mL) (St. Joseph Health Care, 
London ON).   
Mice were euthanized following IPGTT by CO2. Kidneys and pancreas were dissected 
and fixed in 4% PFA for 24 h, then washed in PBS for 24 h prior to incubation in 30% (v/v) 
sucrose overnight, embedded in OCT, and cryosectioned for immunofluorescence analysis.  
Sections were immunostained for insulin, glucagon, Pdx1, and Ngn3 to determine the 
degree of maturation of transplanted cells, and proliferation frequency assessed using Ki67 
antigen.  
 
2.2.7 Media / Basement membrane recombination  
To assess the contribution of basement membrane proteins vs. media compositions 
to differentiation state, islets were cultured in various combinations: (1) dedifferentiation 
media + type 1 collagen; (2) redifferentiation media + type 1 collagen; (3) dedifferentiation 
media + Matrigel; and (4) redifferentiation media + Matrigel. After 4 weeks in these 
conditions, cells were dispersed into single cell suspension and subsequently cultured for 
“redifferentiation” on Matrigel with redifferentiation media containing IGF-II and KGF as 
described.  
 
2.2.8 Mouse pancreatic endothelial cell co-culture  
Mouse pancreatic endothelial cells (ECs) were isolated from C57Bl/6 mice at P10. 
Briefly, pancreata were isolated and placed in 0.25 mg/mL type XI collagenase at 37ºC for 
15 min. Cells were washed in HBSS + 5% FBS twice, then added to 3 mL DMEM/F-12+ 10% 
FBS.  Cells were then aspirated through a 3 mL syringe, followed by sequential aspiration 
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 through 18 G, 20 G, and 22 G needles. The slurry was filtered through a sterile 100 μm nylon 
mesh into single cell suspension.  EC cell selection was accomplished using PECAM-1 
antibody (1:50, CD31) (Hycult, Plymouth Meeting, PA) coated magnetic beads (Dynabeads) 
and a rotary magnet according to manufacturer’s instructions. The isolated ECs were 
cultured on 0.1% (v/v) Fibronectin (Sigma) cultured with EBM-2 media, with all supplements 
(Clonetics, Lonza Group Inc, Basel Switzerland). ECs were passaged a maximum of 3 times, 
splitting the cells 1:5, and media changed twice per week.  
 Eight thousand ECs were mixed with 500 μl DMEM/F-12, then diluted 1:1 with 
Matrigel and plated in a 6-well tissue culture dish. ECs formed branching structures within 
the Matrigel after 7 days and were supplied with EBM-2 media. Alternately, ECs were laid 
on top of the Matrigel, rather than embedding within it.  Differentiated islet-derived cells 
were then cultured on top of this.  
 
2.2.9 Statistical analysis 
Data are presented as percent (%) mean ± SEM, with statistics performed using a 
one-way ANOVA and Tukey’s post-test, or student’s t-tests as indicated, and with an 
acceptable level of significance of p < 0.05. Statistics were analyzed using GraphPad Prism 5 
software (La Jolla, CA).    
 
2.3  Results 
2.3.1 Changes in islet cell morphology  
Islets plated in dedifferentiation conditions (Figure 2.1A) lost all morphological 
characteristics of functional endocrine cells (Figure 2.1B), forming a heterogeneous, 
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Figure 2.1. Neonatal mouse islets cultured in dedifferentiation and 
redifferentiation conditions.  Neonatal (P7) mouse islets plated on collagen 
under dedifferentiation culture conditions, shortly after plating (A), after 4 days 
once monolayer formation had commenced (B), and after 4 weeks (C). Cells 
cultured in dedifferentiation media and harvested after 4 weeks were re-plated 
onto Matrigel under redifferentiation culture conditions. The cells formed 
cellular aggregates which suspended in the media, sometimes exhibiting long, 
duct-like morphologies (D) or alternatively, small spherical aggregates (E). Size 
bar denotes 50 μm, n > 10 experiments.  
B 
D E 
C B A 
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 proliferative epithelial-like monolayer within 4 weeks (Figure 2.1C), consistent with data 
shown by others (10,34). This monolayer could be passaged multiple times without further 
change in morphology (not shown). Similar morphologies were found after culture of 
isolated mouse pancreatic ducts.  
 When subsequently plated in “redifferentiation” conditions containing IGF-II and 
KGF, the dispersed islet-derived and duct-derived cell monolayers re-organized within the 
Matrigel, forming floating cell aggregates. These cell clusters adopted variable 
morphologies, often forming long, branched tube-like structures which resembled ducts 
(Figure 2.1D), or alternatively forming small spherical clusters (Figure 2.1E). These cell 
clusters could be continuously formed for months after plating.  
 
2.3.2 Changes in islet cell gene expression 
 Intact islets demonstrated markers of mature islet function, including Ins, Pdx1, and 
MafA as shown on a composite gel (Figure 2.2A). When cultured in dedifferentiation 
medium these mature markers diminished, instead showing an up-regulation of markers for 
ductal epithelium such as CK19 and CAII (Figure 2.2B), as well as ductal transcription factors 
Sox9, Hnf6, and Hnf1β (Figure 2.2B). MafB expression was maintained while MafA was lost.  
After culture in redifferentiation conditions on Matrigel in media containing IGF-II 
and KGF, the cell aggregates maintained ductal epithelial gene markers (Sox9, Hnf6, Hnf1β, 
CK19, CAII), but exhibited limited re-expression of some endocrine pancreas markers, such 
as Pdx1 and Nkx6.1 (Figure 2.2C).  MafB expression was maintained after cell-cluster 
formation (Figure 2.2C), but Vim expression was lost (not shown). Ins, MafA, and Ngn3 were 
not re-expressed.  
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Figure 2.2. Gene expression profile of cells obtained after culture of mouse 
islets. Expression of cDNA on a composite gel from isolated islets (row A), after 
four weeks on collagen with dedifferentiation media (row B), and from cellular 
clusters after subsequent culture in redifferentiation media (row C). Islet-
specific markers are surrounded by blue and duct-specific markers in red bar; n 
> 10.  
InsI   Pdx1   Gck    Glut2  NeuroD   Ngn3  Pax4   Pax6  Nk2.2  Nk6.1  MafA  MafB  CK19  Sox9  Hnf6  Hnf1b  CAII  β-tub 
A 
B 
C 
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 2.3.3 Changes in islet cell protein presence  
Assessment of protein presence using whole islet confocal microscopy revealed that 
isolated islets displayed immunostaining for insulin (Figure 2.3A, green), and Pdx1 (Figure 
2.3B, red), but not CK19 (Figure 2.3C, red). The dispersed dedifferentiated monolayer 
showed a loss of insulin immunostaining (Figure 2.3D, green), and an increase in 
immunostaining for CK19 (Figure 2.3D, red), as well as positive staining for e-cadherin 
(Figure 2.3E, green). After redifferentiation culture, intact cell clusters showed that both 
small spherical and elongated cluster morphologies were cyst-like, demonstrating a hollow 
core (Figure 2.3F, blue, DAPI). These cyst-like cell clusters maintained positive 
immunostaining for CK19 (Figure 2.3G, green), and e-cadherin (Figure 2.3H, green). Rarely, 
the small, spherical clusters demonstrated limited immunostaining for Pdx1 (Figure 2.3J, 
red), which was never seen in the elongated, branching cell clusters (Figure 2.3I). There was 
extremely low cell replication rates as calculated by EdU incorportion within the clusters 
(<0.1%, not shown). Efforts to promote redifferentiation by addition of other growth factors 
to redifferentiation media such as EGF, nicotinamide, betacellulin, and gastrin were 
unsuccessful, in that expression of key markers of redifferentiation were unchanged (not 
shown). However, when dedifferentiated islet-derived epithelial cells were cultured in 
established redifferentiation conditions shown to promote endocrine maturation (31,32), 
rare cells (<1:1000) demonstrated insulin expression by immunostaining (Figure 2.3K, red).  
 
2.3.4 Transplantation of islet-derived cells  
 Donor islets and islet-derived cell clusters within grafts survived after 
transplantation beneath the kidney capsule of normoglycemic NOD/scid IL-2rγ-/- mice 
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Figure 2.3. Immunofluorescent images of cells obtained after 
dedifferentiation and redifferentiation culture of mouse islets. Isolated islets 
were immunostained for insulin (A, green), Pdx1 (red, B) and CK19 (C, green). 
After dedifferentiation culture to ductal epithelium, there was a significant 
increase in the proportion of cells positive for ductal markers including CK19 (D, 
red) and e-cadherin (E, green). Redifferentiation procedures in the presence of 
IGF-II and KGF yielded cyst-like structures which resembled ducts (F), and which 
maintained expression of CK19 (G, green) and e-cadherin (H, green) and which 
was negative for Pdx1 (I, red). Alternative redifferentiation culture in media 
yielded restricted re-expression of Pdx1 and insulin in the small spherical 
clusters only (J, and K, red). Size bars represent 50 μm, n > 10 experiments.  
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 (Figures 2.4A-G). Transplantation of isolated islets demonstrated no loss of expression of 
insulin (Figure 2.4A, green) or Pdx1 (Figure 2.4B, red).  Transplantation of IGF-II + KGF media 
redifferentiated cell clusters revealed cells containing immunoreactive Pdx1 after 4 weeks in 
vivo (Figure 2.4D, red), as well as cell proliferation shown by staining for Ki67 antigen 
expression (Figure 2.4F, red, not quantified). However, insulin, MafA, and Ngn3 were not re-
expressed in any of these grafts. Ductal markers were maintained in the redifferentiated cell 
grafts, with positive immunostaining for e-cadherin (Figure 2.4G, green, arrows). A glucose 
tolerance test showing normal glycemia after transplant is provided in Figure 2.4H, 
demonstrating that the metabolism of the host mice was not altered following surgery.  
 
2.3.5 Co-culture of dedifferentiated cells with pancreatic endothelial cells 
 Mouse pancreatic ECs could be isolated and grown on fibronectin-coated culture 
dishes (Supplemental Figure S2.1A), and which could be passaged (Figure S2.1B). These 
cells grew substantially within the first 7 d of culture when isolated and mixed with Matrigel 
supplemented with EBM-2 medium (Figure S2.1C). After 7 d, ECs had formed branching 
structures (Figure S2.1D). When dedifferentiated islet cells were overlaid on top of Matrigel 
containing EC isolated from mouse pancreas, the dedifferentiated cells grew well in the 
presence of ECs, although this was not quantified (3 days, Figure 2.5A; +7 days, Figure 2.5B; 
+3 weeks, Figure 2.5C). The dedifferentiated cell morphology was slightly more disorganized 
when ECs were cultured on top of Matrigel with dedifferentiated cells overlaying these 
(Figure 2.5D). In both culture conditions however, there was no re-expression of insulin, 
ngn3, or other β-cell specific markers (not shown).  
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Figure 2.4. Effect of transplantation on cell differentiation state 
Islet grafts transplanted under NOD/scid IL-2rγ-/- mouse kidney capsules 
showing insulin (green, A) and Pdx1 (red, B) immunostaining. 
Redifferentiated cell cluster grafts (C-F) under the kidney capsule (blue, DAPI, 
C, E) demonstrated the presence of Pdx1 (D, red) and ki67 (F, red) but 
retained their ductal phenotype as shown by e-cadherin immunostaining (G, 
green). A glucose tolerance test of transplant recipient mice is shown in H. 
Size bar denotes 50 μm, n = 6 mice.  
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Figure 2.5. Co-culture of islet-derived cells with mouse pancreatic 
endothelial cells After plating dedifferentiated cells on top of pancreas-
derived mouse endothelial cells (ECs), there was significant growth  (+3 
days, A, +7 days B, + 3 weeks, C). Morphology was less uniform when ECs 
were plated on top of Matrigel with dedifferentiated cells overlaying 
these (D). Scale bars represent 50 μm, n = 4.  
B A 
C D 
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 2.3.6 Matrix/media combinations  
 To determine the effects of matrix and medium on islet dedifferentiation, isolated 
islets were cultured in either type I collagen or Matrigel with dedifferentiation medium or 
redifferentiation medium. Islets plated on collagen with dedifferentiation media 
(combination 1) produced a proliferative, heterogeneous epithelial monolayer (Figure 2.1A-
C) and islet morphology was lost within the first week in culture, as described above. Islets 
cultured on collagen with redifferentiation media (combination 2) retained the original islet 
structure, with an increase in fibroblasts; this was also found when islets were cultured in 
dedifferentiation media with Matrigel (combination 3), and when islets were grown in 
redifferentiation media on Matrigel (combination 4) (Figure 2.6A). Islets cultured in 
redifferentiation media with Matrigel became highly disorganized around the original islet 
structure with areas of epithelial as well as fibroblast growth. After dispersing and culturing 
all cells for redifferentiation in Matrigel, combination (1) cells formed ductal-like cell 
clusters which resembled cysts, and which were positive for ductal epithelial markers, as 
previously described.  Cells grown in combinations (2) and (3) both reformed cellular 
clumps, which were positive for fibroblast markers such as vimentin and fibroblast-specific 
protein 1 (FSP1), and which maintained expression of insulin and glucagon (not shown). 
Interestingly, islets grown in redifferentiation conditions from the outset maintained 
expression of islet markers such as insulin and glucagon, increased expression of fibroblastic 
markers, and also formed what appeared to be lipid droplets (Figure 2.6B) although further 
validation is required. Islets cultured in dedifferentiation media without cholera toxin did 
not form an epithelial monolayer and maintained the original islet structure. Overall, these 
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Figure 2.6. Variable cell types arise after culture of mouse islets in altered 
matrix/media combinations.  Changing the combination of media 
(dedifferentiation or redifferentiation) and matrix (type I collagen and 
Matrigel) showed that only islets plated on collagen and supplemented 
with dedifferentiation media caused the islet structure to disappear and a 
dramatic increase in ductal epithelial markers; all other combinations 
maintained the original islet structure (A). Cells with adipocyte-like 
morphology were noted as shown by the appearance of lipid-like droplets 
when isolated mouse islets were grown in Matrigel with redifferentiation 
media, then dispersed and re-plated under the same conditions (B). Scale 
bars represent 50 μm, n = 4.   
A B 
84
 data suggest that the media and matrix combination of type 1 collagen with EGF and 
cholera toxin promotes the most robust change in islet-derived cellular morphology.  
 
2.4  Discussion 
Following islet dedifferentiation to ductal epithelial cells on collagen in the presence 
of EGF and cholera toxin, a highly proliferative epithelial monolayer of cells was generated. 
Subsequent culturing of these cells on Matrigel using IGF-II and KGF yielded cell aggregates 
that maintained ductal genetic markers formed during dedifferentiation, with ductal/cyst-
like morphology. Dedifferentiated cells were also plated for redifferentiation in co-culture 
with mouse endothelial cells, or transplanted under the kidney capsule of immune deficient 
mice, to promote further cell maturation. These manipulations did not further result in the 
generation of insulin-producing cells. However, alternative use of redifferentiation medium 
reported by Russ and colleagues (31) did generate rare insulin-producing cells. It remains to 
be determined which experimental approach (dedifferentiation vs redifferentiation) is the 
limiting step for the generation of sufficient insulin-producing cells for transplant. 
Determination of the lineage origin of cells generated in the culture process would provide 
answers to these questions.  
Developmentally, islets are derived from cells within the pancreatic epithelium 
which share a bipotent progenitor cell state with duct cells (35). Extensive work has 
centered around the neogenesis of islets or insulin-producing cells from ducts, with 
compelling evidence suggesting the ductal compartment contains islet progenitor cells 
(16,36–42). Early lineage-tracing studies using CAII indicated that cells within the ductal 
epithelium were involved in endocrine regeneration (43), and some Ngn3+ lineage-tagged 
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 cells co-localized with duct cells after injury (44). However, recent evidence has indicated 
that the endocrine cells present within the ductal epithelial layer were not generated 
postnatally (45,46), thus restricting the contribution from ductal progenitors after birth to 
endocrine cell replacement.  
The media formulation used for the “redifferentiation” protocol is similar in 
composition to that used in the formation of “islet-like cell clusters” containing IGF-II, KGF, 
and HGF from human fetal pancreas (14,15), and to that used in the trans-differentiation of 
ducts to insulin-expressing cells (16). We have previously shown that IGF-II is an islet anti-
apoptotic factor (47), and KGF has been shown to be a potent ductal epithelial mitogen (48). 
Another study dedifferentiated islets to CK19+ cells, and subsequently used nicotinamide, 
ITS, and HGF for “redifferentiation” to insulin-producing cells (49). The continued use of 
serum in our model may have limited the ability of mature cells to change differentiation 
state; however, we found that the cells did not survive long-term culture without the 
trophic stimulus provided by the serum. Moreover, in the absence of lineage-tracing 
techniques, it is impossible to definitively conclude that the generation of insulin from 
ductal preparations did not arise from insulin-producing β-cells present at the outset. 
Similarly, a recent study by Kim et al generated insulin-expressing cells from isolated human 
ductal cells, using activin-A, exendin-4, and high glucose (50).  These same components are 
present in media used by Russ and colleagues (31), and were shown to generate rare 
insulin+ cells as demonstrated here. However, Kim et al asserted that these cells had derived 
exclusively from the ductal fraction, as they pretreated the pancreatic cell preparation with 
5mM streptozotocin (STZ) to destroy any residual β-cells retained therein (50). Human β-
cells have been shown to be generally resistant to the effects of STZ due to the low 
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 expression of GLUT2 as compared to rodent islets (51), and therefore the possibility that 
pre-existing β-cells present in the ductal cell preparation proliferated and generated 
functional insulin production has not been thoroughly disproved. In all studies of islet 
redifferentiation however, the re-expression of insulin was minimal when compared to β-
cell secretion in freshly-isolated islets (49,52). Even when directly promoting differentiation 
of human fetal pancreas, <5%  of “islet-like clusters” exhibited positive insulin-expression in 
vitro, although this jumped to ~50% after transplantation (26). This evidence suggests that 
these in vitro manipulations do not provide complete re-maturation of β-cells, let alone 
islets, thereby questioning the feasibility of this technique for clinical application. 
 The formation of cysts during islet cell redifferentiation was similarly shown by 
Bonner-Weir and colleagues during the trans-differentiation of ductal cells (16). While that 
study reported the generation of considerably more insulin-producing cells, our 
experiments utilized specific growth factors and serum which created a more mature duct-
like phenotype of long, branched structures. Interestingly, a study was performed using 
embryonic (e11.5) mouse pancreas epithelium to determine the effect of endocrine 
differentiation on basement membrane selection and mesenchyme inclusion (53). The 
authors cultured early epithelium in varying culture environments, including collagen I gels, 
Matrigel, or by transplantation under the kidney capsule of mice, thereby providing a milieu 
of vascular and dynamic temporal changes by the in vivo environment. They found that 
these early epithelial cells transplanted under the kidney capsule formed islets, whereas the 
cells grown in Matrigel formed almost exclusively ducts. The cells grown in collagen did not 
differentiate, and there was no expression of endocrine marker genes.  They also concluded 
that the mesenchyme was only required for acinar cell differentiation (53). Within the 
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 context of the present study, these data indicate that the Matrigel itself preferentially 
promoted ductal cyst formation. However, since we also performed transplant experiments 
and co-culture experiments with endothelial cells, and neither generated functional islets 
nor endocrine hormone-expressing cells, it would suggest that the lineage (re-)specification 
of intact, P7 islets or insulin-expressing β-cells was greatly determined by previous 
dedifferentiation on collagen, and that further manipulation of the cell culture environment 
during “redifferentiation” would have only modest effects.  
In addition to ductal-epithelium and fibroblastic cells, islets grown in Matrigel with 
redifferentiation media were shown to form adipocytes. Culturing pre-adipocytes in the 
presence of insulin, FBS, a glucocorticoid, and a cAMP-elevating agent has been shown to 
promote robust adipocyte differentiation (54), but which did not occur when culturing 
islets. However, when these islet cells were instead grown in Matrigel with media 
containing IGF-II and KGF, cells with an adipocyte-like appearance were generated. This 
could be attributed to the presence of laminin in the Matrigel, a strong pro-adipocyte 
differentiation factor (55), as opposed to the presence of EGF and type I collagen in the 
dedifferentiation media, which independently exert negative effects on adipocyte growth 
(55). Clearly, the interactions between media and basement membrane components 
influence the fate of the cells in question.  
The origin of the ductal-derived cell monolayer remains unknown, and there remains 
the possibility that one or more cell types were capable of ductal differentiation. The α-cell 
is one candidate cell type shown to exhibit a high level of plasticity (56,57), and may 
represent a future avenue for exploration. However, as β-cells compose ~80% of the islet 
compartment by mass, lineage tracing of the β-cell is a top priority for determining the cell 
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 type(s) of origin in the culture conditions purporting to effect dedifferentiation and 
redifferentiation. Barring significant contributions from δ (somatostatin-expressing), PP 
(pancreatic polypeptide-expressing) cells, or contaminating duct cells, the present data 
suggest that the cells obtained after islet growth in epithelial-promoting conditions must 
have derived from β-cells, or from an unidentified progenitor cell type resident within the 
islet which could rapidly and reproducibly proliferate. Therefore, determining the 
contribution of β-cell lineage to the ductal epithelial monolayer will be subsequently 
undertaken.  
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Lineage tracing of the β-cell during Dedifferentiation and Redifferentiation 
In Vitro from Neonatal Mouse Pancreas 
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 3.1  Introduction 
It has been proposed that all β-cells in the postnatal pancreas arise from pre-existing 
β-cells, both during aging and under regenerative circumstances (1,2). However, the 
contribution of “facultative” progenitor cells, which may require a stimulus of injury or 
depend on the maturation status of cells, has not been excluded (3). It has been shown that 
β-cell generation in diabetic mice can be induced by the presence of bone marrow-derived 
cells (4) and that cells with a functional β-cell phenotype can be generated from embryonic 
stem cells (5),  and multiple groups have demonstrated the generation of β-cells de novo 
from multiple pancreatic cell types (6–8). Since β-cells develop from bipotent trunk cells in 
the pancreatic epithelium which share a common precursor population with duct cells, we 
hypothesized that a plasticity of β-cells would exist in early life that would allow for their 
controlled dedifferentiation to a duct-like phenotype, subsequent population expansion, 
and finally redifferentiation to a β-cell phenotype.  It was previously shown that mouse and 
human β-cells can be expanded or dedifferentiated in vitro (9,10), with dedifferentiation 
defined here as the loss of mature and functional characteristics from a partially or 
terminally differentiated cell type. In some cases, this may occur prior to 
transdifferentiation, defined as the change from one differentiated phenotype to another 
involving morphological and functional phenotypic markers (11,12).   However, lineage 
tracing of the de- or transdifferentiated cells from those experiments indicated that the 
proliferation rate of resulting cells was low, insulin expression diminished after culture, and 
the progeny derived from mouse β-cells were ultimately eliminated from in vitro 
techniques.  We adapted a tissue culture protocol to promote dedifferentiation of isolated 
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 mouse islets to ductal epithelium (13,14),  and utilized neonatal mice (postnatal day 7, P7) 
in the expectation that at this age β-cells possess a degree of lineage plasticity.  Using a 
lineage tracing technique where RIPCre;Z/AP+/+ transgenic mice (15,16) are genetically 
tagged with a human placental alkaline phosphatase (HPAP) reporter in the majority of β-
cells, we sought to identify the fate of β-cells and their progeny during the dedifferentiation 
process.  Our results indicate that a sub-population of insulin-expressing cells exists within 
the neonatal mouse pancreas which retains a capacity for multi-lineage plasticity.  
 
3.2  Materials and methods 
 3.2.1 Animal experimentation  
All animal experimentation was approved by the Western University Animal Use 
Ethics Committee, in accordance with the Canadian Council on Animal Care. The transgenic 
mouse RIPCre+/+ (15) was crossed with a LacZ/HPAP reporter strain (16) (Jackson 
Laboratories, Bar Harbor, ME). Genotyping of RIPCre;Z/AP+/+ mice was accomplished by PCR 
amplification using primers for the RIPCre  (FW – gcggtctggcagtaaaaactatc and RV –
gtgaaacagcattgctgtcactt, 100 bp) and LacZ/HPAP transgenes (FW - ccgcttcccatatgtggctct 
and RV- gcatgagctcagtgcggttc, 548 bp)  from P5 pups. LacZ/HPAP- littermates were used as 
controls. Details of genotyping procedures are shown in supplemental methods.  
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 3.2.2 Islet dedifferentiation  
Reagents were obtained from Invitrogen (Carlsbad, CA) unless otherwise specified. 
Islets were isolated from P7 mice as described (17) (Chapter 2). Whole islets were plated 
25/ well in a 6-well plate coated with 1 mL type I (rat tail) collagen, with media as described 
(13) (Chapter 2). All cell culture media contained 100 mmol/L penicillin/streptomycin and 
10 mmol/L fungizone.  
 
3.2.3 Fluorescent immunohistochemistry  
Cell monolayers derived after dedifferentiation on collagen were prepared as 
described in Chapter 2.  Mice were injected with 2 μl 10 mmol/L EdU /g body weight 24 h 
prior to dissection, or, for in vitro incubation, 0.05% (v/v) was added to culture media for 6 h 
prior to fixation. To assess pancreatic cells ex vivo, mice were euthanized on P7 by 
decapitation and at later ages by CO2 asphyxiation, and pancreata were excised and 
immediately fixed in cold 4% paraformaldehyde (PFA) (Electron Biosciences, Hatfield, PA) 
for 24 h, washed in PBS for 24 h, incubated in 30% sucrose/PBS for 24 h, then embedded in 
OCT and snap frozen prior to cryosectioning at 8 nm.  The Ki67 antibody required antigen 
retrieval using 0.1 M Tris-EDTA at 95°C for 30 min. Sections and cells on Mattek dishes were 
permeabilized with 0.3% triton-X-100 /PBS for 10 min before blocking with Background 
SNIPER (Biocare Medical, Concord, CA) for 8 min.  The HPAP antibody made in mouse 
(Sigma-Aldrich, St Louis, MO) required the use of a mouse-on-mouse (MOM) staining kit 
(Vector Labs, Burlingame, CA) to block endogenous immunoglobulins.  Other antibodies 
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 utilized are described in Table 3.1. Antibodies were diluted in Antibody Diluting Solution 
and sections/ cells on Mattek dishes incubated overnight at 4°C. Fluorescent secondary 
antibodies were conjugated to 488/555/647 fluorophores (1/500) appropriately matched to 
the primary antibody, and sections incubated for 2 h at room temperature in the dark.  
Rates of cell proliferation were determined by EdU incorporation using the EdU Click-It 
reaction kit. Cells were counterstained with DAPI for quantification. Slides and Mattek 
dishes were imaged on a Zeiss LSM 510 Duo Vario (Carl Zeiss Ltd, Oberkochen, Germany) 
confocal microscope at the Biotron, Western University using Zen software, and cells 
counted manually using the Zeiss LSM Image Browser (version 4.2).   
 
3.2.4 Quantification of cells  
HPAP+ cells were quantified by co-staining with insulin in P7 pancreas sections (> 200 
insulin+ cells /section).  Isolated islets from each mouse were cultured separately. At least 5 
replicate cultures were performed, with >2000 cells counted per time point/replicate.  Due 
to low reporter protein presence after culturing, all HPAP+ cells were counted per Mattek 
dish.  At least 20 fields of view (FOV) were captured and total cell numbers counted (>50 
cells /FOV). The proportion of HPAP+ /total cells was calculated by extrapolating the average 
number of cells /FOV, then projecting this number to total FOV / Mattek dish.   
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Table 3.1. Antibodies used for immunofluorescent histochemistry 
 
Protein Species Company                              Dilution 
Insulin mouse Sigma Chemical (St Louis, MO)      1:2000 
Insulin rabbit Santa Cruz (Santa Cruz, CA )           1:200 
Insulin guinea pig Abcam Inc (Toronto ON)   1:300 
Glut2 goat Santa Cruz      1:100 
Glut2  rabbit Millipore EMD (Billerica, MA)         1:500 
Glucagon rabbit Santa Cruz    1:200 
Somatostatin mouse Santa Cruz    1:200 
CK19 mouse  Dako (Glostrup, Denmark)   1:100 
CK19 rabbit  Abcam    1:100 
Ki67  mouse BD Biosciences (Mississauga ON)   1:50 
HPAP mouse Sigma    1:500 
HPAP rabbit Abcam    1:200 
GPm6a mouse MBL International (Woburn, MA)  1:100 
GFAP rabbit Millipore    1:200 
β-III tubulin mouse Sigma    1:500 
Amylase mouse Abcam    1:50 
Glut2: glucose transporter 2; CK19: cytokeratin-19; HPAP: human placental 
alkaline phosphatase; GPm6a: glycoprotein m6a; GFAP: glial fibrillary acidic 
protein.  
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 3.2.5 Redifferentiation of islet-derived cells  
Dedifferentiated cells were cultured in redifferentiation media as described by Russ 
et al (18) (Chapter 2). Cells were cultured in 6-well plates coated with 1:25 Matrigel (BD 
Biosciences, Mississauga, ON) and maintained for up to 60 d. Matrigel was dissolved using 
Dispase (BD Biosciences) prior to downstream cellular analysis.  
 
3.2.6 Fluorescent-activated cell sorting  
 Excised pancreata were perfused with 2 mL digestion buffer (1.0 mg/mL collagenase 
V, 0.2 mg/mL BSA, 0.1 mg/mL soybean trypsin inhibitor, in HBSS) and incubated at 37°C, 
shaking, for 30 min. Cells were further dissociated with 0.25% trypsin/EDTA, shaken in a 
37°C water bath for 5 min, then drawn twice through 14 G, 18 G, 20 G, and 22 G needles. 
Enzymes were inactivated by the addition of 5 mL HBSS + 10% FBS + 0.1 mg/mL DNase I. 
After washing, the resulting cells were re-suspended in 1 mL Red Blood Cell Lysis Buffer for 
1 min, then inactivated by adding 5 mL HBSS + 10% FBS + 0.1 mg/mL DNase I. The slurry was 
strained through a 40 µm nylon mesh (BD Biosciences). Viability count was taken using 20 µl 
trypan blue + 20 µl cell mixture. Dispersed cells were immunostained for surface markers 
using antibodies for Glut2 and GPm6a (19) (Table 3.1), with primary and secondary 
antibodies incubated sequentially for 60 min each.  7-Aminoactinomycin D (7-AAD) was 
added as a viability marker. Gating strategy is provided in Figure S3.1. Live 
GPm6a+Glut2HI/MID/LO cells were sorted into separate fractions on a Becton Dickinson 
FACSAria III cell sorter running FACSDiVa software (v. 6.1.2) at the London Regional Flow 
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 Cytometry Facility at the Robarts Research Institute and the University of Western Ontario. 
Cells were recovered for in vitro culture.  
 
3.2.7 Glucose-stimulated insulin secretion (GSIS)  
Cells recovered from flow cytometric sorting were cultured overnight in DMEM/F-12 
+ 10% FBS, or dedifferentiated and redifferentiated in vitro, and stimulated as described for 
static GSIS assays in (20) using 2.8 and 16.7 mmol/L D-glucose. Insulin release was 
determined using an Ultrasensitive Insulin RIA (range 0.02-1 ng/mL) (St. Joseph Health Care, 
London ON).   
 
3.2.8 Neural-lineage differentiation  
Ins+(GPm6a+)Glut2HI/LO cells recovered from FACS were cultured in Neurocult Neural 
Stem Cell (NSC) Basal Media with Proliferation Supplement (Stemcell Technologies Inc, 
Vancouver, Canada) plus EGF and bFGF as per manufacturer’s instructions on low 
attachment plates for 7-14 d. Intact neurospheres were transferred to Matrigel-coated 
(1:25) Mattek dishes, and cultured with NSC Basal Media with Differentiation Supplement 
for 7-14 d.  Cells were fixed and immunostained for neural-lineage markers β-III tubulin and 
glial fibrillary associated protein (GFAP) (Table 3.1).   
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 3.2.9 Statistical analysis  
Data are expressed as mean ± SEM, and comparisons between groups analyzed 
using a student’s t-test or one-way ANOVA where indicated unless otherwise stated, and 
with a minimum acceptable level of significance of p < 0.05. Statistical analysis was 
performed using Graphpad Prism software (v. 5.01, San Diego CA).  
 
3.3  Results 
3.3.1 Loss of islet phenotype after culture  
Freshly isolated islets were cultured as described in Chapter 2 (Figure 2.1 (A-C)). 
Immunostaining for the acinar cell marker amylase was seen in pancreas sections outside of 
the islet (Supplemental Figure S3.2A), and was absent after 1 week in the dedifferentiated 
cell monolayer, as was insulin immunostaining (Figure S3.2B).   
 
3.3.2 Significant increase in CK19 expression during islet culture  
Islets within pancreas sections contained insulin as demonstrated by 
immunofluorescence (IF), and did not express CK19. After islet isolation and 1 week in 
dedifferentiation medium, 75.9 ± 4.5% of all cells expressed CK19 (p < 0.001), and this was 
maintained throughout the remaining culture period.  Cell proliferation was examined by 
the localization of EdU-positive cells, and within all islet cells was 3.1 ± 0.5%. After 
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 dedifferentiation culture for 1 week, the incidence of cell proliferation was 33.1 ± 8.2% (p < 
0.01); and thereafter remained at 6.3 ± 0.4%.    
 
3.3.3 Lineage tracing illustrates rare β-cell dedifferentiation  
We sought to determine the extent to which Ins+ cells contributed to islet cell 
dedifferentiation in vitro using the HPAP lineage tracer localized by immunohistochemistry 
using RIPCre; Z/AP+/+ mice. The HPAP reporter protein (Figure 3.1B, red) identified insulin-
expressing β-cells (Figure 3.1A, green) within the islet (Figure 3.1C, merged) with an 
efficiency of 85.3 ± 1.2% (Figure 3.1F). The staining frequency of HPAP (Figure 3.1E) in extra-
islet β-cell aggregates (BCA) containing <5 β-cells was significantly lower at 39.0 ± 6.9% (p < 
0.01) (Figure 3.1D, insulin, arrows; Figure 3.1F). These BCA were not included in the whole 
islet analysis as they were not cultured due to the physical limitations of handpicking islets.  
RIPCre;Z/AP-/- littermates did not exhibit HPAP immunostaining within pancreas sections 
(Figure 3.1H). CK19-positive cells were identified around ducts (Figure 3.1G, red) but not 
within HPAP+ islets (Figure 3.1G, green) in P7 pancreas sections.  In this system, β-cells 
constituted 78.9 ± 4.4% of total islet cells; thus 67.3 ± 3.9% of total islet cells expressed 
HPAP initially.  
After islet isolation and 1 week in vitro, the dedifferentiated monolayer displayed a 
total loss of insulin immunostaining (Figure 3.2A, red), and the frequency of HPAP 
expression dropped significantly to <0.1% of remaining cells (Figure 3.2B, green, arrow, 67.3 
± 3.9% vs 0.04 ± 0.01% HPAP+ cells/total cells, p < 0.0001, islet vs 1 week), representing 14-
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Figure 3.1. Specificity of HPAP to the β-cell using RIPCre;Z/AP+/+ mice   
(A) RIPCre;Z/AP+/+ transgenic mouse model showing insulin+ β-cells (green, A) 
tracked by the reporter protein HPAP (red, B, and merged, C), and quantified 
in (F). The HPAP expression in β-cell clusters containing fewer than 5 β-cells 
(D, E) was significantly reduced (F). HPAP+ β-cells in pancreas sections (G, 
green) did not co-express CK19 (G, red). RIPCre;Z/AP-/- mouse beta cells (H, 
green, insulin) did not exhibit HPAP immunostaining (H, red). Scale bar 
denotes 50 μm, n > 5. Data are represented as % Mean ± SEM, **p < 0.01.  
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Figure 3.2. Lineage tracing of the β-cell during in vitro islet dedifferentiation. 
After islets were cultured in dedifferentiation media for 7 d,  all insulin 
expression was lost (A, red), and only rare cells retained HPAP expression (A, 
green). CK19 (B, green) expression increased drastically, and the rare 
remaining HPAP+ cells also adopted CK19 expression (C, green, arrows). After 
replating the resultant epithelial-like monolayer of cells in redifferentiation 
media, the majority of the rare remaining HPAP+ cells (D, E, green) re-
expressed insulin (D, red). Scale bar denotes 50 μm, n > 5 replicates.  
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 95 HPAP+ immunostained cells retained per dish (n > 6), and equivalent to ~1/2,000 cells 
deriving from β-cells after 1 week in vitro.   However, of the surviving HPAP+ cells (Figure 
3.2C, green), 87.5 ± 3.9% expressed CK19 (Figure 3.2C, red) after 1 week in culture (islet vs 
all other time points, p < 0.0001). Proliferation of the remaining HPAP+ cells increased 
significantly at 1 week in culture, from 2.7 ± 0.9% to 25.6 ± 1.8% (p < 0.001) by EdU 
immunostaining, then decreased thereafter.  
To confirm that this represented loss of β-cells and not simply loss of insulin 
immunostaining, we examined β-cells early in culture. We found that insulin expression had 
diminished consistently with time, such that after 3 days, 48.1 ± 1.2% of cells present were 
insulin+, and by day 5, only 18.4 ± 2.1% of the cells were insulin+, and that HPAP tracked 
these cells at 85% consistently (Figure S3.3).   
The dedifferentiated cells were subsequently cultured in media shown to promote 
endocrine redifferentiation (18), and greater than 90% of rare remaining HPAP+ (Figure 3.2E 
& F, green) cells re-expressed insulin (Figure 3.2E, red, arrow) over 4 weeks of culture. 
 
3.3.4 Classification of β-cell subpopulations by Glut2 and GPm6a expression  
We examined if the β-cells retained after dedifferentiation (i.e., CK19+HPAP+ cells) 
had a distinct phenotype. Seaberg et al reported that rare, pancreas-derived multi-potential 
progenitor (PMP) cells exist within mouse islets which can generate progeny in both 
pancreatic and neural lineages (21). It was subsequently reported by Smukler and 
colleagues that these PMPs expressed insulin, albeit at reduced proportions as compared to 
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 proto-typical β-cells. Furthermore, these cells displayed a progenitor character, with 
decreased expression of Nkx6.1 and Pdx1, increased expression of Ngn3, and a lack of Glut2 
(22). We hypothesized that HPAP+CK19+ β-cell progeny in dedifferentiated cultures may 
have derived from such insulin+ PMPs. As the proportion of these progenitor cells in islets 
was reported to be only 1-5/10,000 (22), flow cytometric sorting of β-cells from whole 
pancreas from RIPCre;Z/AP+/+ mice was initially used to optimize yield. Cells were selected 
using antibodies for GPm6a (19), a cell surface marker shown to identify the β-cell, and 
Glut2.  GPM6a (red) immunostained insulin-expressing β-cells (green) as shown in Figure 
S3.4. Figure 3.3A illustrates GPm6aHIGlut2HI cells (red, phenotypically mature β-cells) and 
GPm6a+Glut2MID/LO cells (green); these cells were split into GPm6a+Glut2MID and 
GPm6a+Glut2LO groups and collected separately.  Insulin immunostaining was more 
prominent in the GPm6a+Glut2HI cells than in the other populations (Figure 3.3C, red). 
GPm6a+Glut2HI β-cells were immunopositive for Glut2 (Figure 3.3C, green, top panel), but 
this was greatly diminished in the GPm6a+Glut2MID cells (middle panel), and absent in the 
GPm6a+Glut2LO cells (lower panel). Measurement of insulin secretion demonstrated that 
GPm6a+Glut2HI cells secreted 18.6 ± 1.8 ng insulin when stimulated with 16 mmol/L D-
glucose, whereas secreted insulin from GPm6a+Glut2LO cells was below the threshold for 
detection (n = 3, 6000 cells/experiment).  
When cultured in ductal dedifferentiation conditions, the majority of GPm6aHIGlut2HI 
cells did not survive; the few resilient cells being non-proliferative, and failing to stain for 
CK19. Conversely, GPm6a+Glut2MID/LO cells dedifferentiated in vitro and immunostained for 
CK19 (red) and HPAP (green) (Figure 3.4A, arrows and circle).  The GPm6a+Glut2LO cells 
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Figure 3.3.  Pancreatic β-cells flow-cytometrically sorted by Glut2 and GPM6a. 
Whole pancreas (A) and isolated islets (B) were dispersed and flow-cytometrically 
sorted into distinct populations of insulin+ (GPM6a+) cells according to differential 
Glut2 expression:  GPM6a+Glut2+ (red) and GPM6a+ Glut2MID/LO (green), further split 
into GPM6a+Glut2LO (A, green, lower, and B, left population) and GPm6a+Glut2MID 
(A, darker green, upper).   FAC-sorted GPm6a+Glut2LO cells isolated from neonatal 
islets (B) represented only 0.3 ± 0.07% of total insulin+ cells. GPm6a+Glut2MID cells 
were not recovered from isolated islets (B). Cells recovered after sorting were 
immunostained for Glut2 (green) and insulin (red); insulin staining (C, red) was 
more prominent in typical β-cells (GPm6a+Glut2HI, top panel) as compared to 
GPm6a+Glut2MID/LO cells; furthermore, Glut2 immunostaining (green) was 
diminished in the GPm6a+Glut2MIDcells (middle), and was absent in the 
GPm6a+Glut2LO cells (green, bottom). Scale bars denote 50 μm, n = 5.  
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Figure 3.4. Dedifferentiation and redifferentiation of pancreatic GPM6a+ 
Glut2LO β-cells. After flow sorting and 1 week in dedifferentiation culture, the 
majority of Ins+Glut2LO cells co-expressed CK19 (red) and HPAP (green) (A, 
arrows and circle). (B) Redifferentiation of dedifferentiated ductal-like cells 
after 4 weeks of culture, showing the β-cell lineage reporter HPAP (green) co-
localizing with insulin (red) (arrow).  Scale bar denotes 50 μm, n = 5. 
A 
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 exhibited ~2-fold higher proportion of CK19+ cells after 4 weeks dedifferentiation than did 
the GPm6a+Glut2MID cells (72.4 ± 7.7% of Glut2LO vs 42.7 ± 8.9% of Glut2MID cells, p < 0.01, n 
= 5).  
When subsequently cultured for redifferentiation, HPAP+ cells (Figure 3.4B, green) 
demonstrated insulin expression (Figure 3.4B, red); however, the redifferentiated β-cells 
were functionally immature and did not demonstrate robust insulin secretion at low or high 
glucose concentrations (14.1 ± 0.4 pg vs 18.9 ± 0.4 pg insulin, respectively, n = 3, 5 x 104 
cells/experiment). These results are consistent with human stem cell differentiation to β-
cells (23), which demonstrated an immature phenotype in vitro. 
Flow cytometric sorting was performed on β-cells recovered from isolated islets 
(Figure 3.3B), but GPm6a+Glut2MID cells were not recovered in contrast to their presence 
within whole pancreas (Figure 3.3A). GPm6a+Glut2LO cells in isolated islets represented only 
0.3 ± 0.1% of total cells by flow cytometry, indicating that the majority of GPm6a+Glut2LO 
cells exist outside of the islet (Figure 3.3B).  
 
3.3.5 Ins+Glut2- cells are primarily found outside of islets  
To identify the anatomical location of the insulin-positive but Glut2-negative cells, 
pancreas sections were immunostained for insulin, Glut2, and EdU. The majority of these 
cells were found to reside outside of islets; a representative Ins+Glut2-EdU+ cell being shown 
in Figure 3.5A. As a convention, we use the nomenclature “Glut2LO” to represent isolated β-
cells identified by FACs, and “Glut2-“ to denote β-cells identified by IF analysis within 
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Figure 3.5. Location and proliferation of neonatal mouse Ins+Glut2- β-cells 
(A) Immunofluorescent images of a mouse P7 pancreas section 
immunostained for insulin (i, red), Glut2 (ii, green), EdU (iii, yellow), and 
merged images (iv), located in an extra-islet β-cell aggregate (iv, BCA), 
demonstrating an Ins+Glut2-EdU+ cell (arrow). (B) Ins+Glut2- cells were primarily 
located in BCA as compared to islets (B, ***p < 0.001 total vs <5 β-cells, ****p 
< 0.0001 >5 β-cells vs <5 β-cells). (C) The proliferation rate of Ins+ cells was 
higher in BCA than in islets (**p < 0.01, Mann-Whitney test). (D) 
Ins+EdU+Glut2- cells can be found in high proportion in both BCA and islets (D, 
*p < 0.05).  Scale bar denotes 50 μm, n > 5. Data are represented as % mean ± 
SEM. 
* 
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 pancreas sections.  Ins+Glut2- cells represented 3.5 ± 0.2% of all insulin-expressing cells in 
the P7 pancreas by fluorescent immunocytochemical staining (Figure 3.5B, 1,935 cells, n = 5 
pancreata). When separated for quantification into β-cells found within islets (>5 β-cells) or 
within extra-islet β-cell aggregates (<5 β-cells, BCA), Ins+Glut2- cells represented 1.2 ± 0.3% 
of insulin+ cells within islets, and 20.5 ± 3.6% of insulin+ cells within BCA (Figure 3.5B, 
23/1703 cells and 45/232 cells, respectively).  The proliferation rate of Ins+ cells was higher 
in BCA than in islets at P7 (12.6 ± 0.7% vs 2.8 ± 0.2% respectively, Figure 3.5C). These 
proliferating insulin+ cells were examined further, and showed that 12.8 ± 4.1% of Ins+EdU+ 
cells lacked Glut2 within islets, and 20.1 ± 5.6% within BCA (Figure 3.5D), illustrating that at 
P7 Ins+Glut2- cells are proliferative both within and outside of the islet as compared to 
Ins+Glut2+ β-cells.   
 
3.3.6 HPAP+ cells tag non-insulin-expressing-cells after extended time in vivo 
In the young RIPCre/Z/AP+/+ mouse (<14 d), HPAP+ cells that immunostained for 
proteins other than insulin were extremely rare (Figure 3.6C and D, white bars). However, 
when older (>1 yr) RIPCre;Z/AP+/+ mice were examined, the proportion of HPAP+ cells 
(green) labelling non-insulin expressing cells increased, including glucagon (Figure 3.6A, red) 
and somatostatin (Figure 3.6B, red), Quantification of these events is presented in Figure 
3.6C and D (black bars).  
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Figure 3.6. Alternate cell fates of HPAP+ cells in vivo.  
Images from RIPCre;Z/AP+/+ mice demonstrating that some HPAP-tagged cells 
(A, B, green) express non-β-cell markers after a long time period (>1 yr, n = 3 
mice), including  glucagon (A, red) and somatostatin (B, red) as compared to 
young mice (<14 d, n = 5).  Arrows indicate dual stained cells. These were 
quantified into marker+/HPAP+ cells (C) or HPAP+/marker+ cells (D). Scale 
bar denotes 50 μm. Data are represented as % mean ± SEM, C and D, >1 yr vs 
<14 d, t-test, * p < 0.05. 
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 3.3.7 Ins+Glut2- cells generate neurospheres and neural-lineage cells in vitro 
To assess the capacity for cellular plasticity, insulin-expressing cells detected using 
GPm6a were recovered after FACS and cultured in neural differentiation conditions. A 
subset (~1/200) of these GPm6a+Glut2LO cells proliferated and formed neurospheres (Figure 
3.7A); Ins+Glut2HI cells did not proliferate (Figure 3.7B). Once plated for neural 
differentiation, the Ins+Glut2LO-derived neurospheres formed cells with neuronal-like 
processes (Figure 3.7C, D). These cells demonstrated immunostaining for the neuronal 
marker β-III tubulin (Figure 3.7E, G, green) and the astrocyte marker glial fibrillary acidic 
protein (GFAP) (Figure 3.7F, H, red). Both of these resulting cell phenotypes expressed the 
β-cell reporter HPAP (Figure 3.7F, G, red, and Figure 3.7 G, H, green), demonstrating the 
lineage plasticity of Ins+Glut2LO cells. Furthermore, all neurospheres generated both 
neuronal and astrocyte cell types.  
 
3.4  Discussion  
Islet dedifferentiation, expansion, and subsequent redifferentiation have long been 
proposed as a source of insulin-producing cells to facilitate transplantation for the reversal 
of diabetes. Based on a model which postulated “islet trans-differentiation” to a hormone-
negative phenotype with similarities to ductal-epithelium (13), we hypothesized that the 
resultant cell monolayer was derived, in part, from β-cells that could be tracked using a 
lineage tracing technique utilizing HPAP expression. We found that the majority of β-cells 
from isolated islets did not survive in vitro; however, ~1/2,000 of the cells present had 
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Figure 3.7. Pancreatic Ins+Glut2LO β-cells are multi-potential and can 
differentiate into neural cell lineages.  
Insulin+ cells recovered from whole mouse pancreas after FAC-sorting based 
on Glut2 expression were placed in neural proliferation conditions. 
Neurospheres (A) were generated from GPM6a+Glut2LO cells, compared to 
GPM6a+Glut2HI cells (B). After replating in neural differentiation conditions, 
the neurospheres generated multiple morphologies, including neuron-like 
processes (C, D). When immunofluorescently stained, neurons were 
visualized by β-III tubulin (E, G green), and astrocytes by GFAP (H,J, red).  
These neural cells co-stained with HPAP (red, F, G; green, I, J). Scale bar 
denotes 100 μm (A, B), and 50 μm (C-J), n = 5.  
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 derived from β-cells and dedifferentiated to become CK19+ cells. We subsequently 
hypothesized that these HPAP+CK19+ cells represented the progeny of Ins+Glut2- cells, 
reported to denote a pancreatic multipotent progenitor cell pool (22). We have shown that 
these PMPs can be isolated from neonatal mouse pancreas, and which are capable of 
differentiation to a variety of cell types in vitro. Importantly, while Ins+Glut2- cells can 
indeed be found in intact islets as reported (22), a higher proportion are located in 
scattered β-cells outside of islets, and which have a significantly greater proliferative 
capacity at P7 than the Ins+Glut2+ cells.  
More than one cell type populated the islet-derived dedifferentiation cultures, with 
only a minority derived from β-cells.  Other groups have demonstrated similar results by 
lineage tracing experiments, with 1.4% and 0.5% mouse β-cells dedifferentiating in vitro, 
respectively (9,10), and <5% of β-cells dedifferentiating from human islets using similar 
culture conditions (24).  These findings indicated higher rates of dedifferentiation than 
found by us; however, those groups did not further characterize the rare β-cells capable of 
dedifferentiation. As our initial cellular preparation contained multiple cell types, it is 
conceivable that some of the CK19-expressing cells generated during dedifferentiation 
culture were derived from adherent ductal cells present at the time of islet isolation and 
which subsequently expanded in vitro, diluting the cellular contribution from β-cells. 
The concept that progenitor cells may paradoxically express mature markers, such as 
insulin, could explain why such cells in the pancreas have remained elusive. Interestingly, it 
does satisfy the evidence that postnatal β-cells arise from pre-existing β-cells (1), but, as 
shown here,  not all insulin-expressing cells are of equivalent phenotype.  Other precedents 
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 for mature marker presence in stem cell populations exist, such as neural stem cells 
expressing the astrocyte marker GFAP (25). We have shown that Ins+Glut2- cells represent 
1.2% of β-cells in the neonatal islet by immunostaining, but only a subset of these cells are 
capable of differentiation to pancreatic islet and ductal phenotypes; the proportion of 
plastic cells being similar to that found by Smukler et al (22). However, a striking 3.5% of 
insulin-expressing cells within whole pancreas at P7 lacked Glut2, with up to 20% of these 
cells being found within BCA. This suggests that the highest source of β-cells capable of 
demonstrating lineage plasticity is found outside of the islet, and these extra-islet BCAs are 
most abundant in the neonatal period and thereafter decline with advancing age (26). The 
absence of Glut2 expression is likely not the sole identifier of a β-cell progenitor however, 
since the co-expression of other markers such as Ngn3 and Nkx6.1 has been proposed by 
others (22,27). Reports have demonstrated the presence of putative β-cell progenitors 
during adulthood, with or without diabetes, and showed that these cells exhibited higher 
expression levels of Pdx1and MafB, and low/absent expression levels of genes indicative of 
mature gene function, including Nkx6.1 and Glut2 (6,28). Furthermore, these β-cells could 
be subdivided into those with the ability to transition to mature β-cells in culture, and those 
that maintained a progenitor phenotype throughout, illustrating β-cell heterogeneity and 
differing states of functional maturation (28). Mouse β-cells in the immediate postnatal 
period are immature, with poor GSIS and lower expression of Glut2 compared to adult β-
cells (29–31). It was recently reported that neonatal β-cells require a glucose threshold for 
maturation, and that β-cells within BCA of young mice are functionally different than those 
in islets (20). Furthermore, infant human β-cells demonstrate some plasticity in insulin 
secretory machinery as compared to adult β-cells (32). Our data suggests that a lack of 
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 Glut2 expression may reflect not only β-cells with decreased function, but also a subset of 
progenitor cells. Interestingly, Stolovich-Rain et al (33) showed that after β-cell ablation, 
surviving β-cells in the mouse pancreas displayed significantly decreased levels of Glut2, 
purportedly due to glucose toxicity.  While injury models were not examined in the present 
study, it must be assessed whether a decrease in Glut2 expression is a necessary 
mechanism during regeneration, a direct result of environmental toxicity, or whether the 
surviving cells exhibited Glut2 expression at all. As we have shown an increased 
proliferation in the Ins+Glut2- cells, it is conceivable that these could clonally expand to 
replace β-cells after injury, with subsequent maturation to functional β-cells exhibiting high 
Glut2 expression.  
Russ et al (9) showed that human β-cells were able to dedifferentiate much more 
readily than mouse β-cells in vitro.   Despite distinctions between human and rodent islets 
with respect to architecture (34) and higher prevalence of GLUT1 utilization over GLUT2 
(35–39),  Smukler et al (22) demonstrated that Ins+Glut2LO cells from adult human islets had 
a similar phenotype, occurrence, and lineage plasticity to those found in mice.   Moreover, 
GLUT2 has been recently implicated in human neonatal diabetes (40) and its importance for 
glucose transport into human β-cells has been demonstrated (41). If Ins+GLUT2- cells are as 
abundant in the BCA of human pancreas from young donors as we have shown here in 
mice, the inclusion of these cells may enhance the effectiveness and longevity of human 
islet transplantation.  
Dor et al showed that β-cells in adult mice within the small extra-islet clusters had a 
similar labelling index with a genetic lineage tag as did those in larger islets, and concluded 
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 that these simply represented small islets, or islets with β-cells undergoing apoptosis, rather 
than reflecting a new source of β-cells derived from a progenitor population (1). Our 
experiments differ in that; 1) we used a non-inducible transgenic model which results in the 
labelling of a much higher percentage of β-cells allowing for greater discrimination in sub-
population changes, and 2) we studied neonatal as opposed to adult mice. Within this 
paradigm, we have shown that there is significantly lower lineage labelling with HPAP in β-
cells located within the BCA than in anatomically mature islets in P7 mice (39% vs 85%), 
which is likely to reflect the generation of new β-cells from progenitors within the BCA 
during early postnatal life. While the number of extra-islet BCA decreases with age in 
rodents, they are still found in adulthood (26). Chintinne et al (42) found that the majority 
of β-cells in young rats were present in small aggregates (<50 μm diameter, including single 
cells) which formed postnatally, and concluded that the neogenesis and clustering of these 
aggregates is a key process to attaining β-cell mass in adulthood. Our data would suggest 
that such β-cells in mice represent, in part, a population that has recently differentiated 
from insulin- progenitors, which consequently did not tag with HPAP.  
As indicated by Murtaugh (43), the study by Smukler et al (22) used the inducible 
RIPCreER;Z/EG model to tag β-cells and follow them in vivo, a model in which only a subset 
of β-cells are tagged,  and which has been recently suggested to inappropriately label a 
fraction of acinar cells over an extended chase, raising concern over RIPCreER transgene 
stringency (44).  The present study used the non-inducible strain RIPCre to tag a high 
proportion of β-cells with HPAP before islet isolation and in vitro culture. As the amount of 
lineage-tagged β-cells retained was only ~0.05% after 1 week in vitro, we propose that this 
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 number does not over-represent the surviving β-cell population. Furthermore, while the 
lineage-label eGFP was used for sorting β-cells in that study (22), the non-fluorescent HPAP 
reporter in our model required us to employ a proxy β-cell surface marker, GPm6A (19). We 
have shown that Ins+Glut2- cells can be detected and collected using different techniques 
(FACS and immunofluorescence), various markers for β-cells (insulin, GPm6A, and HPAP), 
and two separate antibodies for Glut2, indicating that these findings are unlikely to 
represent artefact. That a sub-population of Ins+ cells can reproducibly create CK19+ duct 
cells, subsequently re-express insulin, or can alternatively differentiate into neural-lineage 
cells indicates a substantial plasticity potential. It has also been questioned whether <0.1% 
of β-cell progenitors within islets could reasonably account for β-cell mass renewal (43). We 
have shown that the majority of Ins+Glut2- cells are found in the scattered BCA of the 
pancreas, which have received little experimental attention. These Ins+Glut2- cells are 
proliferative, and as speculated by Smukler et al, could represent the rare, proliferative β-
cell “clones” described previously (45); findings contrary to studies which indicated that all 
β-cells exhibit an equal proliferative potential (2,46). However, given the scarcity of the 
Ins+Glut2- cells within adult islets, they could have been overlooked. Of note, it was recently 
reported that after pancreatic duct ligation of 8 week old mice, the highest proliferation of 
insulin-expressing cells had occurred in small islets of <20 β-cells, which were found to 
regenerate the pancreas, and which had derived from Ngn3+ cells within small β-cell 
clusters (47). 
This work builds on evidence that the mouse and human pancreas contain Ins+ 
multipotent pancreatic progenitor cells, which can be identified by the absence of Glut2 
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 (21,22). Determining the fate of these progenitors during maturation, and the age at which 
their numbers cease to be a feasible source of renewable insulin-producing cells, may 
elucidate the extent of postnatal β-cell plasticity.  
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 4.1  Introduction 
A replacement of insulin-producing β-cells is required for the reversal of diabetes, 
and may be theoretically obtained by utilizing endogenous pancreatic β-cell progenitors. 
However, the presence of these β-cell progenitors is controversial, with as many 
publications supporting their existence (1–4) as those that reject it (5–7). The debate may 
not be as polarized as appears, since the presence of facultative stem cells (8), age (9–11), 
pregnancy (12–14), obesity (15–17), release from cell-cycle regulators (18),  altered glucose 
metabolism (19), and the type of pancreatic injury (20,21)  may each contribute to the 
milieu of factors putatively capable of effecting regeneration of the endocrine pancreas. 
This debate is further complicated by evidence that rare pancreatic progenitor cells present 
in human and mouse islets are capable of multi-potential differentiation and express insulin 
(22), usually considered to be a marker of a mature β-cell. Importantly, while these cells 
expressed insulin, they lacked Glucose-transporter 2 (Glut2), another feature of mature β-
cells, and furthermore displayed progenitor characteristics, with increased expression of 
early β-cell transcription factors.  Recently, we (Chapter 3) demonstrated that these 
Ins+Glut2- cells were present within neonatal (postnatal) P7 mouse islets which 
demonstrated multi-lineage plasticity, and displayed a loss of glucose responsiveness, 
indicating that these β-cells are atypical. Importantly, there was a higher proportional 
presence of these in the small pancreatic β-cell aggregates of cells (BCA, <5 β-cells) than in 
islets. BCA have been presumed to be of little physiological importance. The relative 
abundance of the cells capable of multi-lineage differentiation ranged from 1/2000 β-cells 
within P7 mouse islets as found by us, to 1/10, 000 in the adult human and mouse islet as 
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 found by Smukler et al (22).  It was established by immunohistochemistry that up to 1% of 
all β-cells present in the P7 mouse pancreas – the majority of them extra-islet β-cells - 
expressed insulin but not Glut2, but that only 1/200 were capable of differentiation; the 
bulk then possibly representing immature and/or glucose-unresponsive β-cells. The present 
study therefore sought to explore two main avenues of interest: first, to identify whether 
Ins+GLUT2- cells were also present in human samples, especially within BCA; and second, to 
determine how the location and abundance of these Ins+GLUT2- cells changed with age in 
both mouse and human pancreas.  
 
4.2  Materials and methods 
4.2.1 Human and mouse pancreas sample collection  
Twenty-five human pancreas samples were assessed, obtained as formalin-fixed and 
paraffin-embedded tissue sections from the Department of Pathology at the University of 
Western Ontario, Schulich School of Medicine (London ON), and the University of Chicago 
(Illinois), with approval from the University of Western Ontario Research Ethics Board 
#103167, and Lawson approval number R-12-501. Inclusion criteria were that pancreas 
samples be selected from cadaveric tissues, taken from donors with no known metabolic 
disease, and body weight within established healthy BMI standards (18-25 kg/m2). Tissues 
utilized were representative of diverse ethnic backgrounds, and evenly split between male 
and female samples (48% female, 12/25 samples).  Paraffin blocks were chosen from mid-
pancreas whenever possible.   
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 All animal procedures were approved by the Western University Animal Use Ethics 
Committee, in accordance with the Canadian Council on Animal Care.  Mouse pancreas 
samples were collected from wild-type littermates and retired breeders from our existing 
transgenic colonies present at the Lawson Health Research Institute, St Joseph Health Care, 
London ON, and with a C57Bl/6 background. Mouse pancreata were fixed in 4% 
paraformaldehyde (PFA, Electron Microscopy Sciences (Hatfield PA)) for 24 h, washed in PBS 
for 24 h, incubated in 30% sucrose for 24 h, and frozen in OCT at -80°C prior to sectioning at 
8 nm.  
Tissues from various ages were chosen to illustrate major developmental stages, 
including early endocrine pancreas development, infancy, childhood, adolescence/sexual 
maturation, adulthood, and late life; human samples are shown in Table 4.1, and a 
schematic of life stages for both species are shown in Figure 4.1.  Tissue samples were age-
matched within each life stage and were collected from both sexes.  
 
4.2.2 Fluorescent immunohistochemistry  
Fluorescent immunohistochemistry was performed using antibodies for insulin 
(human anti-mouse, Sigma-Aldrich (St Louis MO), 1/2000, and rabbit anti-human, Santa 
Cruz Biotechnologies (Santa Cruz, CA) 1/200), Glut2 (goat anti-human, Santa Cruz, 1/200, 
and rabbit anti-human, Millipore (Billerica, MA) 1/500), and Ki67 antigen (mouse anti-
human, BD Biosciences (Mississauga, ON), 1/50). Secondary antibodies were matched to the 
species of the primary antibodies, and conjugated to 488/555/647 fluorophores (Life 
Technologies Inc (Carlsbad CA) 1/500). DAPI (Life Technologies, 1/1000) was used to 
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Table 4.1. Human Pancreas Samples  
Case No.  Sex Age Developmental Stage 
1 F 22 weeks G Fetal 
2 F 30 weeks G Fetal 
3 F 30 weeks G Fetal 
4 M 2 days Infant 
5 F 11 days Infant 
6 M                      14 days Infant 
7 F 5 years Child 
8 M 6 years Child 
9 M 6 years Child 
10 F 6 years Child 
11 F 9 years Child 
12 M 10 years Adolescent  
13 M 11 years Adolescent  
14 F 14 years Adolescent  
15 M 19 years Young Adult 
16 F 20 years Young Adult 
17 M 36 years Young Adult 
18 F 41 years Young Adult 
19 M 50 years Adult 
20 F 52 years Adult 
21 M 54 years Adult  
22 M 56 years Adult  
23 M 65 years Late Adult 
22 F 72 years Late Adult 
24 M 72 years Late Adult  
25 M 79 years Late Adult  
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Figure 4.1. Lifespan of the mouse and human. The entire lifespan was 
examined in human (A) and mouse (B), with ages selected to illustrate 
major developmental stages, including early development, infancy, 
childhood/weaning, puberty/sexual maturation, and adulthood, as 
represented by each red star. When possible, developmental points were 
matched. A significant proportion of mouse islet development occurs 
postnatally, such that 20 weeks gestation in humans is analogous to 
postnatal d8 in mice. n ≥ 4 mice, and ≥ 3 humans/star.  
Infancy Puberty Gestation 
Time  
(years) 
Childhood 
40 wks 0 -1  2-9   10-17   41-64  65+ 
Adulthood   
Birth Wean Gestation 
Time  
21d 0  21d    
Sexual  
Maturity 
28d  18mo 
Adulthood   
12mo 7d 14d 
18-40  
6mo 3mo 
A 
B 
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 counterstain nuclei of all tissues. GLUT2 immunostaining in human pancreas samples 
required the use of tyramide signal amplification (23) using a kit (Perkin Elmer, Waltham, 
MA) conjugated to a Cy3 fluorophore. Ki67 signal visualization required antigen retrieval at 
95°C in Tris-EDTA buffer for 30 min. All tissues were permeabilized for 10 min with 0.3% 
triton-X-100 and blocked with Background SNIPER (Biocare Medical, Concord CA) for 8 min.  
Tissues were imaged by confocal microscope using a Zeiss LSM 510 Duo Vario (Carl 
Zeiss Ltd, Oberkochen, Germany) at the Biotron Facility, Western University, and counted 
manually using Zen software. Minimum cell counts were >250 insulin+ β-cells/section for 
mice (≥2 sections per pancreas), and >1500 insulin+ β-cells/section in human pancreas (1 
section per pancreas from 1 block). Controls were determined by cutting replicate sections 
from the same block (>100 μm apart), and variance around the mean was below 9%.   
 
4.2.3 Statistical analysis 
There were at least quadruplicate samples per cohort per life stage for mouse 
samples and triplicate pancreata analyzed for human samples (Table 4.1).  Data are 
presented as percent (%) mean ± SEM of insulin+ β-cells, with statistics performed using a 
one-way ANOVA and Tukey’s post-test, or student’s t-tests as indicated, and with an 
acceptable level of significance of p < 0.05.  Statistical analysis was performed using 
Graphpad Prism software (v. 5.01, San Diego CA). 
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 4.3  Results 
4.3.1 β- cell Aggregate (BCA) proportion decreases with age in mouse and human 
pancreas 
Pan & Wright (24) showed that mice display significant postnatal endocrine 
development, such that P8 mouse endocrine pancreas is analogous to 22 week gestation 
fetal pancreas in humans; thus, we used these time points to begin our analysis. At 7d, 16.1 
± 0.8% of mouse β-cells were located in BCA (Figure 4.2A, white bar). This proportion 
decreased by 18 months of age to only 2.1 ± 0.7%; the majority instead being present in 
proto-typical islets (Figure 4.2A, black bar, 18 mo vs 7d, p < 0.005).  
In contrast to mice, 41.6 ± 3.3% of human β-cells were located in BCA during the 
fetal period (G22-30w) (Figure 4.2B, white bar, and Figure 4.2C, immunostaining positive for 
insulin (green)). This proportion was significantly larger than the equivalent population in 
mice during the earliest time point studied (G22-30w vs 7d, p < 0.0005, t- test, not shown). 
The proportion of BCA in human pancreas dropped during infancy (0-1 y, hatched bar) and 
childhood (2-9 y, hatched bar) to 28.4 ± 2.2% (Figure 4.2B, 0-1 and 2-9 vs G22-30w, p  
<0.05), then significantly decreased at puberty to 5.5 ± 1.1% (Figure 4.2B, hatched bar, G22-
30w vs 10-17, p < 0.0005, and 4.2D). Interestingly, there was an equivalent proportion of 
BCA at the time of sexual maturation between mouse and human samples (28d mouse vs 
10-17 yr human, t-test, p = 0.68, not shown). The majority of human β-cells were thereafter 
maintained throughout adulthood within islets (Figure 4.2B, black bars, and arrows, Figure 
4.2D). There was a statistically significant difference in the BCA proportion between human 
female and male samples in early adulthood, with 11.0 ± 0.3% vs 4.3 ± 0.7% respectively 
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** *** 
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Figure 4.2. Beta cell aggregate proportion decreases with age in both mouse 
and human pancreas. Similar developmental points were grouped (7d 
(mouse) and fetal (human) samples = white bars, pre-weaning and sexual 
maturation (14-28d) (mouse) and infancy/childhood/adolescence (human) 
samples = hatched bars, and all adult ages  = black bars. β-cells were counted 
and assigned to either the BCA compartment (<5 β-cells) or islet (>5 β-cells). 
(C-E) Representative images from human pancreas immunostained with 
insulin (green) illustrate changes during the maturation of islet structures, 
from fetal age (C, 30 week gestation female) through puberty (D, 14 year old 
female), and late adulthood (E, 72 year female). Graphs are shown as 
proportion (%) mean ± SEM of total β-cells counted; 1-way ANOVA * p < 0.05, 
** p < 0.005, *** p < 0.0005. Size bar denotes 50 μm, n > 3 . 
E D C 
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 (18-41, p <0.05, t-test). By late adulthood, there were very few BCA present within sections 
of human pancreas (Figure 4.2E, arrows). Mouse and human pancreata displayed no 
difference in BCA proportion during adulthood and late adulthood.  It must be 
acknowledged that if islets were sectioned at the periphery, then the size would 
theoretically be equivalent to that of the BCA; however, this would be a relatively rare 
event. Furthermore, if that were true, then these data would not change with age as seen 
here.  
 
4.3.2 Ins+Glut2- cell proportion decreases with age  
We examined the population of Ins+Glut2- cells over the lifespan of both human and 
mouse. Human pancreas sections demonstrated immunostaining for insulin (green) and 
GLUT2 (red) as shown in Figure 4.3. A representative image of human Ins+GLUT2- cells is 
shown in Figure 4.3B (arrows) within the BCA compartment.  In mice, the proportional 
presence of total Ins+Glut2- cells decreased significantly from 3.8 ± 0.8% at 7d to 0.6 ± 0.2% 
at 3 mo (Figure 4.4A, 7d vs 28d-12mo, p < 0.05), which was further exaggerated by 18 mo 
(Figure 4.4A, p < 0.005). The decrease in this population was also significant from pre-
weaning to late adulthood (Figure 4.4A, 14d, 21d vs 18 mo, p < 0.05). There was a similar 
trend found in humans, with total Ins+GLUT2- cells decreasing from the fetal time period to 
adulthood (Figure 4.4B, G22-30w vs all others, p < 0.0005) , as well as from childhood to 
late adulthood (Figure 4.4B, 2-9 vs 65+  p < 0.05). There were twice as many total Ins+GLUT2- 
cells in human pancreas than in mouse at the initial time point studied (7.8 ± 0.9% G22-30w 
vs 3.8 ± 0.8% 7d, p < 0.05).  
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Figure 4.3. Insulin and GLUT2 immunostaining in human pancreas. 
Representative images of an islet (A) and beta cell aggregate (B) stained for 
insulin (green) and GLUT2 (red) in human pancreas. Ins+GLUT2- cells are 
shown in B (arrows). Size bar represents 50 μm.  
A 
B 
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Figure 4.4.  Ins+Glut2- cell proportion decreases with age.   
Ins+Glut2- cell proportion from total β-cells (A, B), islets (C, D), and BCA (E,F) as 
found in mouse (A, C, E) and human (B, D, F) pancreas samples. Graphs are 
shown as proportion (%) mean ± SEM of total β-cells counted; 1-way ANOVA 
with tukey’s post-test or student’s t-test, §,* p  < 0.05; §§ p  < 0.005; §§§, *** 
p  < 0.0005.  
138
 The anatomical location of Ins+Glut2- cells was then examined. Figure 4.4C shows 
that 1.6 ± 0.4% of mouse β-cells lack Glut2 at 7d within the islet (white bar), which is 
consistent with previous findings (Chapter 3).  As hypothesized, this proportion significantly 
decreased by early adulthood (range 0.2 ± 0.1% – 0.4 ± 0.1%, 7d vs 3 mo, p < 0.05). 
 In humans, 1.1 ± 0.2% of the β-cells within the islet lacked GLUT2 during fetal life, 
which decreased significantly by childhood, and further thereafter (Figure 4.4D, G22-30w vs 
10-17, p < 0.005).  There were few Ins+GLUT2- cells present in islets by late adulthood in 
human pancreas (Figure 4.4D, 1.1 ± 0.2 vs 0.07±0.01%, G22-30w vs 65+, p < 0.0005). There 
was a trend towards a decrease in Ins+GLUT2- cells within the islets in early adulthood, and a 
subsequent increase in the population during mid-adulthood (Figure 4.4C and D, black bars; 
0.6 ± 0.1% vs 0.07±0.01%, 41-64 vs 65+, p <0.05).   
The proportion of Ins+Glut2- cells within the BCA compartment was markedly 
different than that within the islet, with 16.1 ± 2.6% of all mouse insulin-expressing cells 
lacking Glut2 within BCA at 7d (Figure 4.4E). This proportion increased at the immediate 
postnatal time period (14d, 21d), but decreased thereafter at 3 mo and 18 mo (Figure 4.4E, 
16.1± 2.6% vs 9.2 ± 2.7%, 7d vs 18 mo, p <0.05). 
 In the human pancreas, a similar proportion of Ins+GLUT2- cells were found in BCA 
in the fetal time period as in the 7d mouse (17.0 ± 1.7% vs 16.1 ± 2.6%, G22-30w vs 7d, ns). 
Ins+GLUT2- cell proportional presence in the BCA was maintained throughout most of life, 
with a significant decrease in Ins+GLUT2- cells in BCA only in late adulthood (Figure 4.4F, 
19.1 ± 1.7% vs 7.1 ± 1.6%, 41-64 vs 65+, p < 0.05).  
 
 
139
 4.3.3 β-cell proliferation decreases with age 
The proliferation index of total insulin+ β-cells was examined in mouse by Ki67 
immunostaining, and was found to be highest at 7d compared to all other time points 
(Figure 4.5A, 3.3 ± 0.1% vs 0.7 ± 0.1%, 7d vs 3mo, p <0.0005). Beta-cell proliferation had 
decreased by weaning (2.0 ± 0.2% at 14d and 1.6 ± 0.2% at 21d), and thereafter 
proliferation was maintained at ~0.6% (Figure 4.5A, black squares). In the human pancreas, 
a similar trend was noted, with the highest total β-cell proliferation found in fetal life, which 
dropped thereafter (Figure 4.5B, 1.4 ± 0.5% vs 0.2 ± 0.1%, G22-30w vs 65+, p <0.05). There 
was significant variability in the pre- and perinatal samples, ranging from 0.9 – 2.3% and 0.2 
– 0.9%, respectively (Figure 4.5B).  
Proliferation of β-cells within islets followed similar patterns as was found in total β-
cell proliferation, with rates of replicating β-cells highest in mice at 7d, and which decreased 
significantly by early adulthood (Figure 4.5C, 2.8 ± 0.2% vs 0.6±0.1%, 7d vs 6mo, p < 0.005). 
In the human, a similar trend was noted as in mice, with proliferation of β-cells being 
highest during the fetal time period, and decreasing thereafter (Figure 4.5D, 1.3 ± 0.5% vs 
0.2 ± 0.03%, G22-30w vs 65+, p < 0.05). There was considerable variability in the β-cell 
proliferation rate within the islet in the fetal and infant samples, ranging from 0. 6-2.2% and 
0.1-1.2%, respectively. After adolescence, β-cell proliferation within the islet was 
maintained <0.5% (Figure 4.5D).  
Within BCA, β-cell proliferation dropped significantly in mice from 7d to 28d and at 
3mo (Figure 4.5E, 7.7 ± 1.0% vs 1.5 ± 0.03%, 7d vs 28d, p < 0.05). A similar trend occurred in 
the human BCA compartment, with a significant decrease in proliferation from mid-
gestation to adolescence (Figure 4.5F, 1.4±0.3% vs 0.0 ± 0.0%, G22-30w vs 10-17, p < 0.05).  
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Figure 4.5. Frequency of β-cell proliferation decreases with age. 
Proliferation of insulin+ β-cells by Ki67 presence is shown in total β-cells  (A, 
B), islets (C, D), and BCA (E,F) within mouse (A, C, E) and human (B, D, F) 
pancreas samples. Scatter graphs show the spread of data points between 
individual pancreata, and  % mean of β-cells counted is indicated by 1-way 
ANOVA; * p < 0.05, ** p < 0.005, *** p < 0.0005.  
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 We have previously shown that Ins+Glut2- cells displayed increased proliferation in 
the mouse at P7, with 12.8 ± 4.1% of Ins+EdU+ cells lacking Glut2 in the islet, and 20.1 ± 5.6% 
of those cells lacking Glut2 in the BCA (Chapter 3). We examined this same population of 
Ins+Glut2-Ki67+ cells throughout the lifespan of mice and humans. Consistent with our 
previous findings, 11.9 ± 5.0% of proliferating β-cells lacked Glut2 in the islet, and 23.2 ± 
4.7% in the BCA at 7d in the mouse. At the equivalent age in humans (G22-30 w), only 1/3 
of pancreas samples exhibited Ins+GLUT2-Ki67+ immunostaining. The total proportion of 
proliferating β-cells which lacked GLUT2 increased at infancy to 14.4 ± 9.9% (0-1 yr, 2/3 
samples), and during childhood to 10.4 ± 6.2% (2-9 yrs, 2/4 samples); in all cases, the cells 
being predominantly found in BCA. After 7d in the mouse and childhood in the human, the 
proportion of Ins+GLUT2-Ki67+ cells diminished greatly, with only rare cells found at all 
subsequent ages in BCA, and none in islets. 
 
4.4  Discussion 
Over the mammalian lifespan, the endocrine pancreas undergoes significant changes 
in terms of cellular maturity, function, replication ability, and cell macro-organization (25).  
Previous studies have shown that a population of Ins+Glut2-, lineage-plastic putative 
progenitor cells can be identified in adult human and mouse islets (22), and which are 
proportionally increased in the small, extra-islet clusters of β-cells of neonatal mice 
(Chapter 3). Hence, we sought to determine if this population was also present in BCA in the 
human pancreas, as well as to assess how this cell population changes with age. We have 
found that human pancreas also contains a significant proportion of Ins+GLUT2- cells both 
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 within and outside of the islet, and this population decreases with advancing age in both 
species.  
Some novel insights may be gleaned from this ontological study of human pancreas, 
specifically regarding pancreas maturation and remodelling at key developmental time 
periods, namely birth and adolescence.  First, a significant proportion of endocrine cell mass 
is present in the young human pancreas outside of proto-typical islet structures, with nearly 
45% of β-cells present in small clusters of cells (<5 β-cells) during mid-gestation, ~30% 
during infancy, and ~20% during childhood. This trend has been shown previously (26), 
however it was not quantified per se. Indeed, there is a lack of consistency in nomenclature 
and size metrics when quantifying these small β-cell aggregates or clusters, with an “islet”  
being identified as 4 (insulin+) β-cells together (26,27), as compared to “β-cell clusters” 
constituting <10 β-cells (5), or <20 β-cells (3) when quantified by cell number, or 
alternatively <50 μm (28,29) or <60 μm(30) when determined by β-cell area grouping size. 
Within the confines of our model, the proportion of β-cells present as single cells/small 
clusters (i.e., BCA, <5 β-cells) outside of the islet only drops substantially around puberty, 
and is thereafter maintained in the adult at ~5%. This dramatic decrease was not seen in 
mouse, which showed a more gradual decline after weaning. However, in both species, β-
cell proliferation in the BCA compartment was extremely low (mouse)/ absent (human) at 
this developmental stage, which may indicate a shift in cell plasticity. The low rate of β-cell 
proliferation during adolescence has been noted previously (26), although not specifically in 
reference to β-cells outside of islets. It is of interest to note that the incidence of type 1 
diabetes in humans peaks between 10-14 years (i.e., puberty/adolescence) (31), which 
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 coincides with the developmental shift to larger islets and fewer β-cell aggregates as 
demonstrated here. We propose that in addition to the hormonal demands and somatic 
growth necessary at this age (26), adolescence may be an especially vulnerable window for 
diabetes if this reserve pool of β-cells is not available for endocrine tissue remodelling. It is 
currently unknown if the Ins+GLUT2- β-cells are equally susceptible to autoimmune 
destruction as mature β-cells. It is speculative to hypothesize that these cells may represent 
the small clusters of β-cells retained in the pancreata of older “Medalist” donor tissues (32).  
Second, it has been shown that human pancreas contain a higher proportion of 
small islets relative to large islets than is found in mice (30). Interestingly, there is evidence 
that small islets are functionally superior to large ones following transplant (33,34). While 
the physiological relevance of extra-islet β-cells in human pancreas remains to be 
determined, the implications of this data are clear: as only intact islets are isolated for 
transplant, a significant proportion of β-cell mass is currently discarded during human islet 
transplant preparations, specifically from young donors. It was recently shown that islet 
transplants from young donors generate superior results, although islet yields are poorer 
compared to those from adults (35). Furthermore, we contend that this population of cells 
contains the highest proportion of Ins+GLUT2- β-cell progenitors.  
There was a surprisingly high degree of correlation between human and mouse in 
the cellular population of interest, given that humans predominantly use GLUT1 (23,36,37) 
and to a lesser extent GLUT3 (23) compared with GLUT2 for glucose transport when 
compared with mice. Regardless, there is clearly a role for the glucose transporter-2 in 
human pancreas. In both species, the population of Ins+Glut2- cells was present in high 
proportion within the BCA compartment, decreasing only in late life. This implies that as 
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 long as there are BCA present, there is a capacity for tissue remodelling, and by extension, 
tissue regeneration potential. Within the context of the complete BCA data however, the 
Ins+Glut2- cell population does decrease in absolute terms as the total population of BCA 
decreases with advancing age.  
Evidence for β-cell proliferation in the human has, until recently, been limited to few 
publications. Kassem et al demonstrated a low rate of proliferation, even in prenatal life 
between 17-32 weeks gestation, the rate of human β-cell replication being only 3.2%, and 
dropping further to 0.1% after 6 months of age (38). Detailed analyses by Meier et al 
showed similar rates of human β-cell proliferation at birth of 2.5% (26,39). Interestingly, 
that group also found higher rates of proliferation in small islets and β-cells found scattered 
throughout the pancreas, and which decreased with advancing age. This same trend was 
also shown by Jo et al, who concluded that large islets were created both from proliferation 
as well as the coalescence of small clusters (27), and this cluster aggregation decreased with 
age (40).  By adulthood, there is the consensus that β-cell proliferation is extremely low, at 
~0.2-0.5%  (26,41–45).  Rates of β-cell proliferation in rodents have been shown to be 
similar to those in humans, with 1-3% β-cells replicating in the young rat (46), and only 
~0.2% by adulthood (45,47). Our results are consistent with the reported rates of human β-
cell proliferation, as well as the observed variability between young human pancreata. 
However, we have demonstrated the mouse β-cell proliferation rate to be higher than has 
been reported by others. 
A limitation to this study was availability of human tissue of specific ages.  Mouse 
pancreas showed some subtle, but potentially important, differences in the Ins+Glut2- cell 
population within the BCA compartment during the immediate postnatal time period and 
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 up to weaning at 21d. However, the human samples we were able to analyze at a similar 
developmental stage were limited to the month around birth only. Assessing human 
pancreata around the time of weaning could potentially yield more information, although 
given the variability in human genetics, lifestyle, and diet which is not found in laboratory 
mice, this is conjecture. Direct comparison between human and mouse developmental 
time-points contains inherent limitations, but even despite these restraints, the data 
demonstrated high correlation. Due to constraints of sample size, we were not able to fully 
analyze gender-specific differences in human pancreas.  Moreover, we did not have 
information regarding whether the human female subjects we studied had ever been 
pregnant. We did not find, however, any differences in any parameter studied (BCA 
proportion, Ins+Glut2- cell population, or proliferation rate) between nulliparous and 
multiparous female mice (48).  
A key goal is to determine the physiological function of the Ins+Glut2- cells.. We have 
demonstrated that these cells are present in substantial number during early postnatal life, 
and that they decline with age. We postulate that this represents a reserve pool of cells 
available for use in times of metabolic need and during endocrine pancreas maturation. 
However, it is theoretically conceivable that β-cells instead undergo a normal cycle of 
developmental transition in glucose-responsiveness, expressing Glut2 in high and low 
proportion, although this phenomena would not likely change with age as shown here.  Our 
data would suggest that some of these Ins+Glut2- cells mature into Ins+Glut2+ cells, similar to 
data proposed by Szabat et al (49), which showed that β-cells can transition between 
Pdx1+Inslocells to Pdx1+Ins+ cells.    
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 The regenerative capacity of the endocrine pancreas decreases with advancing age. 
This coincides with the decline in both Ins+Glut2- (putative progenitor) cells, and the 
location in which they are predominantly found. Determining the role of these cells during 
pathological circumstance or in times of metabolic demand will further elucidate a potential 
role for this cell population in human health and pancreas development.  
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 5.1  Introduction  
The replication of pre-existing β-cells has been shown to be the prominent source of 
cell turnover with age (1,2). However, the contribution of progenitor cells to β-cell mass 
postnally is less understood, especially within the context of induced regeneration, such as 
following pancreatic duct ligation (PDL) (3,4), or administration of the β-cell toxin 
Streptozotocin (STZ) in the young rodent.  
The glucose-transporter 2 (Glut2) is a transmembrane carrier protein that enables 
glucose movement across cell membranes in liver, kidney, and pancreatic β-cells (5). The 
existence of insulin-positive, Glut2-negative (Ins+Glut2-) cells was identified within the 
pancreas over two decades ago (6), but a potential role for these cells was only recently 
elucidated, with their characterization as pancreatic multi-potential progenitor cells in both 
adult mouse and human islets and ducts (7). We have recently shown a significantly higher 
number of these Ins+Glut2- cells in neonatal (postnatal day 7, D7) mice, within islets and 
especially in extra-islet β-cell aggregates (BCA, <5 β-cells) (Chapter 3). These cells are 
proliferative in vivo and in vitro, and a subset retain the capacity to differentiate into 
pancreatic endocrine and ductal lineages. Moreover, these Ins+Glut2- cells are present in the 
highest proportion during the neonatal time period and decrease with age in both mouse 
and human pancreas (Chapter 4).   
We (8–12) and others (13–15) have shown that young rodents retain the capacity to 
partially regenerate β-cell mass after STZ ablation, but this regenerative potential is 
mitigated in adulthood (15–17). As a glucose mimetic, STZ  accesses the β-cell via Glut2 (18–
20) and causes β-cell necrosis within 24 h of administration by DNA alkylation and 
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 fragmentation (21); Glut2-/- mice then are resistant to the effects of STZ  (20).  Given the 
numerous Ins+Glut2- progenitor cells present in BCA, and because the number of BCA are 
highest in the neonatal time period and decrease with age (22) (Chapter 4), it is 
hypothesized that neonatal rodents are able to regenerate their β-cell mass after STZ 
administration in part from Ins+Glut2- cells spared exposure to the toxin. These Ins+Glut2- 
cells then contribute to the regeneration of the endocrine pancreas. Using a pulse-chase 
experiment in which a proportion of insulin+ cells are tagged with a human placental 
alkaline phosphatase (HPAP) reporter followed by STZ administration and EdU 
incorporation, we sought to lineage trace the fate of β-cells after ablation and during 
regeneration, and to determine the contribution of Ins+Glut2- cells to this process.  
 
5.2  Materials and methods 
5.2.1 Animal experiments 
  All animal experimentation was performed with the approval of the animal use 
ethics committee of Western University, London, ON and in accordance with guidelines of 
the Canadian Council on Animal Care. Mice were maintained at the Animal Care Facility at 
Lawson Health Research Institute, St Joseph Health Care, with free access to food and 
water. (Ins2-cre/ERT)1Dam/J (RIPCreER) (23) mice was crossed with a LacZ reporter strain,  
tagged with the human placental alkaline phosphatase (HPAP) gene (24) as a lineage tracing 
technique to follow the β-cell. LacZ/HPAP+/- and RIPCreER+/- mice were purchased from 
Jackson Laboratories (Bar Harbor, Maine).  Mice were genotyped using ear/tail tissue 
samples on D4.  Identification of double-positive mice was accomplished by PCR 
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 amplification using primers (Sigma Chemical, St Louis, MO) for the transgenes RIPCreER 
(FW- aacctggatagtgaaacaggggc, RV- ttccatggagcgaacgacgagacc, 410 bp), and LacZ/HPAP 
(FW- ccgcttcccatatgtggctctgtcc; RV- gcatgagctcagtgcggttccacac, 548bp).  Transgenic control 
experiments are shown in Supplemental Material and Figures S5.1 and S5.2, and details of 
transgenic mouse strain development is described by Dor et al (23).  
To induce β-cell tagging with the HPAP reporter, RIPCreER;Z/AP+/+ pups were 
injected on D4 and D5 with 0.1 mg/g body weight tamoxifen (Sigma), from 20 mg/ml stock 
prepared in corn oil (Sigma). Detail of the dosing strategy for neonatal mice is described in 
Supplemental Material and Figure S5.3.   
 
5.2.2 Induction of hyperglycemia by STZ  
Streptozotocin (Sigma) was injected on D7 (100 μg/g body weight, in 0.1 M citrate 
buffer). Transgene-negative litter mates were used as controls, and injected with corn oil 
and 0.1 M citrate buffer (sham). Both STZ-treated and control mice were pulse labelled with 
EdU on D8 (Invitrogen, Carlsbad, CA) (2 μl/g body weight of 10 mM stock) to assess β-cell 
proliferation immediately following STZ and the transmission of the retained DNA label in 
subsequent progeny. Glucose measurements were taken prior to sacrifice by tail vein blood 
samples using a One Touch Ultra glucometer (Lifescan Inc, Milpitas, CA). An experimental 
schematic is shown in Figure 5.1A, and the lineage-tracing paradigm in Figure 5.1B.  
Mice were euthanized on D9, 14, 21, or 28. Pancreata were excised and prepared for 
cryosectioning as described in Chapter 3. 
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Figure 5.1. Experimental schematic and lineage tracing paradigm. 
(A) Transgenic RIPCreER;Z/AP+/+ mice were induced to express the reporter 
protein HPAP after 2 injections of tamoxifen (TM) on postnatal days (D)4 and 5. 
Streptozotocin was injected 2 days later (D7) to knock down a proportion of 
insulin-expressing β-cells. EdU was injected on D8 to track the cells which 
proliferated immediately following injury. Starting on D9 and up to 3 weeks later, 
pancreata were dissected and analyzed for endocrine regeneration by the 
presence and location of cells expressing of insulin, Glut2, HPAP, EdU, and Ki67. 
(B) Lineage tracing paradigm using a pulse-chase method. Squares represent 
islets, and circles represent unlabelled (white) and labelled (HPAP, black) β-cells. 
After induction of HPAP by TM, β-cells were tracked during aging or following 
injury. A decrease in the labelling index of HPAP indicates that β-cells form from 
cells not expressing insulin initially, i.e., stem cell source (option 1). Conversely, 
maintenance of the labelling index of HPAP indicates that β-cells form by self-
duplication exclusively (option 2).  
TM 
Time 
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 5.2.3 Immunofluorescent histochemistry  
Pancreas sections on slides were subjected to antigen retrieval using 95°C in 0.1 M 
Tris-EDTA buffer for 30 min. Sections were permeabilized with 0.3% triton-X-100/PBS for 10 
min before blocking with Background SNIPER (Biocare Medical, Concord, CA) for 8 min.  
HPAP+ cells were identified using a mouse anti-HPAP antibody (Sigma, 1/500) or with a 
rabbit anti-HPAP antibody (1/200, Abcam, Cambridge, UK); the mouse antibody required 
the use of a mouse-on-mouse (MOM) staining kit (Vector Labs, Burlingame, CA) to block 
endogenous immunoglobulins.  Other antibodies utilized include mouse anti-human insulin 
(Sigma, 1/2000), rabbit anti-human insulin (Santa Cruz Biotechnology, Santa Cruz CA, 
1/200), and goat anti-human Glut2 (Santa Cruz, 1/100). Antibodies were diluted in Antibody 
Diluting Solution (Life Technologies Inc, Carlsbad CA) and sections incubated overnight at 
4°C. Fluorescent secondary antibodies were conjugated to 488/555/647 fluorophores (Life 
Technologies, 1/500) appropriately matched to the primary antibody, and sections 
incubated for 2 h at room temperature in the dark.  Rates of cell proliferation were 
determined by EdU incorporation using the EdU Click-It reaction kit (Life Technologies), and 
by Ki67 immunostaining using a mouse anti-human Ki67 (BD Biosciences, Mississauga, 
Canada, 1/50). Cells were counterstained with DAPI for quantification. Slides were imaged 
on a Zeiss LSM 510 Duo Vario (Carl Zeiss Ltd, Oberkochen, Germany) confocal microscope at 
the Biotron Institute, Western University using Zen software, and cells were counted 
manually using the Zeiss LSM Image Browser.   
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 5.2.4 Beta cell morphometry  
Two pancreas sections per mouse were immunostained with insulin as described 
previously (10), and imaged and analyzed using Northern Eclipse software (v7.0; Empix 
Imaging, Mississauga, ON, Canada). Total pancreas area was traced at 2.5x magnification, 
and β-cell area traced at 40x magnification by insulin immunoreactivity.  β-cell mass was 
calculated by multiplying the fractional  β-cell area by the weight of the pancreas (mg).  
 
5.2.5 Statistical analysis  
Data are expressed as percentage of insulin+ β-cells (% mean ± SEM). Changes 
between means were determined using Student’s t-test or one- or two-way ANOVA, 
followed by Tukey’s post-test where appropriate, and with an acceptable level of 
significance of p < 0.05.  Statistical analysis was performed using Graphpad Prism software 
(v. 5.01, San Diego CA). 
 
5.3  Results 
5.3.1 Hyperglycemia and β-cell mass moderately regenerate after neonatal STZ 
exposure 
Hyperglycemia was noted 2 days after neonatal STZ treatment (i.e., D9), but blood 
glucose recovered by D28 (Figure 5.2A, STZ vs control, p < 0.05). The presence of 
hyperglycemia correlated with the extent of β-cell mass loss (Figure 5.2B), being greatest at 
D14 and moderately recovering by D28 (Figure 5.2B, Control vs STZ, D14 and D21, p < 0.05).  
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Figure 5.2. Induction of diabetes by STZ.  
Glycemia (A, mmol/L) and β-cell mass (B) were measured in control (white 
bars) and streptozotocin (STZ)-treated (black bars) mice over the first 4 
weeks of life. Data were analyzed using 1-way ANOVA and Tukey’ s post-test 
or student’s t-test. Data shown represent % Mean ± SEM. *, § p < 0.05, n > 5.   
§ § 
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 5.3.2 Changes in the proportional presence of Ins+ cells after STZ 
In control mice we previously showed that the proportional presence of Ins+ cells 
within BCA (<5 β-cells) scattered throughout the pancreas significantly decreased with 
advancing age (Chapter 4). Consistent with those results, the proportion of BCA decreased 
in this model from D9-28 (Figure 5.3A, white bars, p < 0.05, D9 vs D14, 21, and 28). In small 
islets (5-15 β-cells, Figure 5.3B) and large islets (>15 β-cells, Figure 5.3C) there was no 
significant proportional change in the distribution of Ins+ cells with age over this range.   
After STZ administration, the relative proportion of Ins+ cells present within small 
islets significantly increased at D14 (Figure 5.3B, black bars, p < 0.05, D14 vs all other ages, 
and p < 0.001, D14 C vs STZ). This correlated with a corresponding decrease in the 
proportion of Ins+ cells present within large islet at D14 (Figure 5.3C, black bars, p < 0.05, 
D14 vs D21).  Unlike controls, there was no decrease in the proportional presence of Ins+ 
cells in BCA following STZ treatment after D9, and instead there was an increase in the 
proportional presence of Ins+ cells in both BCA (Figure 5.3A, p < 0.05 D9 and D14 vs D28 
black bars and D28 STZ vs Control) and small islet proportion at D28 (Figure 5.3B, p < 0.05, 
D28 STZ vs Control). Thus, while the maximal destruction of β-cells seen at D14 following 
STZ administration is likely to have caused the proportional shift of Ins+ cells from large to 
small islet categories, there was significant regeneration of β-cell mass by D28 occurring in 
the BCA and small islet compartments. In addition, the normal age-related decrease in the 
proportion of Ins+ cells located in BCA was prevented following STZ treatment, suggesting 
that an early expansion of Ins+ cell number occurred in BCA shortly after administration of 
STZ. 
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Figure 5.3. Proportional β-cell location changes after STZ administration. 
Proportional presence of β-cells within β-cell aggregates (BCA, <5 β-cells, A), 
small islets (5-15 β-cells, B), and large islets (>15 β-cells, C) in control (white 
bars) and streptozotocin (STZ)-treated mice (black bars) over the first 4 weeks 
of life. Data shown represent % Mean ± SEM, §,*, ɸ p < 0.05, §§,**p < 0.005, 
n > 5.  
* * * 
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ɸ 
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** 
§ 
B  
§ 
C  
* 
§§ 
161
 5.3.3 β-cell proliferation increases after injury and during regeneration 
 The presence of β-cell proliferation shortly after STZ administration was measured 
by injection of EdU on D8. The labeling of Ins+ cell nuclei with EdU was tracked using 
immunohistochemistry over the course of the study on the assumption that the pulse label 
of EdU would be detectable in subsequent β-cell progeny at later time points (Figure 5.4A). 
In control mice, the percent labeling of β-cells with EdU was greater in BCA and small islets 
than in large islets, and a significant peak in the population of EdU-tagged  cells was 
observed at D21 (Figure 5.4Ai, p < 0.0005, D21 vs  other ages, and Figure 5.4Aii, p < 0.005, 
D21 vs other ages), before declining at D28. No significant changes in the relative 
proportion of EdU-labeled β-cell population were observed in large islets with age (Figure 
5.4Aiii).   
 After treatment with STZ there was a trend towards an increase in the percent EdU 
labeling of Ins+ cells in the BCA at D14, a week earlier than was shown to occur in control 
pancreata, although this did not reach significance (Figure 5.4Ai, black bars). There was a 
significant increase in Ins+EdU+ cells within small islets at D21, which disappeared by D28, 
similar to controls (Figure 5.4Aii, black bars, D21 vs D28).  A surge in β-cell proliferation 
within BCA following STZ treatment might be expected to result in many of the BCA 
expanding to be counted as small or large islets at later time points, thus explaining the 
apparent paucity of EdU-labeled cells in the BCA fraction at later ages. In support of this 
possibility, a significant increase in the proportional presence of EdU-labeled Ins+ cells was 
also observed in large islets following treatment with STZ at D28 (Figure 5.4Aiii, black bars, 
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Figure 5.4. Beta cells proliferate to regenerate endocrine cell mass following 
damage.  
Proportional presence of β-cells within β-cell aggregates (BCA, <5 β-cells, i), small 
islets (5-15 β-cells, ii) and large islets (>15 β-cells, iii) in control (white bars) and 
streptozotocin (STZ)-treated mice (black bars) over the first 4 weeks of life.  
(A) EdU. β-cell proliferation immediately following injury was measured by EdU 
incorporation, and retained in cells during aging and regeneration (B) KI67. β-cell 
proliferation at the time of euthanasia was measured by Ki67 immunostaining 
within Ins+ cells. Data were analyzed using 1-way ANOVA and Tukey’s post-test or 
student’s t-test. Data expressed as % Mean ± SEM, §,*p < 0.05, **p < 0.005, ***p 
< 0.0005.  
§ 
 
* 
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 D28 vs D9). This suggests that the pulse label of EdU within β-cells could be ‘chased’ into 
larger islets with time during the recovery of β-cell number after STZ treatment.   
Assessment of β-cell proliferation at the time of euthanasia was measured by Ki67 
immunoreactivity within Ins+ cells. In control animals, β-cells within BCA demonstrated a 
greater proportional presence of Ki67+ cells than either small or large islets at D9 (Figure 
5.4Bi-iii, white bars, p <0.05), and which declined at later ages (Figure 5.4Bi, white bars, p < 
0.05 D9 vs D14-28). There was also an increase in Ins+Ki67+ cells within large islets at D28 
relative to other ages (Figure 5.4Biii, white bars, p < 0.005), likely due to a remodelling of 
the endocrine pancreas following weaning.   
One week after STZ administration (i.e., D14), β-cell proliferation as detected using 
Ki67 presence had increased in both small and large islets by 2.6- and 2.1-fold, respectively 
relative to controls (Figure 5.4Bii and Figure 5.4Biii, p < 0.05, D14, STZ vs control). In BCA, 
Ki67 presence remained in high proportion until after D21, although this was not significant 
(Figure 5.4Bi, black bars). Combined with the EdU proliferation data, the increased rate of 
β-cell proliferation detected in small and large islets after STZ could have resulted, in part, 
from the prior expansion of the β-cell population within at least some BCA. To determine if 
this new population of β-cells could also have arisen from a progenitor cell population not 
previously expressing insulin within either BCA or islets we next employed lineage-tagging 
of β-cells, either with or without STZ treatment. 
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 5.3.4 The proportion of β-cells genetically tagged with HPAP increases with postnatal 
development, and is altered after STZ 
In control mice, 22.2 ± 3.2% of β-cells within BCA (Figure 5.5A, horizontal bar) 
expressed HPAP at D9 (baseline), compared with 28.5 ± 3.1% of β-cells in small islets (Figure 
5.5A, hatched bar) and 31.0 ± 2.8% of β-cells within large islets (Figure 5.5A, vertical bar). 
Representative images are shown in Figure 5.5B, with β-cells immunostained for insulin 
(green) and HPAP (red).  In control mice, the proportion of HPAP-tagged β-cells in all 
compartments more than doubled over the early postnatal time period (Figure 5.5C, BCA, 
white bars,  p < 0.05, D28 vs D9, D14; Figure 5.5D, small islets, p < 0.05, D21 vs D9; Figure 
5.5E, large islets, p < 0.05, D21 & D28 vs D9).  
Following STZ administration, the proportion of HPAP tagged β-cells in BCA did not 
change throughout the study period, and by D28 was significantly lower than in controls 
(Figure 5.5C, black bars, p < 0.001 D28 STZ vs C). A similar profile was seen in both small and 
large islets (Figure 5.5D and 5.5E) with a reduced presence of HPAP-tagged cells by D21 and 
D28 after STZ treatment (Figure 5.5C, p < 0.001 D28 Control vs STZ; Figure 5.5D, p < 0.05, 
D21 Control vs STZ; Figure 5.5E, p < 0.05, D28 Control vs STZ). This implies that 3 weeks 
after administration of STZ, a greater proportion of β-cells were present in each of the three 
cellular compartments that had not derived from pre-existing β-cells, relative to control 
animals. This would be consistent with the regeneration of β-cells being derived in part 
from non-insulin or low-insulin expressing progenitors within both BCA and islets.  
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Figure 5.5. Lineage tracing of the β-cell during postnatal development and 
regeneration after STZ.  
Tagging proportion of the reporter protein human placental alkaline phosphatase 
(HPAP) within β-cells at D9 (A) and over time (C-E) within β-cell aggregates (BCA, 
<5 β-cells, A, horizontal bars, and C), small islets (5-15 β-cells, A, hatched bars, and 
D) and large islets (>15 β-cells, A, vertical bars, and E).  Changes in proportional 
presence of HPAP-tagged β-cells within Control (white bars) and Streptozotocin 
(STZ)-treated mice (black bars) were noted over the first 4 weeks of life depending 
on size compartment (C-E). Representative image of HPAP- tagged (B, green) β-
cells (insulin, red) in a D28 large islet. Data were analyzed using 1-way ANOVA and 
Tukey’s post-test or student’s t-test, and data expressed as % Mean ± SEM.  (C) 
control **D28 vs D9 and D14, §§§ D28 control vs STZ; (D) control *D9 vs D21, § 
D21 control vs STZ; (E) control *D21 and D28 vs D9, § D28 control vs STZ. §,*p < 
0.05, **p < 0.005, §§§ p < 0.0005. Size bar denotes 50 μm, n > 3.  
p = 0.067 
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 5.3.5 Ins+Glut2- cell proportion increases following STZ treatment 
We previously showed that the proportional presence of Ins+Glut2- cells decreased 
with age, representing ~3.6% of total β-cells at D7 but <0.7% by 3 months, with the majority 
of these cells present in BCA (Chapter 4). In the present model, and consistent with earlier 
findings, the proportion of Ins+ cells that did not show the presence of Glut2 was 10-fold 
greater in BCA than in islets (Figure 5.6A), and was maintained at this proportion until D28 
when there was a significant decline (Figure 5.6A, p < 0.05 D21 vs D28).   There was a non-
significant, gradual decline in this population in large islets over the same range (Figure 
5.6C, white bars, D9-28).  
Following treatment with STZ the proportional presence of Ins+Glut2- cells within 
BCA did not alter, but in small and large islets their presence significantly increased relative 
to controls at D14 (Figure 5.6B,C, black bars, p < 0.05 D14 vs D28). Thereafter, the 
population disappeared by D28 in small and large islets (Figure 5.6B, C, D28, Control vs STZ) 
but was maintained in BCA (Figure 5.6A, D28, Control vs STZ). This implies that the 
Ins+Glut2- cells were spared STZ-mediated destruction in all β-cell size compartments, and 
contributed to regeneration in islets at D14, presumably by the differentiation into 
Ins+Glut2+ β-cells. Within BCA however, the lack of increase in cell proportion may have 
been overshadowed by the complex and dynamic changes occurring during both 
development and regeneration after injury. These data are consistent with a return to 
euglycemia in STZ-treated mice by D28 and a moderate recovery of β-cell mass.  
 
167
* 
§ 
Figure 5.6. Ins+Glut2- cell proportion increases after STZ administration.  
Proportional presence of Ins+Glut2- cells within β-cell aggregates (BCA, <5 β-cells, A), 
small islets (5-15 β-cells, B) and large islets (>15 β-cells, C) in control (white bars) 
and streptozotocin (STZ)-treated mice (black bars) over the first 4 weeks of life. Data 
were analyzed using 1-way Anova and Tukey’s post-test or student’s t-test. Data 
expressed as % Mean ± SEM. (A) white bars, *D28 vs D21. (B)(C) black bars, D14 vs 
D9; (B)(C) D28 C vs STZ. §,* p< 0.05, n > 3.  
§ 
* 
* 
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 5.4  Discussion 
It was demonstrated here that modest endocrine regeneration is possible in the 
neonatal rodent pancreas. Consistent with data presented by others, it was shown that 
most β-cells indeed arise from pre-existing β-cells after endocrine pancreas damage induced 
by STZ. It was further demonstrated that some of the β-cells that recovered during 
endocrine cell regeneration arose from a subtype of pancreas progenitor cell. These 
progenitor cells express insulin but lack Glut2. The finding that these cells normally diminish 
in number with advancing age provides a basis that may explain the enhanced β-cell 
regenerative capacity in the young which is not evident in older mice.  
For many decades, STZ has been used extensively as a model for type I diabetes 
research and has been the agent of choice for the induction of β-cell damage due to its 
relative stability during administration (25). While newer damage models such as those 
using tetracycline-dependent diphtheria-toxin (26,27) have recently gained favour, we have 
learned much information from STZ-administration regarding β-cell death (and its corollary, 
regeneration), pancreas development, and diabetes progression. Furthermore, while the 
diphtheria-toxin based ablation method exhibits higher specificity for β-cell death without 
confounding effects from inflammation or non-pancreatic organ damage, diabetes itself 
presents as an inflammatory condition at the time of onset, and in this way STZ 
administration in mice mimics disease progression in humans more closely than other 
methods.  A limitation of the use of STZ as a means of effecting diabetes is that due to 
differences in human pancreatic glucose transporter utilization of GLUT1/3 over GLUT2, STZ 
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 administration in rodents cannot identically parallel diabetes progression in humans, as 
human endocrine pancreata are less susceptible to the effects of the drug (28,29).  
The ability to recover β-cell mass after STZ is age-related, with moderate 
regeneration after subtotal ablation in young, but not old, rodents.  We (Chapter 4) and 
others (22,30) have shown that the proportion of β-cells present in single cells and small 
clusters decrease with advancing age, concomitant with islet maturation and coalescence 
into large islets. This coincides with a transition in the proportion of Ins+Glut2- β-cells during 
neonatal life, a time of significant endocrine pancreas remodelling (31–33). Indeed, the 
finding that there was an increase in BCA and small islet proportion after STZ demonstrates 
the validity of the diabetes model: these cells were spared STZ-mediated death, with the 
majority of β-cells instead dying from within islets [where mature β-cells reside (34)]. As 
others have also illustrated, rodents exposed to STZ during neonatal life consequently 
(re)develop hyperglycemia in adulthood (10,17). This is perhaps explained by the loss of the 
putative “reserve β-cell pool” (i.e., the Ins+Glut2- cells, present in early life), which were 
recruited to maintain normoglycemia following STZ-mediated injury, and were therefore 
unable to contribute to normal tissue turnover thereafter. Conceivably, in humans similar 
mechanisms may contribute to misalignment of β-cell supply and demand, as observed in 
instances such as obesity, pregnancy, or autoimmunity.  
β-cell proliferation is the primary mode of β-cell replacement in the postnatal 
pancreas. In this model, Ki67 expression doubled within Ins+ cells present in small and large 
islets 7 days following STZ administration. These data are, although slightly lower, broadly 
aligned with data shown by others using older mice (15). The difference may be resulting 
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 from both increased (baseline) proliferation in early life, and some β-cell regeneration from 
Ins+Glut2- cell maturation, and not cell proliferation exclusively.  Results from the Ki67 
analysis were otherwise as expected, but data from EdU incorporation yielded some 
interesting insights. First, it was shown that the β-cells present in BCA and small islets which 
proliferated early in development peaked at D21 (i.e., weaning), and the population 
thereafter declined. This indicates that these cells either died, or were incorporated into 
larger, proto-typical islets. After STZ however, and in agreement with the regeneration 
model, these EdU+ β-cells peaked at D21 in small islets and thereafter disappeared from this 
compartment. Subsequently there was a peak of EdU+ β-cells at D28 in large islets, 
indicating that the proliferative cells present in the early postnatal pancreas could be 
chased into large islets.   
Based on the lineage tracing paradigm established by others (23,35), it was predicted 
that if β-cells arose from stem cells, there would be a dilution in lineage tag (HPAP) over the 
course of study. The corollary being that if there was no change in lineage tagging 
frequency, then β-cells arose from pre-existing β-cells present at the time of induction. 
Interestingly, in the present model, HPAP expression increased during early endocrine 
development, which may be interpreted as β-cells primarily arising from self-duplication 
postnatally. Conversely, after STZ exposure and during recovery, the reporter protein was 
maintained at the initial tagging proportion in all β-cell grouping compartments, indicating 
that a significant proportion of β-cells arose from cells not tagged initially (i.e. new β-cells).  
Differential interpretations of this phenomenon are that (i) the reporter labelling 
continues longer than the two-day window between tamoxifen injection and STZ exposure 
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 (36);  (ii) that β-cells arose from cells that previously did not greatly express insulin at D4-5 
and therefore did not label with HPAP, but could still have been an immature β-cell subtype; 
(iii) STZ preferentially destroyed HPAP-labelled β-cells; or (iv) that the HPAP-tagged a highly 
proliferative sub-population of β-cells present in early  postnatal life. We can dismiss 
scenario (i), as this would be true only if there was an increase in reporter protein 
proportion shortly after tamoxifen administration. Since the reporter protein continued to 
increase thereafter in control, but not STZ-treated mice, we can conclude this is not the 
cause. Evidence from Reinert et al showed that after high doses of tamoxifen, there was 
indeed continued reporter labelling long after the expected window for cell tagging; 
however, our dosing regime was similar to the low dose model in that report (37), and 
which could be expected to account for only ~5% increase in reporter labelling shortly (<1 
week) after administration. In the second and third options, considering that only mature β-
cells demonstrate active transcription of the insulin promoter, these options are 
theoretically conceivable, as there was  a difference in labelling index between BCA and 
islets at D9, albeit non-significantly. HPAP itself would not (theoretically) render those β-
cells more susceptible to STZ-mediated damage, but by the fact that mature cells would tag 
with HPAP and therefore express high Glut2 presence, these are de facto linked.  The fourth 
option is also theoretically possible, given the increase in β-cell mass concomitant with 
somatic growth during this stage in life, and could be in fact due to the Ins+Glut2- cell 
population, although this was not confirmed. As evidenced here, the established lineage-
tracing paradigm did not originally allow for the possibility that the putative stem cell 
source could also express insulin.  
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 These lineage-labelling trends are partly consistent with aspects of other studies.  Liu et 
al found that there was a substantial increase in reporter protein frequency with aging, as 
was shown here, but also after STZ (35). That study showed an increase in PLAP+ [HPAP] Ins+ 
cells, which the authors contend arose from β-cell progenitor cells which lacked insulin but 
retained the β-cell reporter HPAP.  The authors found that these HPAP+Ins- cells 
demonstrated an immature phenotype, with positive expression of Pdx1 and MafB, but 
being negative for both Nkx6.1 and Glut2, and which were proliferative after STZ 
administration. The relative proportion of these cells remaining after injury was found to be 
0.1% of all insulin+ (β-) cells. Taken together, the authors concluded that these cells 
represented β-cell progenitors which, by virtue of expressing the β-cell reporter, must have 
exhibited active insulin promoters at the time of induction. Only after injury or aging, and 
hence after differentiation to proto-typical mature β-cells, was insulin re-expressed, and 
which accounted for the increase in HPAP+ labelled Ins+ cells with increased age.  
The data presented here also partly align with a study by Dor et al, which demonstrated 
no change in lineage reporter expression during normal aging, nor after insult induced by 
partial pancreatectomy (23). All three studies used the same mouse strain for analyses, but 
demonstrated differences in data trends and interpretation.  We assert that these 
differences are directly related to age, as those previous papers are used adult mice, and as 
such, the population of β-cells available was largely established and functional. One point of 
discrepancy is the difference in function between β-cells located within and outside of 
islets. Multiple groups have previously purported differences in function based on location 
of β-cells (38–43), but the definitive evidence from lineage-tracing experiments by Dor et al 
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 demonstrated no differences in β-cell lineage labelling frequency as stratified by location 
(23), thus ending the debate. The defining difference in our study is the examination of β-
cells not just by location, but crucially also at a young age. We have shown that the β-cells 
located in small clusters outside of the islet to be substantially different than those located 
within it, in terms of proliferation rate, lineage-label tagging frequency, and Glut2 
expression. 
While multiple papers have sought to determine the role of (unidentified) stem cells to 
endocrine regeneration, we questioned specifically the contribution of Ins+Glut2- cells 
during this process. As has been shown previously, the β-cells that can be targeted by STZ 
must express Glut2 (20), and as previously demonstrated, the population of Ins+Glut2- cells 
decrease with age (Chapter 4). We show that under control (non-diabetic) conditions, the 
proportion of Ins+Glut2- cells present in both BCA and islets decrease in the first 4 weeks of 
life. In agreement with our hypothesis, these cells increased in relative proportion in both 
islet compartments in the immediate time-course following STZ exposure indicating that 
they were spared destruction. This was followed by a dramatic reduction in the cell 
population in islets after weaning, which we speculate to illustrate a maturation of these 
cells into functional, glucose-responsive β-cells to compensate for the loss after damage.  
However, this assumption requires a conclusive assessment of cells present at the time of 
damage versus during regeneration, and thus correlating the HPAP tagged β-cells with the 
(lack of) expression of Glut2 would theoretically illustrate this phenomenon. Attempts to 
track the Ins+Glut2- cells using HPAP were unsuccessful, as the expected frequency of 
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 HPAP+Ins+Glut2- cells in control mice at P7 was only ~0.3% of total β-cells in islets and <3% 
in BCA; furthermore, the BCA proportion decreases shortly thereafter in control mice.  
We sought to answer three questions in this study: first, do Ins+Glut2- cells survive STZ 
mediated death?; second, do these cells contribute to endocrine regeneration following 
damage?; and third, what is the origin of these Ins+Glut2- cells? However, limitations arose 
which made full assessment of all three questions difficult. The first is that the baseline 
(control) conditions are in fact, constantly changing. During the first month of life in 
rodents, there is significant growth of β-cells concomitant with growth of the pancreas, and 
which has demonstrated an even more pronounced change around the time of weaning. 
Overlaying this rapidly changing phase with severe insult and subsequent regeneration 
yields a considerable number of variables.   
The second limitation was that the pharmacological agents used to (independently) tag 
and destroy β-cells are likely targeting different populations of cells. We anticipated that the 
Ins+Glut2- cells would have a decreased β-cell-tagging frequency and would be selectively 
spared ablation by STZ. However, this lineage tracing technique relies on general trends 
only and which has made interpretation difficult, especially in the absence of a definitive 
lineage label for the Ins+Glut2- cells. It would be useful to examine a cohort of mice weeks 
or months after STZ ablation to determine if the Ins+Glut2- cells are replenished in 
adulthood, and if so, from which compartment. It would be also informative to determine if 
the lineage-label frequency continues to increase after D28. 
Despite these limitations however, we show substantial changes in proliferative 
subpopulations and in BCA proportion supporting our hypothesis that some β-cells have 
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 both survived STZ-mediated death, and subsequently matured from Ins+Glut2- cells into 
Ins+Glut2+ cells. It was also demonstrated that these Ins+Glut2- cells were primarily located 
in BCA, and coalesced from the BCA into islets.  Therefore, the temporally-defined nature of 
STZ-mediated partial regeneration in the young rodent can be attributed in part to the 
presence of Ins+Glut2- β-cells, which normally diminish with age and are therefore unable to 
aid in the rescue of the endocrine pancreas if β-cells are ablated after this window of time.  
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CHAPTER 6 
 
Summary and Perspectives 
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 6.1  Summary of findings 
Given the improvements in islet transplant procedures, with many patients 
experiencing >3 years post-transplant without exogenous insulin injections, a sustained 
improvement in glycemia, and a reduction in diabetes-related complications (1), we sought 
to find alternate sources of cells, given the paucity of β-cells available from cadaveric 
donors. We dedifferentiated isolated islets to duct-like cells based on an established 
protocol (2), with the intention of enhancing cell number while in the dedifferentiated 
state, then redifferentiating the cells back to an insulin+ condition.  
Our results were consistent with those found by Yuan et al (2), demonstrating a 
substantial increase in the number of cytokeratin-19 (CK19) expressing cells, as well as a 
loss in islet morphology, insulin hormone presence, and β-cell and islet-specific 
transcription factors (Chapter 2). However, and similar to findings by others, we were 
unable to effect significant redifferentiation to insulin+ cells using Matrigel, insulin-like 
growth factor –II (IGF-II) and keratinocyte growth factor (KGF), or following the addition of 
trophic factors such as gastrin, nicotinamide, epidermal growth factor (EGF), nor with other 
established redifferentiation protocols (3,4),  co-culture with endothelial cells in vitro, or 
after transplantation of the cells into immune-deficient mice. This was surprising, given the 
substantial production of ductal cells. As β-cells compose ~80% of mouse islet cell 
proportion, we next sought to determine the cell type of origin during in vitro 
dedifferentiation and hypothesized that it would involve the β-cell.  
Lineage tracing of the β-cell using the non-inducible RIPCre;Z/AP mouse model 
revealed that during the dedifferentiation process only a rare minority of β-cells survive 
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 culture and adopt a duct-like cell phenotype (Chapter 3), which explained the relative rarity 
of insulin-producing β-cells generated after redifferentiation techniques. We sought to 
characterize those rare β-cells capable of differentiation, and found evidence in support of a 
progenitor cell population present in mouse and human islets which express insulin, albeit 
at lower hormone levels than is present in fully mature cells. These cells were previously 
described as having decreased expression of key transcription factors such as Nkx6.1 and 
Pdx1, increased expression of Ngn3, and, importantly, they can be identified by the lack of 
the glucose-transporter 2 (Glut2) (5). We showed that these Ins+Glut2- cells are present in 
the neonatal mouse islet and provided evidence that the same cells were responsible for in 
vitro differentiation to duct-like cells, and could alternatively be differentiated to neural-
lineage cells (Chapter 3). Importantly, the relative proportion of these cells is higher in the 
neonatal islet than is present within the adult islet, and furthermore, that there is a 
significant population of these cells in the β-cell aggregates (<5 β-cells, BCA) that exist 
outside of the proto-typical islet (Chapter 3). Not all Ins+Glut2- β-cells were capable of multi-
lineage differentiation however, with many more Ins+Glut2- β-cells present in the neonatal 
pancreas than can demonstrate the capacity for altered cell fate. This result provides 
further evidence that β-cells exist within a spectrum of functional and developmental 
heterogeneity.  
We consequently sought to identify whether the population of Ins+GLUT2- cells 
could be identified in the human pancreas, specifically within the BCA compartment, and 
how the population changed with age in both mouse and human. We showed that 
Ins+GLUT2- β-cells were present in very high proportion in human BCA, and that in both 
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 human and mouse, these cells decreased with age, concomitant with a decrease in BCA 
proportion and proliferation rate (Chapter 4). Our analysis of β-cell proliferation in the 
human and mouse pancreas was consistent with data from previous publications, and 
showed that the proliferative potential of the Ins+GLUT2- cells declines significantly before 
adulthood is reached, further contributing to the loss of regenerative potential with age. 
While this immunohistochemical study did not directly illustrate the functional capacity of 
the Ins+GLUT2- in terms of multi-potential fate decisions, data from the van der Kooy group 
do show that these cells are retained in (at least) islets during adulthood (3,5), and provide 
a clear direction for future research.  
 We finally sought to assess the role of Ins+Glut2- β-cells in the context of a diabetes 
model. It has been long known that β-cells can moderately recover their cellular mass after 
exposure to the β-cell toxin streptozotocin (STZ) in the neonatal time period, but not as 
adults. We theorized that because STZ accesses the β-cell via Glut2, and because there is a 
significant proportion of Ins+Glut2- β-cells in the neonate and not in the adult pancreas, that 
neonatal endocrine pancreas could regenerate after STZ exposure because a significant 
component of β-cell mass is not damaged and can subsequently re-establish 
normoglycemia. We therefore examined the changes in β-cell mass, β-cell proliferation, and 
proportional changes in Ins+Glut2- cells during the first month of life, with and without STZ, 
while lineage tracing the β-cell using the inducible RIPCreER;Z/AP+/+ mouse model.  
We found that there was indeed modest β-cell regeneration in the early postnatal 
time period after neonatal STZ administration. We also showed that there was retention of 
BCA, and an increase in proportion of specifically Ins+Glut2- cells within islets during the 
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 regenerative phase, which significantly decreased in islets 3 weeks after damage, which is 
likely to indicate a maturation of these progenitor cells into glucose-responsive β-cells. 
Interestingly, the origin of the β-cells present after 3 weeks in the early postnatal mouse 
pancreas indicated self-duplication as their main source in the normal developmental 
program, but not during regeneration as indicated by the altered trends in β-cell labelling 
with HPAP. Explanations of these opposing trends point to the presence of immature β-cells 
contributing to regeneration after β-cell loss, but not during normal postnatal development. 
Their contribution to β-cell regeneration seems to be age-related, as these trends only 
partially align with similar experiments performed in adult mice (6,7). However, further 
analysis at later ages may yield further insights. Overall, this project illustrated the extensive 
changes that occur in the endocrine pancreas during the neonatal time period, in terms of 
β-cell phenotype, anatomical location, and proliferative capacity.  
While we did not generate significant numbers of β-cells as a potential donor source 
for use in transplant, we were able to identify a novel subset of progenitor cells in both the 
mouse and human pancreas, complementing evidence previously published which has not 
been replicated before now. We have contributed knowledge about these progenitor cells 
by showing that their predominant location is, in fact, outside of the islet, and their number 
significantly decrease with age. These findings may have implications in altering transplant 
criteria, and on a broader scale, illustrate a new parameter for study in pancreas 
maturation. Moreover, these results identify subpopulations of cells which may be 
responsible for adaptive growth during times of increased metabolic need such as 
pregnancy or diabetes.  
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6.2  Progenitor cell activation versus β-cell replication: the debate revisited  
Much evidence has supported hypotheses favouring both progenitor cell 
differentiation and pre-existing β-cell replication as the mode for regeneration of endocrine 
cell mass during normal development, aging, and after injury. However, the breadth of 
convincing data for both arguments suggests that the timing of injury, as well as the manner 
and severity of damage play important roles in dictating the degree of endocrine 
regeneration, and which mechanism is responsible, i.e. pre-existing β-cell replication versus 
progenitor cell recruitment, activation, or cell trans-differentiation. This was illustrated by a 
study by Criscimanna and colleagues, which used models to destroy either “all” acinar and 
endocrine tissues (but not ductal cells) utilizing PdxCre;R26DTR mice, or the less-severe 
damage model created  using ElaCre- ERT2;R26DTR mice, which selectively destroys only 
acinar tissue (8). The authors found that in the Pdx1-diptheria toxin model, 97% of all 
endocrine and acinar cells were destroyed, and both recovered by approximately 60% 
within 4 weeks, which was shown to be a result of the recapitulation of the endocrine 
developmental program. In contrast, knocking out the acinar compartment alone elicited 
trans-differentiation from ductal to acinar cells. That study is complemented by evidence 
from Thorel et al, which showed that under extreme β-cell loss, α-cells could trans-
differentiate to become insulin-producing cells (9).  
These data would indicate that under “normal” circumstances, i.e. aging, pregnancy, 
obesity, and even some damage models, β-cell (re)generation occurs through proliferation 
of existing cells exclusively. The trigger, or degree of damage, which elicits some other 
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 mode of tissue regeneration, either from resident progenitor cell activation, or trans-
differentiation from other tissue types, remains to be determined in both its scale and 
ability to regenerate functional endocrine mass.  Indeed, nearly 2 decades ago this concept 
was purported (10); however, in the absence of lineage-tracing technology, and under the 
current and now-canonical model of exclusive β-cell self-duplication, it was dismissed.  
Superimposed on this, of course, is the role of autoimmunity in diabetes; the loss of 
β-cell mass and attempts at regeneration, no matter whether β-cells are produced from a 
progenitor cell source or by self-duplication, being countered by T-cell-mediated 
destruction. This has been likened to a bathtub filling with water:  new sources of β-cells, 
from replication or progenitor cell source, contribute new water to the tub from the faucet, 
while rates of cell death oppose this, and water flows out of the drain. In normal physiology, 
these two forces are roughly equal, and the net result is a maintenance of β-cell mass 
and/or function, which allows glucose homeostasis to be achieved. However, in the case of 
diabetes, the “drain” gets bigger (i.e., increased β-cell death), which far exceeds the 
potential of “new water” (insufficient β-cell regeneration and/or extremely slow β-cell 
proliferation), and hyperglycemia results (11). Furthermore, even when β-cell regeneration 
was shown to occur, anti-rejection drugs commonly used in the transplant setting mitigated 
the regenerative process (12).  Whether the Ins+GLUT2- cells are also targeted for 
destruction during T1D disease progression has yet to be ascertained, and the data 
presented here provides a novel arena for investigation. 
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 6.3  Progenitor cells and β-cells exist within a spectrum of maturity 
The concept that stem/progenitor cells may express mature markers, such as insulin, 
opens up the field to semantic arguments regarding what constitutes a stem cell; the 
present conclusion hinging on the premise that cell state can be assigned according to a 
binary code. Our findings suggest that a more appropriate assessment of cell maturity may 
include the concept of a continuum of cell “stem-ness” (or its corollary, maturity). As was 
noted by Murtaugh, it also contributes to the long-held debate over stem cell 
differentiation versus  replication of pre-existing cell with regards to generation of 
postnatally-formed β-cells: it is both, in the same cell; or as Murtaugh states, “yes” [to both 
questions] (13). Furthermore, if progenitor cells can express insulin, substantial work by 
Melton (7) and Kushner (14), that  β-cells are formed postnatally by self-duplication 
exclusively, are reconciled with the evidence of progenitor cell origin (5). In other words, the 
contribution from (the Ins+Glut2-) progenitor β-cells is masked because they are (mis) 
interpreted to be mature, insulin-expressing β-cells.   
The concept of β-cell heterogeneity has recently emerged as a major contender in 
understanding the population of cells available for clinical use, either for retention of β-cells 
in vivo or for transplant procedures.  It may be a philosophical argument, but is 
heterogeneity defined by cell maturity only? Is cell maturity defined exclusively by age? 
And, could β-cell anatomical location also dictate its function?   
It is well known that mouse β-cells in the immediate postnatal period are immature, 
with poor GSIS and lower expression of Glut2 compared to adult β-cells (15–17). It was 
recently reported that neonatal β-cells require a glucose threshold for maturation, which 
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 can be shown by gene expression changes in Urocortin3 (Ucn3) (18). This peptide hormone 
has been shown to be expressed in mature mouse β-cells after P7, and acts as a maturation 
marker (19). Similarly, human infant β-cells demonstrate some plasticity in insulin secretory 
machinery not seen in the adult state (20).  
β-cells that reside outside of islets have long been thought to reflect newly 
generated, and hence immature, cells (10,21–25). However, none of these publications 
utilized lineage tracing, and hence none determined cell origin.  The dogmatic publication 
by Dor et al then showed that there was no significant difference in lineage labelling index 
between β-cells found within and outside of islets during aging or after injury in the adult 
pancreas (7), implying that the anatomical location of β-cells was irrelevant to function or 
maturity. However, recent work has shown that, indeed, β-cells found in clusters outside of 
the islet demonstrate lower levels of Ucn3, especially in the young pancreas (18). 
Furthermore, β-cells outside of islets lack the exquisitely intimate contact with both the 
vascular network and innervation patterns as found in islets, as well as cell-cell contact with 
other β-cells for communication (26). We (Chapter 4) and others (27,28) have shown that 
age influences location of endocrine cell mass, concomitant with maturation. Taken 
together, it would appear that β-cell function, maturity, and location are intrinsically 
conflated.  
For completeness this concept requires an investigation into the origin of the Glut2-
negative β-cells, to test the assumption that “immature” equates to “newly generated” 
cells. The abundant evidence in the literature suggests that “all” (if not the majority) of new 
β-cells present during aging or after injury are derived from pre-existing β-cells. It is 
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 presently unknown if the Ins+Glut2- β-cells act as facultative progenitor cells in vivo. 
However, we do know that in the absence of pathologic metabolic challenge, the presence 
of multi-potential β-cells is extremely rare in the adult mouse and human pancreas. As 
posited in Chapter 5, the Ins+Glut2- cells may represent a reserve pool of β-cells present in 
the postnatal pancreas, available for recruitment and/or utilization during remodelling of 
the endocrine compartment in early life. This reserve pool theory then implies that there is 
a finite number of Ins+Glut2- β-cells, and perhaps, all β-cells, in the postnatal pancreas. Data 
from the Melton laboratory supports the idea of a set number of progenitor cells in the 
young, and a final β-cell number in the established pancreas (7,29).  Our findings suggest 
that Ins+Glut2- cells represent a part of this progenitor pool. Differential utilization of “true” 
stem cells within this population (the rare, multi-potential cells versus the majority of 
Ins+Glut2- β-cells present in the early postnatal pancreas) as a means of changing the 
ultimate size of the β-cell pool remains to be examined. We can speculate that the majority 
of Ins+Glut2- cells present in the young, mammalian pancreas normally mature directly into 
Ins+Glut2+ cells, and the multi-potential cells only undergo lineage expansion under 
pathological situations of β-cell loss. The signals required for activation of these stem cells in 
the adult context, and whether they can realistically contribute to β-cell regeneration to 
rectify hyperglycemia, is currently unknown. It was shown that these  Ins+GLUT2- cells 
normally ceased to be proliferative in vivo by adulthood (Chapter 4), but in vitro 
manipulation of β-cells was shown to select for a population of cells capable of 
differentiation towards proliferative “neurospheres”, which after transplantation into 
diabetic mice was shown to be effective at combating glycemic excursions (5).  We were 
also able to replicate these experiments from young mice, generating neurospheres from β-
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 cells present in neonatal islets and BCA (Chapter 3). Moreover, the evidence that a minority 
of β-cells and their progeny have been shown to change cell fate in vivo, by expressing 
proteins other than insulin after injury or a long chase (5,6) (Chapter 3), suggests that β-
cells do demonstrate some plasticity in vivo.  However, the minority cell presence or activity 
in vivo during diabetes progression or treatment suggests that there are strong mechanisms 
within the body to control growth, in addition to known mechanisms within β-cells 
themselves which limit proliferation, such as accumulation of p16INK4a. Indeed, if the 
Ins+GLUT2- cells are to have any meaningful role in human diabetes mitigation, they likely 
require manipulation in vitro before they can be re-introduced into a mammalian system.  
Identification of these progenitor cells is therefore paramount, and the roadmap of 
what might define a β-specific progenitor cell is extensive. Putative β-cell progenitors have 
been proposed to express higher levels of early endocrine transcription factors such as 
Pdx1, Ngn3 and MafB (5,30) and low/absent expression levels of genes indicative of mature 
gene function, including Nkx6.1 and Glut2 (6,31). Some β-cells have been shown to be 
capable of transitioning into mature β-cells during culture, distinct from those that 
maintained a progenitor phenotype regardless of in vitro conditions. As described by Szabat 
et al,  “together, these findings suggest multiple levels of complexity underlying functional 
maturation in adult β-cells, and that maturation state in part underlies functional 
heterogeneity” (31).  
Other markers have been proposed to represent maturity markers for β-cells, 
including Flattop (Fltp) (32), a planar cell polarity gene important for the ordered 
arrangement of cells in a plane of tissue.  Fltp was recently shown to maintain the rosette-
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 like structure of mature β-cells around a blood vessel, and increased in expression up to 
80% during postnatal β-cell growth. Furthermore, during pregnancy, proliferation increased 
in Fltp- β-cell progenitors more than 6-fold (33). Fltp expression was also shown to correlate 
to other markers of maturation, including Ucn3, Glut2, and transcription factors including 
Nkx6.1 and MafA (33).   
Pax4 is a transcription factor with a well-defined role in β-cell maturation (34,35). 
Recent work has shown Pax4 to be present in a subpopulation of β-cells which are capable 
of expansion during pregnancy (36).  Furthermore, evidence from the Melton laboratory has 
shown that certain transcription factors usually present in other [non-pancreatic] tissues 
representing the transition from fetal to adult programs were expressed in altered 
proportion during human stem cell differentiation to insulin-expressing β-cells, such as 
NFIB, PROX1, HHEX, and KLF9 (37).   
Overall, these data suggests that β-cell progenitors may be identified by the 
combined presence or absence of multiple factors, as depicted in detail in Figure 6.1.  We 
propose that Ins+Glut2- cells themselves exist within a spectrum of immaturity, and 
represent a reservoir of cells present during developmental, ranging from rare early β-cell 
progenitors (capable of multi-potential cell fate) to glucose non-responsive β-cells. Indeed, 
further sub-categorization of Ins+Glut2- cells will likely be necessary in the future. Moreover, 
phenotype identification of these progenitor cells preceding insulin expression would 
potentially yield a larger cell pool for manipulation.  
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STEM  
CELL 
MATURE  
β-CELL 
PROGENITOR  
β-CELL 
Ins+Glut2- cells 
Multi-potential 
capability 
IMMATURE 
β-CELL  
INS LO            Nkx6.1 LO 
MafA LO       Fltp LO  
MAfB HI       Ucn3 LO 
Pdx1            Pax4 
Ngn3 HI       Glut2 -/LO 
INS HI           Nkx6.1 HI 
MafA HI       Fltp HI 
MAfB LO      Ucn3 HI 
Pdx1 HI        Pax4 
Ngn3 LO      Glut2 HI 
Figure 6.1. Proposed model of Ins+Glut2- progenitor β-cells.  
β-cells exist within a spectrum of maturity, especially during early postnatal 
development. A subpopulation of β-cells can be identified by the lack of 
Glut2, and which have been identified by others as having low expression of 
Urocortin 3 (Ucn3), insulin, Flattop (Fltp),  MafA, Nkx6.1, and increased 
expression of Pdx1 and Ngn3. Within this spectrum of maturity exist rare 
multi-potential cells; however, the majority represent immature β-cells which 
are not glucose responsive. Most Ins+Glut2- β-cells may be found outside of 
the islet,  scattered throughout the pancreas in small clusters of cells. As the 
endocrine pancreas matures and ages, fewer Ins+Glut2- cells found and which 
coincides with a decrease in the proportion of small clusters, as more β- cells 
reside within islets. This also coincides with a decrease in endocrine 
regeneration potential.  
AGE 
β-CELL 
LOCATION 
Young Adult 
Scattered 
β-cell aggregates  
Islet 
MATURATION 
STATE 
Glucose  
unresponsive 
Glucose  
responsive 
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 6.4  Limitations and Uncertainties 
6.4.1  Lineage tracing: a necessary evil? 
Lineage tracing studies are qualified by the design of the genetic system, and involve 
multiple decisions including promoter selection and transgene inducibility, and are effected 
by pharmacological intervention. The implications of introducing another drug into a 
physiological system, however commonly used, should not be underestimated. Tamoxifen is 
widely used to cause transgene induction in a dose-dependent manner as described in 
Chapter 5.  However, the primary application of this drug is for the prevention of estrogen-
receptor- expressing breast cancer recurrence.  In humans the standard dose is 20-40 
mg/day (38), whereas the dosing regimen in transgenic mice is 3-5 doses of 0.1 mg/g body 
weight (i.e, ~3 mg/dose), and in some instances is increased to 4-8 mg/dose (7,39). In mice, 
this translates into drug exposure of several-fold higher dose in a much shorter timeframe 
than would be given to humans, and which has been shown to be poorly tolerated. While it 
was initially established, and widely assumed, that tamoxifen was only active in tissues for 
~48 hours after administration (30), it was recently shown that the drug may persist, and 
hence continue to label cells, for weeks in vivo, particularly when used at high doses, and 
which may confound the interpretation of a pulse-chase experiment (39). While 
administration of tamoxifen via oral gavage instead of injection may mediate some of these 
discrepancies in absorption, physiological consequences of the drug may influence health 
outcomes independent of the disease model, such as the effect of tamoxifen on fertility 
(39,40). Due to a limited time frame between tamoxifen dosing and STZ exposure in our 
model, it cannot be conclusively determined that the results yielded, showing a doubling of 
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 lineage-label over the first 4 weeks of life, were due to selective tagging of a highly 
proliferative subpopulation, or whether the tamoxifen continued to label β-cells in the 
normal developmental program for longer than was expected. Nonetheless, as this trend 
was not experimentally demonstrated after STZ exposure, this result points to the 
differential utilization of β-cells during regeneration, and implies the existence and 
involvement of a progenitor population (Chapter 5). 
A similar universal challenge of lineage tracing experiments is that only a subset of 
cells are tagged, and after such careful design, we are left to rely on overall trends alone.  As 
was shown in our inducible animal model in Chapter 5, ~30% of β-cells in islets were tagged 
with HPAP after tamoxifen administration, and fewer in BCA. Considering that only ~1% of 
β-cells in islets lack Glut2 at P7, and which decreases with age, our assessment of lineage-
tagged Ins+Glut2- cell proportion at the initiation of the experiment was <0.3% in islets, and  
<3% in BCA, making definitive conclusions challenging. Many groups have shown positive 
reporter presence in a small population of cells than was expected after lineage-tracing, but 
which was consequently dismissed as an artifact of Cre transgene “leakiness” (41,42), 
negating the impact of details which can drastically alter interpretation. The assessment of a 
rare population of cells using a system that is even minimally imperfect creates an 
opportunity for criticism; however, it also highlights that our reliance on lineage tracing 
technology has both reformed, and perhaps paradoxically restricted our knowledge of β-cell 
biology.  The mounting, and seemingly contradictory results provided by multiple groups 
trying to answer the same question does lead one to ponder if there is in fact more than 
one correct answer.  The bold conclusion by the Melton laboratory that β-cells are formed 
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 exclusively through self-duplication and not stem-cell differentiation may be too restrictive 
in the face of years of research showing alternate phenomena. As was testified by Bonner-
Weir and Sharma in reference to this controversy, there exists “... the difficulty of 
definitively proving that something does not happen” (43).  
In a similar vein, limitations in lineage tracing technology restricted us from 
following Ins+Glut2- cells  Ins+Glut2+ cells directly as there is no specific marker available 
for the absence of the glucose transporter. We also do not have the technology to 
differentially label β-cells present within BCA versus islets, which could be used to 
determine their hypothesized maturation and coalescence. It would be useful if multiple 
transgenic lines could be combined to label both insulin and Glut2 with separate reporters, 
however as shown in Chapter 5 and above, pharmacological effects and a short window for 
transgene induction in young mice would make this system difficult to appropriately study.  
As discussed in Chapter 3, the use of the cytoplasmic protein HPAP as a reporter in 
our system required us to employ an alternate cell marker for use in fluorescent cytometric 
sorting procedures. It was previously demonstrated by the Grompe laboratory that 
membrane-bound, non-endocrine, non-hormonal proteins efficiently labelled islet and 
acinar cell subpopulations, such as Glycoprotein M6a as a proxy marker for β-cells (44). 
Within the pancreas, it can be confidently ascertained that Gpm6a+ cells further defined by 
positive expression of Glut2 appropriately selects for the mature β-cell. However, using a 
neural marker and the absence of Glut2 as the selection criteria for a progenitor β-cell 
population does allow for some degree of uncertainty. Despite insulin immunostaining of 
recovered, FAC-sorted fractions and ex vivo tissue sections using the Gpm6a antibody, there 
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 exists the theoretical possibility that resident neurons could be collected along with β-cells. 
Furthermore, while the culture of Ins+Glut2- cells in neural-differentiating conditions 
generated neurospheres, and which expressed HPAP, it is theoretically possible that 
neurons use insulin as a neurotransmitter (45), and could therefore also retain the reporter 
protein, suggesting that this result is not wholly conclusive, however statistically unlikely 
this is. Moreover, this has been further complicated by recent evidence from the van der 
Kooy laboratory which showed that there are in fact two populations of progenitor cells 
within the pancreas: the majority derived from the Pdx1 lineage and which produce the 
insulin-expressing cells as described, and a rarer population which is derived from Wnt1 
neural crest lineage (46).  
 
6.4.2  Animal models as proxy for human disease 
Besides the limitations of interpreting data obtained through lineage tracing, we 
must be cautious in extrapolating data provided by studies on rodents directly to the human 
context. Knowledge about human β-cell cell biology and proliferation has been obtained 
largely through static, post-mortem examination, and which has recently been questioned 
as artificially low due to warm ischemia time which influences antibody immunostaining 
(47). Relatively few studies have been able to lineage trace human β-cells ex vivo (48,49), 
and none in vivo, due to obvious ethical reasons. Data from Chapter 4 showed a surprisingly 
high degree of correlation between human and mouse in the progression of Ins+GLUT2- cells 
during endocrine pancreas development. However, the numerous species differences 
known, with differential utilization of primary glucose transporter subtype, islet macro-
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 organization with regards to cell-cell contact, vascular arrangement, basement membrane, 
and innervation patterns (50–56), timing of endocrine pancreas maturation, widely variable 
genetics, and lifestyle factors among others, render paralleling these situations directly as 
unsuitable. Furthermore, animal models of diabetes do not directly educate diabetes 
disease progression in humans. While it is commonplace to effect hyperglycemia by 
pharmacological methods, and much can, and has been learned by the damage and 
regeneration models used in mice, STZ-mediated hyperglycemia is not a direct substitute 
for the complex physiological changes occurring in patients with type 1 diabetes, such as 
continued β-cell damage and lack of C-peptide exposure in the human context.   Indeed, 
promising results from animal studies have generally failed in human clinical trial (especially 
with regards to autoimmune mitigation), forcing frank reassessment on the appropriateness 
of basing diabetes therapy on data gleaned from a 30g rodent. This is, however, nominally 
reconciled with the advent of studies involving humanized mice (57,58), as well as a strong 
push within the islet biology community to include experiments with human tissue to 
ensure that appropriate conclusions are being drawn. It is therefore critically important, and 
reassuring, that the results by Smukler et al (5) and by us in Chapter 4 did indeed illustrate 
that this population of progenitor cells is present and active within the human pancreas, in 
addition to its presence in mice.  
 
6.5  Future Studies 
To complete the studies in Chapter 3, quantitative PCR experiments are currently 
underway to examine the genetic differences between subsets of P7 RIPCre;Z/AP+/+β-cells, 
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 flow cytometrically-sorted by the expression of Glut2. Similar to data by Smukler et al (5), 
we will assess the relative proportion of β-cell-specific genes (Ins, Glut2, Ngn3, Pdx1, 
Nkx6.1).  
The model which we have established to stratify β-cells according to function can be 
applied to study multiple related endocrine pathologies. We have defined a time-course for 
these Ins+GLUT2- cells, a primary location, and that the actions of STZ are (indirectly) 
influenced by their presence, at least in mice. To ascertain conclusively if there are 
differences in β-cells based on location, experiments will be undertaken to separate these 
cells. Islet isolation will be performed as previously described; however, the ~98% of 
pancreas-cell content remaining will then be retained and examined. These two 
compartments of β-cells – intra- islet vs extra-islet – would be independently separated into 
single cell suspension and prepared for flow cytometric sorting for insulin, or its appropriate 
cell surface proxy marker, such as GPm6a, as shown in Chapter 3 (44), or by transgenic β-
cell lineage marker, such as green fluorescent protein present in MIP-GFP mice (5). And, as 
shown by us in Chapter 4, these experiments should be undertaken using young (<21 days) 
and old (>6 months) mice to characterize the multi-potential population, and if it 
concurrently changes with age.  
 The obvious next step is to interrogate the human pancreas, islets and BCA alike, to 
assess whether the Ins+GLUT2- cells also demonstrate a multi-potential lineage capacity, 
specifically over different ages. Furthermore, it must be determined whether the added 
labour and expense of collecting extra-islet β-cells in addition to intact islets yields 
improvements after transplant. With the introduction of new cell-surface markers for 
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 human β-cells allowing for their isolation by flow cytometry (59), this capability should soon 
be within reach.  
The multitude of physiological situations requiring enhanced metabolic substrates, 
and the situations in which they fail (i.e., diabetes subtypes) could all be examined for the 
role of Ins+GLUT2- cells during their progression. As we have successfully identified these 
cells in sections of human pancreas, tissue samples from newly diagnosed versus 
established type 1 diabetes pancreata could be examined, including those around 
adolescence, as speculated in Chapter 4.  
Investigation of the role of Ins+Glut2- cells during pregnancy is currently underway, 
using RIPCreER;Z/AP mice. β-cells are tagged prior to pregnancy with HPAP, and 
proliferation assessed by EdU and Ki67. Pancreata are collected at key points prior to 
parturition, with the intent of determining if compensatory β-cell mass increases involve 
these putative progenitor cells. We also anticipate a correlation of Ins+Glut2- cells with 
Ucn3-  (18,19), Fltp- (33) and Pax4+ (36) cells. Examination of human pancreata during 
pregnancy and postpartum will also be ideally performed, although the availability of these 
samples is limited.  
Our study illustrating the progressive decline in Ins+GLUT2- cells with advancing age 
was accomplished using lean human individuals alone (Chapter 4); examining this 
population in overweight humans, with and without diabetes present could also identify 
(pre)clinical parameters for study. Both of these conditions can be mirrored using 
appropriate animal models, with the use of non-obese diabetic (NOD) mice to track the role 
of immune attack in type 1 diabetes (60),  the role of insulin resistance without obesity 
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 using β-cell-specific insulin-receptor knock-out mice (IRKO) (61), and the use of C57Bl6 (62) 
or liver specific insulin-receptor knockout (LIRKO) mice (63) fed a high fat diet to induce 
glucose intolerance and type 2 diabetes with obesity present.  
 
6.6  Conclusions 
The work presented here has contributed to the body of knowledge regarding 
pancreatic β-cells in three primary ways: first, that a subset of β-cells demonstrates lineage 
fate plasticity, which can be stratified into categories of maturity and function based on the 
expression of Glut2 in both human and mouse. This has allowed the identification and 
retrieval of these cells relatively simply, while integrating succinctly into the current 
paradigm of β-cell biology. Second, that this β-cell subtype is temporally defined, with fewer 
Ins+Glut2- cells present in mouse and human pancreas with advancing age, which identifies 
a window for clinical intervention. And third, that these progenitor β-cells are 
predominantly found outside of mature islets, which provides an anatomical location 
wherein research efforts can be focussed, and has been heretofore untapped.    
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Figure S2.1. Pancreatic endothelial cells. Freshly isolated mouse endothelial 
cells  (ECs) grown on fibronectin-coated dishes with EBM-2 media (A), and 
which could be passaged up to 3 times (B). Alternatively, ECs were harvested 
and mixed in Matrigel (C). After 7 days, ECs had formed tubular structures (D). 
Scale bars represent 50 μm, n = 4.  
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Figure S3.1. Strategy for gating neonatal pancreas cells used for flow cytometric 
cell sorting by GPM6a and Glut2. Dissociated pancreatic cells were selected by 
the ‘Live’ gate based on 7-AAD exclusion (A). Forward scatter (FSC) and side 
scatter (SSC) voltages were adjusted to clearly visualize cells as indicated by the 
‘Cells’ gate (B). Doublets were excluded based on consecutive gates on FSC-
Height vs FSC-Width and SSC-Height vs SSC-Width plots (not shown). Viable 
GPM6A (insulin)-expressing cells (B, C) were selected based on differential Glut2 
expression (C, red and green) by comparison to cells lacking GPM6a expression 
(C, purple). Gates were set based on fluorescence minus one controls and cluster 
gating. The FACSAria III cell sorter is equipped with a 30 mW Coherent solid state 
405 nm violet laser, a 20 mW Coherent Sapphire solid state 488 nm blue laser,  a 
50 mW Coherent Compass solid-state diode-pumped 561 nm yellow-green laser, 
and a 17 mW JDS Uniphase Helium Neon 633 nm red laser. The blue laser trigon 
was configured to detect AlexaFluor 488 from detector B (530/30 bandpass and 
502 longpass filter). The yellow-green laser octagon was configured to detect 
AlexaFluor 594 from detector D (610/20 bandpass and 600 longpass filter), and 7-
AAD from detector C (670/14 bandpass and 630 longpass filter). Cells were 
sorted at 4oC using a 100 μm nozzle at 20 psi and at a maximum of 6,000 
events/second.  
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Figure S3.2. Neither insulin nor amylase are expressed after 
dedifferentiation of neonatal mouse islets to ductal epithelium.  
Pancreatic beta cells within P7 islets immunostained for insulin (A, 
red), and were negative for amylase (A, green), which immunostained 
the acinar compartment. After isolation and culture of islets for 7 d 
towards a ductal epithelial phenotype, insulin expression was lost (B, 
red), as was amylase expression (B, green). Scale bar represents 50 
μm, n = 3.  
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Figure S3.3. HPAP faithfully tracks the β-cell during dedifferentiation in 
vitro.   
RIPCre;Z/AP+/+ mouse islet stained for insulin (red) and HPAP (green) after 
culturing for 3 days in dedifferentiation conditions. Note that insulin 
immunostains only 3/8 cells present, with HPAP immunostaining 2/3 β-
cells. Scale bar denotes 50 μm, n = 3. 
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Figure S3.4. Insulin-expressing β-cells immunostained by GPM6a.  
Beta cells were immunostained for insulin (green) and the cell  
surface marker GPM6a (red) within an islet. Scale bar denotes 50 μm, n = 3. 
INS GPM6a 
Merge 
Appendix 2 
211
Supplemental Methods: Genotyping  
 
At maturity, one RIPCre+/+ and one LacZ/HPAP+/- mouse of the opposite sex were 
caged together for mating. Genotyping of resultant P5 mouse pups was accomplished by 
ear/tail snips. The DNA extraction  buffer consisted of 5 μL 0.5 M NaCl, 2.5 μL each 1 M Tris 
pH 8.0 and 20 mg/ml proteinase K (Roche Ltd, Mississauga ON), 0.1 μL 0.5 M EDTA, 0.5 μL 
10% SDS, and 39.2 μL DNase-free , RNase-free H20, to a final volume of 50 μL per tissue 
sample. Samples were heated at 56°C for >3 h, vortexed, then centrifuged at 600 x G for 15 
min at 4°C. Samples were stored at -20°C, and 0.5 μL of DNA within the supernatant was 
used in downstream PCR reactions.  
The PCR reaction master mix contained 5 μL each 10x buffer and MgSO4 (UBI Life 
Sciences Inc, Saskatoon, SK), 2 μL 10 mM dNTPs (Invitrogen, Carlsbad, CA), 1 μL each 20 mM 
forward and reverse primers (Sigma-Aldrich, St Louis MO), and 1 U (0.2 μL) Taq (UBI), to a 
final volume of 50 μL in DNase-free, RNase-free water. The following primer sequences for 
the transgenes of interest were used: RIPCre (FW – gcggtctggcagtaaaaactatc and RV –
gtgaaacagcattgctgtcactt, 100 bp), Z/HPAP (FW- ccgcttcccatatgtggctctgtcc; RV- 
gcatgagctcagtgcggttccacac, 548bp), and the internal control (FW- caaatgttgcttgtctggtg; 
RV- gtcagtcgagtgcacagttt, 200 bp). All primer sequences were available from Jackson 
Laboratories.   PCR reactions were performed using an initial denaturation at 94 C for 3 min, 
followed by 35 cycles of denaturation (30 sec at 94°C), primer annealing (1 min at 59°C), and 
transcript extension (1 min at 72°C). cDNA was run on a 2% agarose gel as described in 
Chapter 2.  
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Supplemental  Material 
  S5.1. Identification of LacZ-expressing tissues 
 To confirm the presence of β-galactosidase, sections from LacZ/AP mouse pancreas 
were subjected to the X-gal reaction (1) containing X-gal reagent (5-bromo-4-chloro-indolyl-
β-D-galactopyranoside) (Sigma Chemical, St Louis, MO), potassium ferricyanide, and 
potassium ferrocyanide. Cells expressing β-galactosidase demonstrated an indigo-blue 
precipitate in RIPCreER;Z/AP+/+ mouse pancreas sections without tamoxifen administration 
within the islet (Figure S5.1A, red circle). Conversely, RIPCreER;Z/AP+/+ mouse pancreas 
sections stained for X-gal after tamoxifen induction did not contain the blue precipitate 
(Figure S5.1B), and neither did sections from RIPCreER;Z/AP-/- mouse pancreas (Figure 
S5.1C). 
 
S5.2  Identification of HPAP-expressing tissues using NBT/BCIP 
HPAP+ cells were identified using multiple methods: (A) the alkaline phosphatase 
substrate chromogen Nitro-Blue Tetrazolium Chloride/ 5-Bromo-4-Chloro-3'-
Indolyphosphate p-Toluidine Salt (NBT/BCIP, Sigma) which produces a purple-blue 
precipitate in alkaline phosphatase-expressing cells; (B) a fluorescent substrate using the 
Vector Red Alkaline Phosphatase Substrate Kit (Vector Labs, Burlingame, CA), which works 
similarly to NBT/BCIP but by adding a red fluorescent tag; or (C) immunohistochemical 
staining of HPAP+ cells using a Mouse-on-Mouse (MOM) kit (Vector Labs) with a mouse anti-
human HPAP antibody (Sigma), or a rabbit anti-human HPAP antibody (Abcam, Cambridge, 
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UK). Blocking of endogenous pancreatic alkaline phosphatase, but not HPAP, was 
accomplished by pre-treatment with levamisole (2) (Dako, Glostrup Denmark), or by 
incubating slides in 70°C PBS for 20 min for the chromogenic assays.   
By NBT/BCIP staining, HPAP+ cells within islets could be visualized in P7 RIPCreER;Z/AP+/+ 
sections as indicated by the presence of purple-blue precipitate  after tamoxifen 
administration (Figure S5.2A); islets from RIPCreER;Z/AP-/- mice did not stain (Figure S5.2B), 
and neither did RIPCreER;Z/AP+/+ mouse pancreas sections not induced by tamoxifen (not 
shown). Pancreas sections not pre-treated with levamisole/heating in PBS to block 
endogenous alkaline phosphatase displayed substantial background staining, especially 
within ducts (Figure S5.2C).  
 
S5.3  Dose response to tamoxifen in RIPCreER;Z/AP+/+ pancreas and specificity 
of HPAP to the β-cell 
 RIPCreER;Z/AP+/+ pancreas sections from P7 pups were stained for insulin (green) 
and Vector Red alkaline phosphatase substrate (red) demonstrated no positive areas of 
staining for AP when tamoxifen (TM) was not administered (Figure S5.3A). After induction 
with TM, the HPAP protein clearly and faithfully tracked insulin in the β-cell, showing a 
graded increase in  AP presence after one (Figure S5.3B) and two injections of TM (Figure 
S5.3C).  However, there was considerable variability in staining frequency between islets 
after 2 doses of tamoxifen when stained using either chromogenic method (between 10-
90%), likely due to the enzymatic nature of the NBT/BCIP and Vector Red substrate 
reactions, and not directly to HPAP-expressing cells. More than 2 injections of TM were not 
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tolerated by the pups (not shown). Moreover, any pup injected with tamoxifen were not 
viable breeders as adults, indicating a negative effect on fertility.  None of the non-insulin+ 
cells at P7 positive for AP (red) co-stained for glucagon (Figure S5.3D, green).  Pancreas 
sections not pre-treated with levamisole or heated to 70°C in PBS show endogenous 
alkaline phosphatase presence, primarily around ducts (Figure S5.3E, red).  
Due to the heterogeneity of Vector Red staining within islets, we utilized anti-HPAP 
antibodies for quantification, although the enzyme-based methods were still used to quickly 
and easily assess transgene induction presence. 
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Figure S5.1. X-gal staining for β-galactosidase presence in transgenic 
(LacZ/HPAP) mouse pancreas.  
RIPCreER;Z/AP+/+ mouse pancreas without tamoxifen injection (A). Blue 
precipitate inside the islet (red circle) indicates areas of positive beta-
galactosidase enzyme, correlating with lacZ content. RIPCreER;Z/AP+/+ mouse 
pancreas after tamoxifen induction (B) was absent for blue precipitate, as 
were sections from RIPCreER;Z/AP-/- mouse pancreas (C). Cells were 
counterstained with Carazzi’ s haematoxylin. Scale bars denote 50 μm, n > 3.    
A 
B 
C 
Appendix 3 
216
Figure S5.2. NBT/BCIP staining of alkaline phosphatase-expressing  
pancreatic tissue.  
RIPCreER;Z/AP+/+ islet stained  for AP indicated by purple-blue precipitate 
(A). RIPCreER;Z/AP-/-  pancreas section pretreated with levamisole, 
indicating a lack of blue precipitate (B). Pancreas section neither pre-
treated with levamisole nor 70°C PBS; positive staining for AP is seen 
within the islet (red circle), however there is substantial background 
staining for endogenous AP, especially within ducts (C, arrow). Cells were 
counterstained with Carazzi’s haematoxylin. Scale bars denote 50 μm, n  
> 3.  
B 
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Figure S5.3. Dose response to tamoxifen in RIPCreER;Z/AP+/+ pancreas, and 
specificity of HPAP to the β-cell.  
P7 RIPCreER;Z/AP+/+ pancreas sections stained for insulin (green) and Vector 
Red alkaline phosphatase substrate (red) shows no staining for AP when 
tamoxifen was not administered (A), minimal staining for AP after one dose of 
TM (B), and a moderate proportion of AP staining in insulin-expressing cells (C) 
after 2 injections of TM. Alpha (α)- cells immunostained for glucagon (green) 
and AP (red) clearly occupy different cells within the islet (D). Pancreas section 
not blocked for endogenous AP expression shows AP staining (red) around 
ducts (E, white circle). Size bar represents  50 μm, n > 3.  
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